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Differentiation of B cells into antibody secreting plasma cells is an indispensable step to 
cope with pathogens. Antigen binding to the B cell antigen receptor (BCR) initiates 
signaling cascades leading in combination with co-stimulatory signals to the differentiation 
of B cells. A hallmark of early B cell activation is the mobilization of Ca2+ from internal and 
external sources into the cytosol. Several proteins are reported to orchestrate Ca2+-
mobilization downstream of the BCR including the adaptor protein SLP-65 that forms 
together with key signaling enzymes the central signaling complex in that context. 
Components of that multi-protein complex are members of the Vav protein guanine 
nucleotide exchange factor (GEF) family consisting of Vav1, Vav2 and Vav3, which based 
on genetic mouse models are predicted to fulfill important tasks in BCR signaling. 
However, the operating principle by which the Vav GEF family acts in BCR-induced Ca2+-
mobilization is poorly understood. In my PhD project, I showed that Vav proteins 
constitute crucial signaling elements, controlling Ca2+-mobilization after BCR stimulation in 
B cells. For my investigations, I used the TALEN and CRISPR/Cas gene targeting 
technologies to generate new genetic model systems in a human B cell line. I found that 
especially Vav1 and Vav3, but not Vav2, are potent signaling factors in human B cells that 
enable BCR-induced Ca2+-mobilization. Genetic and biochemical approaches showed, 
that the functionality of Vav1 strictly depends on interactions mediated by its SH2-domain. 
In that context, I characterized a so far undiscovered interaction of Vav1 with the BCR. 
Furthermore, I showed that Vav1 localization within the BCR signalosome is not restricted 
to a specific signaling complex, since both exclusive binding to the BCR or the well-known 
Vav interaction partner SLP-65 enabled BCR-induced Ca2+-flux. In addition, I showed by 
mutational analysis that the functionality of Vav1 in BCR-induced Ca2+-mobilization strictly 
depends on two mechanisms carried out by different protein domains, the CH-domain and 
the DH-PH-ZF-domain unit. The DH-PH-ZF-domain unit is reported to be exclusively 
responsible for the binding and activation of Rho family G-proteins such as Rac1/2 and 
RhoA. In connection to that, I found that the structural integrity of the DH-PH-ZF-domain 
unit is a prerequisite for the functionality of Vav1 in BCR-induced Ca2+-mobilization, 
highlighting a potential role of small G-proteins in this process. The generation of a Rac2-
deficient DG75 B cell line, however, showed no alteration of Ca2+-mobilization, so that 
other small G-proteins might be more important. The CH-domain supports the function of 
the DH-PH-ZF-domain unit probably by recruiting additional signaling factors, which need 
to be identified in future experiments. Collectively, my results demonstrate the paramount 
function of the Vav protein family in controlling the BCR-induced Ca2+-signaling cascade 






2.1 The immune system at a glance 
The immune system of mammals is a complex composition of individual cell types and 
molecules that in contrast to other organs is distributed over the complete body. In 
general, it can be divided into two different sections, the innate and the adaptive immune 
system. The innate immune system constitutes the first barrier of host defense against 
pathogens. Here, granulocytes, macrophages and dendritic cells encounter invading 
pathogens that were able to cross physical barriers such as mucosal or epithelial layers. 
To recognize pathogens efficiently and fast, cells of the innate immune system are 
equipped with specific pattern recognition receptors on their surface that are able to detect 
widespread molecular patterns found on many microorganisms. After detection, 
pathogens are cleared primarily by phagocytosis (Janeway and Medzhitov, 2002; Iwasaki 
and Medzhitov, 2015). 
Despite the elaborate organization of the innate immune system, it shows certain 
disadvantages in the context of adaptation to newly arising or changing pathogens, which 
are not efficiently detected by pattern recognition receptors. In addition, the innate 
immune system cannot mount a stronger response against pathogens that have been 
encountered before, as opposed to the adaptive immune system (Medzhitov and Janeway 
Jr., 1997; Parkin and Cohen, 2001; Flajnik and Kasahara, 2010).  
The adaptive immune system consists of two branches, a cell-mediated and a humoral 
immune system. The former is carried out by antigen specific T cells responsible for 
detection and elimination of intracellular pathogens. This is accompanied most commonly 
by the release of cytokines, which in turn activate further effector cells of the adaptive as 
well as the innate immune system. In contrast, humoral immunity is mediated by B cell 
produced antibodies that have a broad variety of functions. These range from 
neutralization of bacterial toxins and virus particles to opsonization of pathogens, followed 
by activation of the complement system or phagocytes to promote the elimination of the 
pathogen (Flajnik and Kasahara, 2010; Cooper, 2015).  
On primary encounter with a pathogen, innate immune cells control the first days of 
infection. The differentiation of B cells into either antibody secreting, short-lived plasma 
cells or long-lived memory B cells takes a couple of days. Short-lived plasma cells 
dominate the primary immune response, which is rather moderate concerning velocity and 
specificity. A faster and more specific immune response is initiated upon the secondary 





recognition of a specific antigen by the B cell antigen receptor (BCR) expressed on the 
cell surface (LeBien and Tedder, 2008; Cooper, 2015; Kurosaki et al., 2015). 
  
2.2 The B cell antigen receptor - How to become a functional B 
cell 
Arrangement of a functional BCR is a crucial step in each B cell’s life, since it controls B 
cell development. Each B cell expresses a BCR with a unique specificity on its surface 
that stepwise underwent structural rearrangements during B cell development (Pleiman et 
al., 1994; Kraus et al., 2004). The BCR is a multi-protein complex consisting of a 
membrane-bound immunoglobulin (mIg) responsible for the detection of the antigen and a 
heterodimer consisting of the two transmembrane proteins Igα and Igβ constituting the 
signaling unit of the complex (Reth and Wienands, 1997). Noteworthy, antibodies that are 
ultimately secreted by a B cell possess the same specificity as the mIg of the BCR. 
Evolutional pressure generated a sophisticated system to achieve an adequate antigen 
receptor repertoire for the detection of an almost unlimited number of potential antigens 
without extremely increasing the size of a cell’s genome. In other words, the 
approximately 20000 genes of the human genome (Pertea and Salzberg, 2010) are far 
too few to provide as many distinct BCRs that would be necessary to cover all potential 
antigens (Flajnik and Kasahara, 2010). B cells undergo a process called somatic 
recombination in which Ig encoding genes are rearranged during B cell development. In 
detail, gene segments of Ig heavy chain (H) genes are present in segmented form in 
many copies and are named VH, DH and JH segments. These segments are rearranged to 
code together with the CH loci for a complete Ig heavy chain, whereas light chain (L) gene 
segments, VL and JL, are rearranged to code with the CL loci for a complete Ig light chain. 
This somatic recombination is a random process in which one gene segment from many 
copies is randomly chosen in each developing B cell (Schatz and Ji, 2011). In total, two 
identical Ig heavy chains as well as two light chains assemble together to form the mIg 
that constitutes the antigen-recognition element of the BCR. Although the function of the 
BCR stands and falls with antigen recognition, association of mIg with the Igα/Igβ 
heterodimer is an absolute requirement for BCR expression, since Igα/Igβ contain not only 
the signaling capacity of the BCR complex, but are also responsible to guide the mIg to 
the cell surface (Kraus et al., 2004). While disulfide bonds covalently link the Igα/Igβ 
heterodimer, the association of the mIg and Igα/Igβ occurs non-covalently. Having a 





functions: Antigen recognition and antibody secretion (Kraus et al., 2004; Siegers et al., 
2006). 
After the first encounter with their specific antigen, B cells can undergo two differentiation 
fates. They can either develop into a plasma cell secreting low affinity IgM antibodies or 
enter specialized regions of secondary lymphoid organs, namely germinal centers, in 
which optimization of BCRs takes place (Kurosaki et al., 2015). Here, processes like 
somatic hypermutation of V gene regions and Ig class-switch recombination increase their 
antigen affinity and equip the BCR as well as the secreted antibodies with a different 
constant domain and thus new traits (Odegard and Schatz, 2006; Stavnezer et al., 2008). 
In the process of Ig class-switch recombination, the CH gene segment encoding the 
constant region of the BCR heavy chain is rearranged leading to antibody isotype 
switching. In the end, B cells can generate one of five different antibody classes, which 
can be of IgM, IgD, IgA, IgG or IgE type (Xu et al., 2012). While IgM antibodies are 
predominantly produced during the first pathogen encounter, IgG antibodies account for 
approximately 70% of circulating antibodies and are produced during memory responses. 
By contrast, IgA and especially IgE are found in lower amounts. While IgA antibodies are 
the only ones that can pass epithelia and therefore fulfill important functions in the gut and 
the lung, IgE antibodies mediate allergic reactions by the binding of mast cells. IgD is 
found as membrane bound form as well as in low amounts in the blood serum, its exact 
function is not well understood (Schroeder and Cavacini, 2010). 
Until the point of antibody secretion, various signaling processes have to be carried out, 
starting with activation of the BCR. In cooperation with activating co-receptors like CD19 
and CD40 or inhibiting co-receptors like CD22, BCR-derived signals are integrated and 
dictate the B cell fate. For that reason, signals from the BCR and its co-receptors have to 
be tightly regulated, since they are responsible to keep the balance between proliferation 
and apoptosis to prevent B cell responses that might lead to autoimmunity (Marshall et al., 
2000; Niiro and Clark, 2002). 
 
2.3 Initiation of BCR signaling  
Nowadays, two opposing activation models describing the initiation of BCR signaling are 
discussed. According to the generally accepted text book model, antigen binding leads to 
clustering of a vast number of monomeric BCRs that associate with membrane 
microdomains known as lipid rafts (Cheng et al., 1999; Harwood and Batista, 2010; Pierce 
and Liu, 2010). In contrast, a new model in which BCRs are in a pre-clustered state in the 





of antigen leads to the dissociation of pre-clustered BCRs, which allows signaling 
activation in defined membrane areas (Yang and Reth, 2010). Both models have in 
common that BCRs locate into specific membrane microdomains. Here, Src family 
kinases (SFK) like Lyn and Fyn are enriched due to their N-terminal myrestoylation. 
Subsequently, immunoreceptor tyrosine-based activation motifs (ITAMs) of the Igα/Igβ 
heterodimer become phosphorylated by SFKs (Campbell and Sefton, 1992; Yamanashi et 
al., 1992; Casey, 1995). Each of the Igα or Igβ chains contain one ITAM sequence in their 
cytoplasmic tail that is in charge of transmitting signals to the cell interior (Sanchez et al., 
1993). ITAMs are widely spread among immune receptors found in various cell types of 
the adaptive as well as the innate immune system (Humphrey et al., 2005). The ITAM 
consensus sequence is Yxx(I/L)x6-8Yxx(I/L) (single letter code for amino acids, x can be 
any amino acid) and constitutes a binding site for the tandem Src-homology 2 (SH2)-
domains of the Spleen tyrosine kinase (Syk) (Reth, 1989; Kurosaki et al., 1995; Fütterer et 
al., 1998). Upon Syk-ITAM interaction, autoinhibition of Syk is relieved. In addition, 
structural rearrangements lead to the exposure of Syk regions that were previously 
masked by its own tandem SH2-domains. Transphosphorylation as well as 
autophosphorylation of several conserved tyrosine residues in Syk finally lead to its 
activation (Kurosaki et al., 1995). Active Syk can also phosphorylate ITAM tyrosine 
residues and thereby support its own activation process in a feed-forward loop (Rolli et al., 
2002).  
While Syk is recruited to phosphorylated ITAMs, a phosphorylated non-ITAM tyrosine 
residue (pY204) that is exclusively found in Igα recruits the SH2-domain-containing 
leukocyte adaptor protein of 65 kDa (SLP-65, also named BLNK or BASH) (Fu et al., 
1998; Goitsuka et al., 1998; Wienands et al., 1998; Engels et al., 2001). Upon SLP-65 
recruitment to pY204, ITAM-bound Syk phosphorylates SLP-65 on various tyrosine 
residues that function as docking sites for further SH2-domain containing proteins (Fu et 
al., 1998). In addition, several proline-rich interaction motifs in SLP-65 mediate further 
contacts with Src-homology 3 (SH3)-domain containing proteins (Grabbe and Wienands, 
2006; Oellerich et al., 2011). In that sense, SLP-65 represents the main signaling platform 
in BCR signaling, influencing several downstream signaling pathways (Oellerich et al., 
2009). This model is supported by the phenotype of SLP-65-deficient mice showing 
reduced numbers of B cells as well as defective Ca2+-signaling and proliferation 
responses (Jumaa et al., 1999). Assistance receives SLP-65 from its constitutive 
interaction partner Cbl-interacting protein of 85 kDa (CIN85) that serves as crucial factor 
in SLP-65 plasma membrane recruitment (Oellerich et al., 2011). At the plasma 
membrane, SLP-65 nucleates the so-called Ca2+-initiation complex. Besides SLP-65, it 





phospho-tyrosine residues in SLP-65 by virtue of their SH2-domains (Engelke et al., 2007; 
Scharenberg et al., 2007). The formation is supported by the Pleckstrin-homology (PH)-
domains of both Btk and PLCγ2 that mediate binding to phosphatidyl-inositol-3,4,5-
trisphosphate (PIP3) in the plasma membrane (Salim et al., 1996; Falasca et al., 1998). 
Following recruitment of Btk to SLP-65, Btk gets phosphorylated and activated, which 
allows the activated Btk to phosphorylate and thereby activate PLCγ2. (Hashimoto et al., 
1999; Engelke et al., 2007). Activated PLCγ2 in turn hydrolyzes its substrate phosphatidyl-
inositol-4,5-bisphosphate (PIP2) into the second messengers diacylglycerol (DAG) and 
inositol-1,4,5-triphosphate (IP3), which is the starting point for diversification of BCR 
signals (Reth and Wienands, 1997).  
 
2.4 Beyond the Ca2+-initiation complex 
The soluble second messenger IP3 diffuses in the cytoplasm and binds to IP3-receptors, 
which are ligand-gated Ca2+-channels located in the membrane of the endoplasmic 
reticulum (ER). Receptor binding by IP3 induces channel opening leading to a Ca
2+-flux 
following the Ca2+-concentration gradient from the ER into the cytoplasm. 
Sarcoplasmic/endoplasmic Ca2+-ATPases, which are constantly active, accomplish 
restoration of the ER Ca2+-depot (Kurosaki, 1999). Once the ER Ca2+-depot is exhausted, 
store-operated Ca2+-channels (SOCs) in the plasma membrane are opened leading to a 
sustained Ca2+-influx from the extracellular milieu into the activated B cell. This is 
achieved by the interaction of two different types of proteins, namely the stromal 
interaction protein (STIM) and the Ca2+ release-activated Ca2+-channel (CRAC) ORAI 
(Cahalan, 2009). STIM is located in the membrane of the ER and contains a Ca2+-binding 
EF-hand-domain at the ER-luminally located N-terminus to monitor Ca2+-levels within the 
ER lumen (Zhang et al., 2005). Binding of Ca2+ to STIM causes its dimerization. Following 
Ca2+-depletion from the ER, STIM starts to oligomerize, which leads to formation of 
aggregates migrating along tubulovesicular structures to juxtamembrane regions of the 
cell periphery (Zhang et al., 2005). Here, STIM-cluster can directly interact with ORAI 
enabling its complete assembly and activation (Park et al., 2009). As a result, Ca2+ is able 
to pass the CRAC-channel leading to a sustained Ca2+-influx. From here, BCR signals 
start to diversify into many downstream signaling pathways, that are regulated by the 
second messenger Ca2+ and DAG (Kurosaki et al., 2010). 
For example, the activation of transcription factors of the NFAT (nuclear factor of activated 
T cells) family is regulated in a Ca2+-dependent manner. Increasing cytosolic Ca2+ levels 





dephosphorylates NFAT proteins and thus enables their translocation into the nucleus for 
gene regulation (Kawasaki et al., 1998; Crabtree and Olson, 2002). 
In contrast to IP3, DAG remains within the plasma membrane and recruits the 
serine/threonine protein kinase C (PKC) family member PKC-β, which also depends on 
Ca2+-binding for complete activation (Takai et al., 1979). This is the starting point of the 
canonical NF-κB (Nuclear factor of κ light polypeptide gene enhancer in B cells) pathway 
resulting in the translocation of NF-κB into the nucleus, where it can fulfill its transcription 
factor role (Guo et al., 2004; Sen, 2006). One further example for DAG dependent 
signaling is the recruitment of Ras guanine nucleotide release proteins (RasGRP) to the 
plasma membrane. These are guanine nucleotide exchange factors for G-proteins of the 
Ras family that in lymphocytes control the Erk/MAP kinase pathway leading to lymphocyte 
proliferation (Oh-hora et al., 2003).   
Besides the previously described BCR-induced formation of the Ca2+-initiation complex 
and its downstream effects, BCR engagement induces also membrane recruitment of 
phosphoinositide 3’-kinase (PI3K) family members, which phosphorylate the PLCγ2 
substrate PIP2 to generate PIP3. PIP3 constitutes a docking site for proteins with PH-
domains such as Btk and PLCγ2, supporting the membrane recruitment of the Ca2+-
initiation complex (Salim et al., 1996; Falasca et al., 1998). Furthermore, Akt (also named 
protein kinase B, PKB) is recruited to the membrane anchor PIP3 (Mee et al., 2010; Hersa 
et al., 2011), which subsequently leads to its phosphorylation and activation by PDK1 
(phosphoinositide-dependent kinase-1). Activated Akt in turn phosphorylates several 
downstream factors, which influence lymphocyte survival and proliferation (Okkenhaug 
and Vanhaesebroeck, 2003; Hersa et al., 2011).  
The functionality of BCR signaling is of tremendous importance, since the absence or 
dysfunction of single components can lead to severe B cell deficiencies. For example, 
mutations in Btk result in X-linked agammaglobulinemia (XLA) in humans and X-linked 
immunodeficiency (Xid) in mice that are characterized by a complete lack of antibodies 
(Satterthwaite et al., 1998). Collectively, BCR-induced signaling pathways have critical 
impacts on the fate of a B cell. However, unexplored factors remain, so that BCR-induced 
signaling is not entirely understood. One of these less-well characterized factors in the 
BCR signaling cascade is the Vav guanine nucleotide exchange factor family that 






Figure 2.1: Schematic drawing of BCR-proximal signaling events. BCR cross-linking by antigens leads to 
phosphorylation of ITAMs within the Igα/Igβ heterodimer by Src family kinases like Lyn. Subsequently, Syk is 
recruited to phosphorylated ITAMs leading to the phosphorylation of SLP-65, followed by the assembly of the 
‘core’ Ca
2+
-initiation complex on the key adaptor protein SLP-65. In addition, further signaling factors are 
gathered on this platform like CIN85, Grb2 and Vav1. From that point, several downstream signaling pathways 
are triggered (see text for details). Red arrows indicate phosphorylation processes, solid arrows indicate 
translocation processes, dashed arrows indicate multistep signaling pathways, Ca
2+
 is indicated by black dots. 
Color-code: IgM-BCR and CD19 are depicted in light green, antigen in dark pink, tyrosine kinases in dark 
purple, other kinases in blue, adaptor proteins in turquoise, second messengers in light grey, membrane 
phospholipids in dark grey, small G-protein Rho (family) and the guanine nucleotide exchange factor Vav 
(family) in green, RasGRP in brown, IP3R, STIM and Soc in yellow. 
 
2.5 Vav - guanine nucleotide exchange factors of Rho family G-
proteins 
Since signals emanating from the BCR are responsible for cell fate decisions of each B 
cell, they have to be tightly controlled. BCR signaling is an interplay of enzymes and 
adaptors. The latter ones orchestrate the assembly and disassembly of activating as well 
as inhibitory signaling complexes. A small group of proteins that can combine both, 
enzymatic as well as adaptor functions is the family of Vav guanine nucleotide exchange 






Vav1 was discovered in gene transfer assays determining the presence of transforming 
genes in human esophageal carcinomas in 1989 (Katzav et al., 1989). Since VAV1 was 
the sixth transforming gene discovered in the laboratory of Prof. Barbacid, it was named 
according to the sixth letter of the Hebrew alphabet, as the native language of its 
discoverer was Hebrew (Katzav et al., 1989). In the following years, the Vav family was 
stocked up by the discovery of the further members Vav2 and Vav3 (Henske et al., 1995; 
Movilla and Bustelo, 1999), which share a high degree of similarity regarding domain 
architecture and amino acid sequence homology (50-60 %). Despite their homology, 
individual Vav protein family members are adjusted to their specific signaling pathway, 
which is reflected by their different expression profiles. While the Vav2 and Vav3 
expression pattern includes almost any cell type in mice, Vav1 expression is rigorously 
restricted to the hematopoietic cell lineage (Schuebel et al., 1996; Ogilvy et al., 1998; 
Movilla and Bustelo, 1999). Nevertheless, experiments in mice revealed a certain 
redundancy between Vav family members, as Vav1-deficient mice show a normal T and B 
cell development. In contrast, Vav1/Vav2 double-deficient mice revealed a block of B and 
T cell development at early developmental stages. In accordance with defects of 
lymphocyte populations, B and T cell antigen receptor signaling is impaired in Vav1/Vav2 
double-deficient mice including Ca2+-mobilization (Tedford et al., 2001). Furthermore, 
Vav1/Vav2/Vav3 triple-deficient mice support these findings and show more pronounced 
defects compared to Vav1/Vav2 double- or Vav1-deficient animals (Fujikawa et al., 2003). 
Collectively, mouse experiments pushed the Vav family members to the focus of attention, 
since they represent a central signaling knot in B and T cells regulating the cellular fate of 
both lineages. Nevertheless, despite intensive investigations over the last decades, the 
exact mechanisms by which Vav proteins control these processes are only partially 
understood.    
 
2.5.1 Vav1 - a multi-domain protein with diverse functions 
Vav1 is a multi-domain protein with an approximate molecular weight of 100 kDa 
consisting of several protein domains (figure 2.2). In principle, Vav1 can be divided into 
two segments. The N-terminal segment contains five different protein domains or regions 
including a Calponin- (CH), a Dbl- (DH), a PH-, a Zinc-finger (ZF)-domain and an acidic 
stretch. These regions act in concert for efficient activation of small Rho family G-proteins 
by catalyzing the exchange of GDP to GTP and therefore comprise the enzymatic function 
of Vav1. In contrast, the C-terminal segment contains an adaptor region including an SH2-





segments in the context of BCR-induced Ca2+-mobilization remains poorly understood. 
(Bustelo, 2001; Tybulewicz, 2005) 
 
Figure 2.2: Domain architecture of Vav1. Individual protein domains are depicted and their respective 
functions are indicated. Phosphorylation of the acidic region is done by Syk and Src family kinases. Grb2 
interacts with N-terminal SH3 domain, whereas SLP-65 and Syk are binding partners for the SH2-domain. 
(CH: Calponin-homology-domain, AR: Acidic region, DH: Dbl-homology-domain, PH: Pleckstrin-homology-
domain, ZF: Zinc finger-domain, PR: Proline rich region, SH3: Src-homology 3-domain, SH2: Src-homology 2-
domain)   
 
The DH-PH-ZF-domain unit 
The DH-, PH-, ZF-domains form a functional unit that mediates the enzymatic GEF activity 
of Vav1. In that context, the DH-domain is responsible for the exchange of GDP with GTP 
in Rho family poteins (Hoffman and Cerione, 2002). The spectrum of Vav1-activated G-
proteins is not completely defined, since Vav1-mediated G-protein activation might 
depend on cell type and signaling pathways. Furthermore, in vitro and in vivo 
experimental conditions might influence Vav1’s catalytic specificity towards small G-
proteins. In fact, two coupled events, binding and subsequent enzymatic reaction, are 
critical for efficient and specific Vav1-mediated G-protein activation. Both depend on the 
interaction with two separate regions of Rho proteins (Movilla et al., 2001). In B-cells, 
Vav1 has been shown to activate several G-proteins including Rac1, Rac2, RhoA and 
RhoG (Saci and Carpenter, 2005; Brezski and Monroe, 2007; Arana et al., 2008; Malhotra 
et al., 2009). The Vav1-activated G-proteins mediate downstream effects like 
rearrangement of the cytoskeleton, cell proliferation and survival (Bustelo, 2001; Zugaza 
et al., 2002).  
The activity of the Vav1 DH-domain is regulated by several mechanisms. First, the 
adjacent PH domain makes intramolecular contacts with the DH-domain and thus 
stabilizes its 3D structure (Hoffman and Cerione, 2002). Second, the PH-domain 
influences the catalytic activity of the DH-domain depending on the PIP-species it binds 
to. Binding of PIP2 to the PH-domain decreases DH-domain activity, whereas binding of 





contains three tyrosine residues that block the active center of the DH-domain, thereby 
acting as inhibitory loop (Zugaza et al., 2002) that is strengthened through a further 
internal interaction between the CH- and ZF-domains. Phosphorylation of tyrosines within 
the acidic stretch leads to opening of inhibitory structures and enhanced DH-domain-
mediated GEF activity (Zugaza et al., 2002). Fourth, also the ZF-domain might act as 
structural DH-domain stabilizer, since mutations in the ZF-domain diminish Vav1 GEF 
activity (Zugaza et al., 2002). Taken together, the Vav1 GEF activity is tightly regulated in 
a stepwise process to prevent unintended G-protein activation.   
The relationship between Vav1’s GEF activity and antigen receptor-mediated Ca2+-
signaling in lymphocytes was investigated in mice focusing primarily on T cell activation. 
Mice expressing Vav1 with an inactive DH-domain showed no altered Ca2+-mobilization 
upon TCR stimulation (Saveliev et al., 2009). In contrast, mutations affecting the GEF 
activity of Vav1 that are located away from the active center of the DH-domain, lead to a 
dramatic defect in TCR-induced Ca2+-mobilization (Ksionda et al., 2012). These mutations 
probably influence the structural integrity of the DH-domain causing a loss of GEF-
dependent functions. In B cells, little is known about the relation between the Vav1 DH-
domain function and BCR-induced Ca2+-mobilization. However, loss of Vav3 in the 
chicken B cell line DT40 leads to reduced Ca2+-mobilization upon BCR stimulation, which 
might be caused by impaired Rac1 activation (Inabe et al., 2002). Further investigations 
focused on the role of Vav1-mediated activation of Rac1 and Rac2 for B cell development, 
proliferation and survival (Walmsley et al., 2003). In addition, Vav1-mediated Rac 
activation leads to cytoskeletal rearrangements and promotes BCR endocytosis (Arana et 
al., 2008; Malhotra et al., 2009). The connection between BCR-induced Ca2+-mobilization 
and the function of the Vav1 DH-domain, however, remains unclear. 
 
The CH-domain  
CH-domains comprise roughly 100 amino acids and occur in five different types. 
Originally, type 1 and 2 CH-domains, when arranged in tandem, were shown to form an 
Actin-binding domain (ABD) that binds to the Actin cytoskeleton. Based on amino acid 
sequence analysis, each ABD contains three different stretches of conserved residues 
characterized as Actin-binding sites (ABS) that mediate the direct contact to the Actin 
cytoskeleton. However, only type 1 and type 2 CH-domains contain the conserved ABS, 
whereas type 3, 4 and 5 CH-domains lost these residues during evolution. Therefore, 






Regarding type 3 CH-domains, it is currently assumed that the exact task of each domain 
is strongly connected to the individual protein function (Gimona et al., 2002). The Vav1 
type 3 CH-domain was shown to be a crucial regulator of Vav1 GEF activity, since its 
deletion leads to an increased transforming potential, which is reflected by an enhanced 
Vav1 GEF activity towards Rho family G-proteins (Katzav et al., 1991; Zugaza et al., 
2002). Based on these results, the Vav1 CH-domain fulfills an inhibitory function in the 
context of Vav1 GEF activity. Structural investigations further support this hypothesis, 
since they show formation of an inhibitory loop that is stabilized by a direct contact 
between the CH-domain and the central DH-PH-ZF-domain unit (Zugaza et al., 2002; Yu 
et al., 2010). Furthermore, the Vav1 CH-domain is essential for TCR-induced Ca2+-
mobilization, since its deletion leads to a dramatic Ca2+-mobilization defect (Li et al., 
2013). The reason for this defect in Ca2+-mobilization might be based on the loss of 
protein-protein interaction. Only a few binding partners of the Vav1 CH-domain have been 
described including the ubiquitous Ca2+-sensor protein calmodulin and a Rho GDP 
dissociation inhibitor named Ly-GDI (Groysman et al., 2000; Li et al., 2013). However, 
their function in Vav1-mediated Ca2+-mobilization is vague. In B cells, little is known about 
the function of the CH-domain, except its operating principle in the context of G-protein 
activation. A putative function with regard to BCR-induced Ca2+-mobilization remains 
unknown.  
 
The adaptor part of Vav1 
The C-terminal Vav1 adaptor region consists of three protein binding domains in an SH3-
SH2-SH3-domain arrangement (figure 2.2). SH2-domains interact with phosphorylated 
tyrosine-containing motifs in active signaling complexes, whereas SH3-domains most 
commonly mediate rather constitutive protein-protein interactions by binding to proline-rich 
motifs (Alexandropoulos et al., 1995; Birge et al., 1996). Hence, Vav1 can localize to 
active signaling spots via its SH2-domain and integrate additional proteins via SH3-
domain-mediated interactions.  
The N-terminally located SH3-domain of Vav1 (hereafter referred to as N-SH3) binds the 
adaptor protein Grb2 (Kim et al., 1998; Jang et al., 2009). This interaction is mediated by 
an unusual face to face interaction between the C-terminal Grb2 SH3-domain and the N-
SH3-domain of Vav1 (Kim et al., 1998; Nishida et al., 2001). Canonical binding of the N-
SH3-domain to a proline-rich motif is not possible due to a binding pocket blockage by an 
intramolecular proline-rich motif and missing prerequisites for correct proline-rich peptide 





not completely defined. However, Grb2 mediates in concert with SLP-65 membrane 
recruitment of Vav3 in chicken DT40 B cells leading to an efficient activation of Rac1 (Kim 
et al., 1998; Salojin, 2000; Johmura et al., 2003). Further interaction partners have not 
been described until today. Nevertheless, other Grb2 family members might be able to 
interact with the Vav1 N-SH3-domain as well. 
In contrast, the C-terminal SH3 domain (hereafter referred to as C-SH3) of Vav1 binds to 
proline-rich motifs in a common manner. Deletion of the C-SH3-domain leads to a loss of 
Vav1 GEF activity (Zugaza et al., 2002). In fact, various binding partners of the C-SH3-
domain were identified however, a functional connection of the interaction partners with 
the GEF activity of Vav1 was not reported. The identified interaction partners include 
nuclear proteins involved in DNA-repair (Ku-70) and mRNA processing (hnRNP-K, 
hnRNP-C) as well as the focal contact protein zyxin (Hobert et al., 1996; Romero et al., 
1996; Romero et al., 1998). The functional relevance of theses interactions is not known.  
In addition to the C-SH3-domain, the centrally located SH2-domain of the Vav1 adaptor 
region is of primary importance, since it guides Vav1 to active signaling regions. It 
preferentially binds phosphorylated YxEP motifs that can be found in essential proteins of 
the BCR as well as TCR signaling cascade including Syk, ZAP70 (70 kDa zeta-chain 
associated protein), SLP-65 and SLP-76 (SH2 domain-containing leukocyte 
phosphoprotein of 76 kDa) (Songyang et al., 1994; Deckert et al., 1996; Wu J. et al., 
1996; Wu J. et al., 1997; Wienands et al., 1998), indicating that Vav1 is part of the 
signaling platform formed by the key adaptor SLP-65. Based on in vitro peptide affinity 
purification experiments, the Vav1 SH2-domain was shown to exclusively bind to the 
phosphorylated tyrosine 91 (pY91) of chicken SLP-65 (Chiu et al., 2002). Nevertheless, it 
remains unclear whether the SLP-65-Vav1 interaction has any functional consequences in 
B cells. Inactivation of the SH2-domain leads to a complete loss of GEF activity as well as 
to defects in Ca2+-mobilization and TCR microcluster formation in T cells (Zugaza et al., 
2002; Sylvain et al., 2011). In B cells, the Vav1 SH2-domain binds to the phosphorylated 
tyrosine residues Y341 and Y345 of Syk upon BCR stimulation. In turn, Syk 
phosphorylates tyrosines in the acidic region and thereby activates Vav1’s GEF function 
(Deckert et al., 1996; Lopez-Lago et al., 2000). In addition, Vav1’s GEF activity is fine-
tuned by the activating and inhibiting co-receptors CD19 and CD22, respectively (Sato et 
al., 1997). Phosphorylation of the intracellular tail of CD19 leads to the recruitment of 
Vav1 and the Src-kinase Lyn, which also results in Vav1 phosphorylation and activation in 
addition to BCR-induced Vav1 activation (Weng et al., 1994; Sato et al., 1997; Fujimoto et 





(PTPN6) to CD22 inhibits Vav1 activity via dephosphorylation of tyrosine residues (Sato et 
al., 1997).  
Taken together, the Vav1 adaptor region fulfills essential tasks that are mainly correlated 
with the Vav1 GEF activity. Investigations concerning antigen receptor signaling focused 
primarily on TCR-induced Ca2+-mobilization and showed a critical role of the Vav1 adaptor 
region in that context. Yet, whether or not the Vav adaptor region has a similar function in 
BCR-induced signaling events remains unclear.     
 
2.6 Aim of this thesis 
The Vav guanine nucleotide exchange factor family has been shown to be a crucial factor 
for adaptive immunity, where it influences the antigen receptor signaling capacity in 
mature and developing lymphocytes and the maturation of lymphocytes starting from early 
developmental stages (Tedford et al., 2001; Fujikawa et al., 2003). Nevertheless, how 
Vav1 exerts its function in B cell antigen receptor signaling remains poorly understood. 
Therefore, the goal of my thesis was to elucidate the mechanisms by which Vav1 controls 
signaling processes emanating from the BCR. 
During my PhD project, I focused on the following issues: 
1. Generation of a Vav1-deficient human B cell line to study the role of Vav family 
members in BCR-proximal Ca2+-signaling.  
2. How is Vav1 connected to the BCR signalosome? Which protein-protein 
interactions are important in that process? 
3. Is the guanine nucleotide exchange activity of Vav1 involved in BCR-induced Ca2+-
mobilization? Which other Vav1 domains might be important in Ca2+-mobilization? 
4. Are small G-proteins of the Rho family involved in BCR-proximal Ca2+-signaling?       




3 Materials and Methods 
3.1 Materials 
3.1.1 Chemicals and reagents 
Chemicals and reagents were purchased from Invitrogen, Merck, Roth or Sigma, unless it 
is not directly indicated in the following materials and methods chapters. 
 
3.1.2 Consumables  
Table 3.1: Consumables used in this study. 
Consumables Company 
Blotting Paper WhatmanTM Sartorius Stedim 





6x DNA-loading buffer NEB 
dNTPs NEB 
FCS PAA 
Ficoll-Paque Plus Amersham Bioscience 
Filtropur filters Sarstedt 
Glutathione-sepharose GE Healthcare 
Hexadimethrine Bromide (Polybrene) Sigma 
Immersion oil Merck 
Indo-1 AM Invitrogen 
IPTG (Isopropyl-β-D-thiogalactopyranosid) Sigma 
MACS columns (LS) Milteny Biotec 
Microscope paper neoLab 
Neubauer improved counting chamber Brand 
Nitrocellulose membrane Hybond ECL Amersham Biosciences 
Prestained Protein Marker, Broad Range  
(6.5-175 kDa) 
NEB 
Protease Inhibitor Cocktail (P2714) Sigma 
Pyruvat Biochrom 
Streptavidin-sepharose GE Healthcare 




TransIT®-293 Transfection Reagent Mirus 
Trypsin/EDTA (0.05 %) Gibco 





3.1.3 Enzymes  
All enzymes were used according to the manufacturer’s instructions. 
Table 3.2: Enzymes used in this study. 
Enzymes Company 
Blunting kit NEB 
Calf intestine phosphatase NEB 
Phusion DNA polymerase NEB 
Plasmid-SafeTM Biozym 
Restriction endonucleases NEB 
Taq polymerase PCR master mix Qiagen 
T4 DNA ligase NEB 
 
3.1.4 Reaction systems (kits) 
Table 3.3: Reaction systems (kits) used in this study. 
Reaction systems Application Company 
TA Cloning® Kit Cloning Invitrogen 
Human B Cell Nucleofector® 
Kit 
Nucleofection of DG75 cells Lonza 
Human B cell isolation kit Isolation of primary human B 
cells 
Milteny Biotec 
QIAprep® Spin Miniprep Plasmid-DNA purification Qiagen 
Wizard® Plus SV Minipreps 
DNA Purification System 
Plasmid-DNA purification Promega 
Pure YieldTM Plasmid Midiprep 
System 
Plasmid-DNA purification Promega 










3.1.5 Synthetic DNA oligonucleotides 
Synthetic DNA oligonucleotides were purchased from Eurofins Genomics and used 
according to the manufacturer’s instructions.   
Table 3.4: Primer used in this study.  
Primer used for cloning in this study. 
Name Sequence 5’-> 3’ Application 
CHLVav1_CTG_fw TAATGGATCCCTGGAGCTGTGGCGC
CAATG 




















































Cloning of mVav3 in 
pMSCVpuro, pCitrine 
 






Cloning of mVav3 in 
pCitrine 























Cloning of ∆CH Vav1 
deCH_Vav1_XhoI_fw TAATCTCGAGATGCGCTCGGAGCCC
GTGTC 








Cloning of Vav1 CHCT 
V1_CH_Ct_re TAATACCGGTAGGCGCATGAGGTCC
TCATAGATCTCGTC 










Cloning of [CH]2 β-
Spectrin-Vav1 
 






























Cloning of ΔAR Vav1 
V1_deltaAcid_re CTCTGTCATCTTGGGCGGCATGGAG
AAGGGCATGATCCCCCTGTTCTG 
Cloning of ΔAR Vav1 
NSH3_Vav1_fw2 TAATGAATTCGGCCGACATGGGCAA
GAT 
Cloning of C2 adaptor 
region into pGEX-4T1 
Vav1_cSH3_re1 TAATCTCGAGTCAGCAGTATTCAGA
ATAATCTTCCTCC 
Cloning of C2 adaptor 
region into pGEX-4T1 
Vav1_SH2_fw TAATGAATTCCCTCCTCAGGACCTG
TCTGTT 




















Cloning of Vav1-Syk 
[SH2]2 
 
































































Cloning of PIP5K1a 
into pMSCVpuro 















Cloning of Vav1-Rac1 
Vav1Rac1_re CACACACTTGATGGCCTGCAGGCAG
TATTCAGAATAATCTTCCTCC 
Cloning of Vav1-Rac1 
Rac1_BamHI_re TAATGGATCCTTACAACAGCAGGCA
TTTTCTCTTCCTC 
Cloning of Vav1-Rac1 
SykSH2_BglII_fw TAATAGATCTTCCGGCATGGCTGAC
AGCG 


































Cloning of PIP5K1acore 
variants 








Standard primer used for sequencing in this project.  
Name Sequence 5’-> 3’ 




MSCVfw CCCTTGAACCTCCTCGTTCGACC  
MSCVre CAGACGTGCTACTTCCATTTGTC  
 
Primer used for TALEN in this study.  
Name Sequence 5’-> 3’ Application 
pCR8_F1 TTGATGCCTGGCAGTTCCCT Sequencing 
pCR8_R1 CGAACCGAACAGGCTTATGT Sequencing 
TAL_F1 TTGGCGTCGGCAAACAGTGG Sequencing 
TAL_R2 GGCGACGAGGTGGTCGTTGG Sequencing 
SeqTALEN_5-1 CATCGCGCAATGCACTGAC Sequencing 
TALseq3_re GGGCACCCGTCAGTGCAT Sequencing 
TALseq4_re TTCAGATTTCTTCTCTTCCAATTCAGA Sequencing 
TALseq5_fw CGGATCAGGCGTCTTTGCAT Sequencing 
TAL_Seq6_fw ATACGAGCCGGAAGCATAAAGTGT Sequencing 
TAL_Seq7_re ACATGCTTAACGTAATTCAACAGAAA Sequencing 
Vav1Ex3Seq_fw GGCTCATTTGAGAGAACGATGGTAT Sequencing/activity 
test 
Vav1Ex3Seq_re CTCAGGCAAGGTTGTGTGCC Sequencing/activity 
test 
SLP65_Ex5_fw2 TTGAAGTCAACCTCTCCAAGCCTTGT Sequencing/activity 
test 
SLP65_Ex5_re2 CTGCTTGGAGGTGGCGGGAG Sequencing/activity 
test 
SLP65_Ex6_fw2 GTCAATAAGCAGTTGAAATTTTGGGCCT Sequencing/activity 
test 
SLP65_Ex6_re2 GGAGGGGATAATATGAGGGGCACA Sequencing/activity 
test 
Rac2_Ex3_fw GCGACAGAGCGTGATTCCATTTCAA Sequencing/activity 
test 




Rac2_Ex3_re ACTATCCACCATCTGATTACCGGCC Sequencing/activity 
test 
CC2_Rac2_Ex3_1 CACCGAGGAGGACTACGACCGTCTC CC2 construct 
CC2_Rac2_Ex3_2 AAACGAGACGGTCGTAGTCCTCCTC CC2 construct 
U6 fwd GAGGGCCTATTTCCCATGATTCC Sequencing 
pFUS_A5A/B_fw CGGTGGTCTCGTGCAGCGGCTGTTGCC Modification 
pFUS_A5A/B_re AGTGAGCGCAACGCAATTAATG Modification 
pFUS_A5A/B_re2 GAGCGCAACGCAATTAATGTGAG Modification 
















pTAL3+63_fw TCCCAGCTAGTGAAATCTGAATTGGAAG Modification 
pTAL3+63_re GGCAACGCGATGGGACG Modification 
+63_mut_fw ATCGCGTTGCCTCCCAGCTAGTGAAA Modification 
+63_mut_re TTTCACTAGCTGGGAGGCAACGCGAT Modification 
TAL3 delta152_fw GTGGATCTACGCACGCTCGG Modification 
TAL3 delta152_re ATTCTAGACCAACCACTTGCGTCC Modification 
delta152_mu_fw2 GTTGGTCTAGAGTGGATCTACGCAC Modification 







TAL_HA_Mu_fw AGGAGGTTCAACAATGTACCCATACG Modification 

















Tal4_K441E_fw GTTATCGTGGTGAACATTTGGGTGGAT Modification 
Tal4_K441E_re ATCCACCCAAATGTTCACCACGATAAC Modification 
 
Primer used for mutagenesis in this study.  


















































3.1.6 Vectors and Plasmids 
Table 3.5: Plasmids used for cloning and expression in this study.  
Vectors for cloning and cDNA sources. cDNA of DG75 cells for the amplification of IQGAP and β-Spectrin 
CH-domains was kindly provided by Kanika Vanshylla.  
Name Source 
pBlueScript SK+ Stratagen 
pCitrine M. Engelke 
pCR2.1 Invitrogen 
pGEX-4T1 GE Healthcare 
pmaxKS N. Engels 
pmaxKS IRES-EGFP N. Engels 
pmaxKS IRES-tagRFP This work 
pMiRFP Lars König 
pMSCVpuro Clontech 
pMSCVblast M. Engelke 
pEX-A-5’-CHVav1 Eurofins Genomics 
pCR2.1 Btk N. Engels 
pCR2.1 Itk N. Engels 
pOTB7 Vav1 GE Dharmacon 
pCR4-TOPO Vav2 GE Dharmacon 
pCR-XL-TOPO Vav3 GE Dharmacon 
pBluescript mVav1 provided by Klaus-Dieter Fischer 




pYX-Asc mVav2 provided by Klaus-Dieter Fischer 
pYX-Asc mVav3 provided by Klaus-Dieter Fischer 
pCMV-SPORT6 Rac1 GE Dharmacon 
pOTB7 PIP5K1a GE Dharmacon 
pMSCVpuro EGFP-rPLCγ2 N. Engels 
 
Retroviral expression vectors. 
Name Insert Source 
pMSCVpuro EGFP M. Engelke 
pMSCVpuro Vav1 Cit This work 
pMSCVpuro Vav2 Cit This work 
pMSCVpuro Vav3 Cit This work 
pMSCVpuro mVav1 Cit This work 
pMSCVpuro mVav2 Cit This work 
pMSCVpuro mVav3 Cit This work 
pMSCVpuro Vav1 W10A Cit This work 
pMSCVpuro Vav1 D39A Cit This work 
pMSCVpuro Vav1 D98A Cit This work 
pMSCVpuro Vav1 L213Q Cit This work 
pMSCVpuro Vav1 LK334/335AA Cit This work 
pMSCVpuro Vav1 Q542A Cit This work 
pMSCVpuro Vav1 Y544A Cit This work 
pMSCVpuro ∆CH Vav1 Cit This work 
pMSCVpuro Vav1 CHCT Cit This work 
pMSCVpuro CH IQGAP-Vav1 Cit This work 
pMSCVpuro [CH]2 β-Spectrin-Vav1 Cit This work 
pMSCVpuro Lynmyr-∆CH Vav1 Cit This work 
pMSCVpuro ∆CH Vav1-Syk [SH2]2 Cit This work 
pMSCVpuro ∆AR Vav1 Cit This work 
pMSCVpuro Vav1-Btk SH2 Cit This work 
pMSCVpuro Vav1-Itk SH2 Cit This work 
pMSCVpuro Vav1-SLP-65 SH2 Cit This work 
pMSCVpuro Vav1-SLP-65 SH2 R372L Cit This work 
pMSCVpuro Vav1-Syk [SH2]2 Cit This work 
pMSCVpuro Cit Vav1-Rac1 This work 




pMSCVpuro Cit Vav1 L213Q-Rac1 This work 
pMSCVpuro Vav1 L213Q-Syk [SH2]2 Cit This work 
pMSCVpuro PIP5K1a Cit This work 
pMSCVpuro Cit [SH2]2 Syk-PIP5K1acore This work 
pMSCVpuro EGFP-rPLCγ2-PIP5K1acore This work 
pMSCVpuro hSLP-65 M. Engelke 
pMSCVpuro hSLP-65 Y72F This work 
pMSCVpuro hSLP-65 Y84F This work 
pMSCVpuro hSLP-65 Y119F This work 
pMSCVpuro hSLP-65 Y72/84F This work 
pMSCVpuro hSLP-65 Y72/119F This work 
pMSCVblast Ecotropic Receptor L. König 
pMSCVbleo CD8/Igα M. Engelke 
pMSCVbleo CD8/Igα Y204F M. Engelke 
 
Expression of GST-fusion proteins. 
Name Insert Source 
pGEX-4T1 Vav1 SH2 This work 
pGEX-4T1 Vav1 SH2 R696A This work 
pGEX-4T1 Syk [SH2]2 M. Engelke 
pGEX-4T1 C2 Vav1 This work 
pGEX-4T1 C2 Vav1 R696A This work 
pGEX-4T1 C2 Vav1-SLP-65 SH2 This work 
pGEX-4T1 C2 Vav1-Syk [SH2]2 This work 
pGEX-4T1 C2 Vav1-Btk SH2 This work 
pGEX-4T1 C2 Vav1-Itk SH2 This work 
 
TALEN and CRISPR/Cas cloning vectors. 
Name Source 
Golden Gate TALEN and TAL Effector Kit Addgene 
pTal4Titanium This work 
pFusA5A This work 
pFusA5B This work 
pFusA5C This work 




pFusB1B This work 
pFusB2B This work 
pFusB3B This work 
pFusB4B This work 
pSpCas9(BB)-2A-GFP Addgene 
 
Transient expression of gene targeting constructs. 
Name Insert Source 
pmaxKS IRES EGFP 22 This work 
pmaxKS IRES tagRFP 40 This work 
pmaxKS IRES EGFP 39 This work 
pmaxKS IRES tagRFP 55 This work 
pSpCas9(BB)-2A-GFP CC2 This work 
 
3.1.7 Antibodies 
Table 3.6: Antibodies used in this study. 
Primary antibodies. Antibodies were mixed in TBS-T with 1 % BSA and 0.01 % NaN3 and used according to 
the manufacturer’s instructions.   
Primary antibody Isotype Company 
α-Akt rabbit CST 
α-pAkt (Ser473) (D9E) rabbit CST 
α-Actin rabbit CST 
α-pBLNK (pTyr96) rabbit CST 
α-BLNK  mouse IgG2a BD 
α-CD79a (EP3618) rabbit Abcam 
α-CD79a (EPR6861) rabbit Abcam 
α-Erk (16) mouse IgG2a BD 
α-pErk1/2 (E10) mouse IgG1 CST 
α-GST rabbit Molecular Probes 
α-Lyn (44) rabbit Santa Cruz 
α-PLCγ2 (Q20) rabbit Santa Cruz 
α-Rac2 (C11) rabbit Santa Cruz 
α-Syk (4D10) mouse IgG2a Santa Cruz 
α-pTyr (4G10) mouse IgG2b Upstate 




α-Vav1 (D45G3) rabbit CST 
α-Vav2 rabbit Epitomics 
α-Vav3 rabbit Millipore 
 
Secondary antibodies. Antibodies were mixed in TBS-T 1:10000. 
Secondary antibody Isotype Company 
α-mouse IgG1-HRPO goat Southern Biotech 
α-mouse IgG2a-HRPO goat Southern Biotech 
α-mouse IgG2b-HRPO goat Southern Biotech 
α-mouse IgG-HRPO goat Southern Biotech 
α-rabbit IgG-HRPO goat Southern Biotech 
 
Antibodies for FACS. 
Antibody Isotype Company 
α-human CD8-FITC (Mem-31) mouse IgG2a Immunotools 
α-human CD19-PE mouse IgG1 MACS Milteny Biotec 
α-human IgM-APC mouse IgG1 Southern Biotech 
 
Antibodies for stimulation. 
Antibody Type/Isotype Company 
α-human CD8 (Mem-31) mouse IgG2a Provided by Vaclav 
Horejsi 
goat-α-human-IgM 




3.1.8 Synthetic peptides 
The biotinylated peptides of Igα used in this study were purchased from Eurogentec. 
Table 3.7: Synthetic peptides used in this study. 
Antibody Type/Isotype Company 
α-peptide I ENLYEGLNLDDCSMYEDISR Eurogentec 
p-α-peptide I ENLpYEGLNLDDCSMpYEDISR Eurogentec 
α-peptide II YEDISRGLQGTYQDVGN Eurogentec 
p-α-peptide II YEDISRGLQGTpYQDVGN Eurogentec 





Table 3.8: Instruments used in this study. 
Instruments Company 
Analytical balance MC1 Sartorius 
Bacteria incubator Heraeus Kelvitron®t Heraeus 
Bio Photometer  Eppendorf 
Cell culture incubator HeraCell 150 Heraeus 
Cell culture safety cabinet Herasafe Heraeus 
Centrifuge 5415D Eppendorf 
Centrifuge Multifuge 3 S-R Heraeus 
Centrifuge RC 3B Plus Sorvall 
Centrifuge 5417R Eppendorf 
Chemi Lux Imager Intas 
Confocal Laser scanning microscope TCS 
SP2 
Leica 
Cytometer LSRII BD 
Electrophoresis Power Supply Amersham Biosciences 
FACS Calibur BD 
Freezer HERAfreeze  Heraeus 
Freezer Platilab 340 Angelantoni 
Galaxy Mini centrifuge VWR 
Gel Electrophoresis system Peqlab 
Gel Imager Intas 
Ice machine Ziegra Eismaschinen 
Inverted microscope Axiovert 35 Zeiss 
Magnetic stirrer M21/1 Framo®-Gerätetechnik 
Mastercycler epgradient Eppendorf 
Mini-PROTEAN Tetra Electrophoresis 
System 
Bio-Rad 
MiniRocker MR-1 Peqlab 
NanoDrop 2000 Spectrophotometer Thermo Scientific 
Nucleofector®II Amaxa Biosystems 
pH meter InoLab 
Platform shaker Duomax 1040 Heidolph 
Platform shaker 3005 GFL 




Rotator SB3 Stuart 
SE 600 Ruby standard dual cooled vertical 
unit 
Amersham Biosciences 
Shaking Incubator Infors Unitron 
TE77 semidry western blot transfer unit GE Healthcare 
Thermomixer comfort Eppendorf 
Ultra-low Temperature Freezer (-150 °C) Panasonic 
Ultrasonic device Sonoplus Bandelin 
UV illuminator Intas 
Vortex-Genie 2 Scientific Industries 
Water bath GFL 
Water purification system arium® G11 Sartorius 
 
3.1.10 Software 
Table 3.9: Software used in this study. 
Software Company 
BD FACSDiva Software v 5.0.3. Flow cytometry data recording 
Citatvi 5 Bibliography editing 
Core DRAW X7 Graphic editing 
Intas Chemostar Immunoblot imaging 
FinchTV Sequencing viewer 
FlowJo (TriStar) Flow cytometry data analysis 
Gel documentation software GDS Gel imaging 
ImageJ Image editing 
Leica Confocal Software Imaging 
MS Office Text and image editing 
pDRAW 32 DNA sequence analysis 
 
3.1.11 Data base 
Table 3.10: Data base used in this study. 
Program Application 
http://crispr.mit.edu/ CRISPR/Cas design 
http://elm.eu.org (eukaryotic linear motif 
resource) 
Motif investigations 








http://www.ebi.ac.uk/Tools/msa/ Multiple alignment (clustalw2) 
http://www.ensembl.org Genomic blasts 
http://www.ncbi.nlm.nih.gov Genomic blasts 
 
3.2 Methods 
3.2.1 Molecular biology 
3.2.1.1 Bacteria strains 
Three different Escherichia coli (E. coli) strains were used during the PhD project. The 
bacteria strain E. coli Top10F’ (Invitrogen) was used in standard cloning experiments. For 
maintenance of basic TALEN plasmids (pHD1-10, pNG1-10, pNI1-10, pNN1-10), the 
bacteria strain E. coli GeneHog (Invitrogen) was used. In the case of protein expression 
experiments, I used the bacteria strain E. coli BL21. 
Table 3.11: Escherichia coli strains used in this study. 
Escherichia coli strains Genotyp 
Top10F’ F´[lacIq, Tn10(TetR)]mcrAΔ(mrrhsdRMS- 
mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(araleu) 7697 galUgalKrpsL 
(StrR) endA1 nupG 
GeneHog F- mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX74 recA1 araD139 
∆(ara-leu)7697 galU galK rpsL (StrR) 
endA1 nupG fhuA: IS2 (confers phage T1 
resistance) 
BL21 fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B 
int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
 
 




3.2.1.2 Media for bacteria 
LB-medium was used as growing medium for the E. coli strains Top10F’ and Gene Hog, 
whereas YT-medium was used for the E. coli strain BL21. 
LB-medium: 10 g/L tryptone YT-Medium: 16 g/L tryptone 
 5 g/L yeast extract  15 g/L yeast extract 
 5 g/L NaCl  5 g/L NaCl 
 pH 7.0   pH 7.0  
 
    →autoclaved (121 °C, 1.25 bar, 30 min) 
Selection was performed using LB-medium or YT-medium with the following antibiotic end 
concentrations:          
   Ampicillin  100 μg/ml     
   Kanamycin  50 μg/ml     
   Spectinomycin 50 μg/ml     
   Tetracyclin  10 μg/ml 
 
3.2.1.3 Agar plates 
Agar plates were cast with LB-medium containing 2 % (w/v) agar-agar, which was added 
before autoclaving (121 °C, 1.25 bar, 30 min). After cooling down to 60 °C, the required 
antibiotic was added and the LB-agar was poured in petri dishes. Agar plates were stored 
at 4 °C.  
 
3.2.1.4 Sterilisation procedure 
Solutions, culture media for bacteria and none-sterile consumables were autoclaved at 
121 °C and 1.25 bar for 30 min. 
 
3.2.1.5 Isolation and purification of nucleic acids 
3.2.1.5.1 Isolation of genomic DNA 
For the isolation of genomic DNA, 1x106 DG75 cells were lysed in 200 μl Tag-lysis buffer 
containing 1 μl proteinase K (20 mg/ml, Promega) for 2-3 h at 56 °C. Afterwards, the 
proteinase K was heat-deactivated at 95 °C for 15 min. Storage of genomic DNA was 
done at -20 °C. 




Tag-lysis buffer: 10 mM Tris/HCl pH 8 
 50 mM KCl 
 0.45 % NP40 
 0.45 % Tween20 
 in ddH2O 
 
3.2.1.5.2 Isolation of plasmid DNA (Mini-preparation) 
For the extraction of bacterial plasmid DNA, 4 ml LB-medium containing the required 
antibiotic were inoculated with one E. coli colony. After overnight incubation at 37 °C on a 
shaker, bacterial plasmid DNA was isolated using the Wizard® Plus SV Miniprep DNA 
Purification System (Promega) or the QIAprep® Spin Miniprep kit (Qiagen) according to 
the manufacturer’s instructions. 
 
3.2.1.5.3 Isolation of plasmid DNA (Midi-preparation) 
To gain higher amounts of bacterial plasmid DNA, 4 ml LB-medium containing the 
required antibiotic were inoculated with one E. coli colony. After 8 h incubation at 37 °C on 
a shaker, bacteria were used for a second inoculation of 250 ml LB-medium containing 
again the required antibiotic, followed by an incubation period at 37°C shaking overnight. 
Finally, isolation of bacterial plasmid DNA was performed with the Promega Pure YieldTM 
Plasmid Midiprep System kit according to the manufacturer’s instruction.     
 
3.2.1.5.4 Measurement of nucleic acid concentration 
Measurement of nucleic acid concentration was performed using a NanoDrop2000 
according to the manufacturer’s instructions. 
 
3.2.1.6 Cloning techniques 
3.2.1.6.1 Restriction of DNA using endonucleases 
Specific endonucleases (NEB) were used to cleave plasmids, vectors and PCR products 
to produce compatible sticky or blunt ends. Cleaved DNA fragments were used in ligation 
and transformation experiments. All enzymes in this study were used according to the 
manufacturer’s instructions.    
 




3.2.1.6.2 DNA gel extraction 
The extraction of DNA fragments out of agarose gels was performed using the Promega 
Wizard® SV Gel and PCR Clean-Up System kit according to the manufacturer’s 
instructions.  
 
3.2.1.6.3 Sub-cloning of PCR products 
For sub-cloning of PCR products, Taq-polymerase was used to amplify the desired DNA 
regions. The polymerase contains a transferase activity and thus adds further A-
nucleotides at the 3’-end of PCR products, called ‘A-tail’. After gel extraction, the PCR 
products can be directly used in ligation reactions with the pCR2.1 vector, which contains 
5’-T-overhangs.  
 
3.2.1.6.4 Ligation of DNA fragments 
Ligation reactions were performed with the T4 DNA ligase according to the manufacturer’s 
protocol. In the case of a preceded single endonuclease restriction reaction, the vector 
was treated with calf intestine phosphatase for 1 h at 37 °C. This removes phosphates 
from the 5’- and 3’-ends of linearized vectors and thus prevents vector religation. When 
two or more endonucleases were used for vector linearization, no calf intestine 
phosphatase treatment was performed. All endonuclease and phosphatase treated 
vectors were purified via agarose gel extraction using the Promega Wizard® SV Gel and 
PCR Clean-Up System kit. 
 
3.2.1.6.5 Transformation of competent bacteria 
Transformation of E.coli Top10F’ and GeneHog (50 μl) was done using 5-10 μl of the 
ligation reaction. After a 30 min incubation on ice, a heat shock was performed for 45 s at 
42 °C, followed by a 2 min incubation on ice. Subsequently, the transformation mix was 
incubated with 500 μl LB-medium without antibiotics for 30 min shaking at 37 °C. In the 
end, the complete transformation mix was plated on LB-plates containing the required 
antibiotic. Transformations of E.coli Top10F’ with the pCR2.1 and TALEN plasmid were 
performed with blue-white screening. Therefore, 50 μl X-gal (5-bromo-4-chloro-3-indolyl-
beta-D-galacto-pyranoside) (50 mg/ml in DMF) and 50 μl IPTG (Isopropyl-β-D-thiogalacto-
pyranoside) (0.1 M) had been distributed on agar plates before the transformation mix 
was added.  




3.2.1.7 Gel electrophoresis 
Gel electrophoresis was done using 1 % agarose gels containing 0.5 μg/ml ethidium 
bromide in TAE buffer. Before loading, samples were mixed with 6x DNA-loading buffer 
(NEB). DNA fragments were separated at 220 mA and 100 V for 30-50 min depending on 
the DNA fragment size. A 1 kb DNA-ladder (Fermentas) was used as scale to determine 
the size of DNA fragments.  
TAE buffer: 40 mM Tris/acetic acid pH 7.8 
 10 mM  NaOAc 
 1 mM EDTA 
  ddH2O 
  pH 8 
 
3.2.1.8 Polymerase chain reaction (PCR) 
The PCR reaction is used to amplify specific DNA fragments in-vitro (Erlich et al., 1988). It 
can be divided into three steps. First, double stranded template DNA is denaturized to 
allow annealing of oligonucleotides (primers) within the second step. Third, elongation of 
annealed primers is started using optimal conditions for the specific polymerase according 
to the manufacturer’s instructions. Repetition of the described three step process leads to 
vast amplification of DNA fragments.    
 
3.2.1.8.1 Standard PCR 
The standard PCR reaction was used to amplify specific DNA regions of genomic or 
plasmid DNA templates. In my PhD project, I exclusively used the phusion polymerase for 
DNA fragment amplification. The annealing temperature was chosen according to the 
primer3 software recommendation and elongation was performed following the 
manufacturer’s instructions. The basic PCR cycle is described in table 3.11. 
Table 3.12: Standard PCR cycle conditions. *with regard to the annealing temperature calculated with the 
primer3 software. 
Step Time Cycles Temperature 
Initial denaturation 2 min 1 98 °C 
Denaturation 20 s  98 °C 
Annealing 20-40 s     30 * 
Elongation 0.5-4 min  72 °C 
Final elongation 1-5 min 1 72 °C 




3.2.1.8.2 Overlap PCR 
The overlap PCR reaction was used to connect two different DNA fragments. To do that, 
phusion polymerase was used according to the PCR cycle program described in table 
3.11. However, the first 10 PCR cycles were carried out without primer to increase the 
amount of desired template using the internal overlapping DNA regions of the two DNA 
fragments as elongation start points. 
 
3.2.1.8.3 Sequencing PCR 
Sequencing was carried out by the Seqlab company. Samples were prepared according 
to the company guidelines. In brief, 1.2 μg DNA and 3 μl of primer (10 pmol/μl) were 
mixed with ddH2O in a total volume of 15 μl. 
 
3.2.2 Biochemistry 
3.2.2.1 Preparation of cleared cellular lysate 
Cleared cellular lysates (CCL) were prepared from resting or stimulated human cell lines 
or primary B cells to analyse proteins by western blotting. Therefore, 1x106 cells per 20 μl 
NP40-lysis buffer were lysed in 1.5 microcentrifuge tube for 30 min on ice. Afterwards, the 
cell lysates were centrifuged for 10 min, at 4 °C and 16000 x g. The resulting CCL was 
transferred into a new 1.5 microcentrifuge tube and the cell debris was discarded. In the 
end, the CCL was mixed with 3x Laemmli buffer, heated for 5 min at 95 °C and stored 
at -20 °C. 
NP40-lysis buffer: 0.1375 M  NaCl 
 0.05 M  Tris/HCl (pH 7.8) 
 1 mM  sodium-ortho-vanadate 
 0.5 mM  EDTA 
 10 %  Glycerol 
 1 %  NP40 
  + Protease inhibitor (Sigma P2714) 











3x Laemmli buffer:  62.5 mM  Tris/HCl pH 6.8 
 2 % (w/v)  SDS 
 0.025 % (w/v)  Bromphenol blue 
 20 % (v/v)  Glycerol 
 5 %  β-mercaptoethanol 
  in ddH2O 
 
3.2.2.2 Stimulation of B cells 
DG75 cells were harvested and washed once with 1x PBS (300 g, 4 °C, 4 min). Cells 
were resuspended in 1 ml FCS-free RPMI 1640 medium (R0) with a final cell number of 
3x107 DG75 cells/ml.  After the transfer of cells to 1.5 ml microcentrifuge tubes, they were 
incubated for 30 min at 30 °C to reduce pre-stimulatory effects of the FCS containing 
RPMI culture medium. Stimulation was done using 20 µg/ml anti-human IgM F(ab’)2 
fragments or 10 µg/ml anti-human CD8 antibodies for desired time points. Subsequently, 
DG75 cells were spun down in a microcentrifuge, the medium was discarded and cells 
were lysed in 200 μl NP40-lysis buffer per 1x107 DG75 cells on ice for 15-25 min. Then, 
cell debris was removed by centrifugation (16000 x g, 4 °C, 10 min) and the cleared 
cellular lysate (CCL) was transferred into a new 1.5 ml microcentrifuge tube. Afterwards, 
30 μl of the CCL was mixed with 3x Leammli buffer and incubated for 5 min at 95 °C for 
denaturation of proteins. The remaining CCL was used for affinity purification 
experiments. 
 
PBS: 137 mM NaCl 
 2.4 mM KCl 
 4.3 mM Na2HPO4 x 12 HPO4 
 1.4 mM  KH2PO4 
  ddH2O 
  pH 7.4 
 
3.2.2.3 Expression of recombinant GST-fusion proteins 
For the generation of GST-fusion proteins, the respective cDNA was cloned into the 
pGEX-4T1 vector (GE Healthcare). The resulting plasmid was transformed into the E.coli 
strain BL21 and plated on a LB-agar plate (37 °C, overnight). Next, an overnight culture 
was inoculated using one E.coli colony and 4 ml LB-medium containing ampicillin (37° C, 
shaking). The following day, the overnight culture was used to inoculate 200-300 ml YT-
medium containing ampicillin (37 °C, shaking). The expression of the GST-fusion protein 




was induced at OD 0.6 with 100 μM IPTG at 37 °C shaking for 4 h. In the case of low yield 
of GST-fusion protein, the temperature was reduced to 25 °C or 30 °C during protein 
expression. Afterwards, the bacteria were harvested in 50 ml tubes by centrifugation 
(3000 x g, 15 min, 4 °C) and the obtained bacteria pellet was stored at -80 °C.  
 
3.2.2.4 Preparation of recombinant GST-fusion proteins 
One bacteria pellet was resuspended in 20 ml cold 1x PBS and lysed by ultrasonification 
on ice (3x30 s, 1 cycle, 50 %). To support the lysis of bacteria, 200 μl 10 % Triton-X-100 
were added, followed by an incubation for 10-15 min on ice. Next, the bacteria cell debris 
was removed by centrifugation (3000 x g, 20 min, 4 °C). The supernatant was used for 
GST-fusion protein purification. For that purpose, 200 μl of gluthatione-sepharose beads 
were added to the supernatant, followed by a 2-3 h incubation at 4 °C on a rotator. 
Afterwards, beads were pelleted by centrifugation (400 x g, 5 min, 4 °C), the supernatant 
discarded and the beads transferred into a 1.5 ml microcentrifuge tube, followed by three 
washing steps with 1 ml cold 1x PBS (300 x g, 3 min, 4 °C). In the end, the beads were 
resuspended in 250 μl cold 1x PBS and stored at 4 °C.    
 
3.2.2.5 Elution of GST-fusion proteins 
200 µl of sepharose beads binding the desired GST-fusion protein were mixed with 100 µl 
reduced L-Glutahione (10 mM in 1x PBS) in a 1.5 ml microcentrifuge tube. The mixture 
was incubated for 10 min on a rotator at RT followed by a centrifugation step (500 x g, 5 
min, RT). The GST-fusion protein containing supernatant was transferred to a new 1.5 
microcentrifuge tube and stored at 4 °C, whereas the sepharose beads were mixed again 
with 100 µl reduced L-Glutahtione. In total, three elution cycles were performed. The 
preparation (3.2.2.4) as well as the elution of GST-fusion proteins were controlled by 
SDS-PAGE followed by Coomassie staining. For Coomassie staining, SDS-gels were 
incubated for 15 min at RT on a shaker. Afterwards, the Coomassie solution was replaced 
with tap water to de-stain the SDS-gel overnight.  
Coomassie staining solution: 0.1 % Coomassie Brilliant Blue R-250 
 40 % MeOH 
 10 % acetic acid 
 




3.2.2.6 Affinity purification (AP) 
Affinity purifications were perfomed in three different ways using either GST-fusion 
proteins, synthetic peptides or antibodies. For affinity purification with GST-fusion 
proteins, 15 μg of the desired GST-fusion protein was added to the CCL and incubated for 
4 h rotating at 4 °C. In the case of synthetic peptides, 2 μM of biotinylated peptides were 
added and incubated for 1 h rotating at 4 °C. Afterwards, 25 μl Streptavidin-sepharose 
beads were added, followed by 1 h incubation at 4 °C on a rotator. For the affinity 
purification with antibodies, 2 μg/ml anti-PLCγ2 antibodies were added to the CCL and 
rotated for at least one hour at 4° C. Following, 25 μl protein A/G-agarose beads (Santa 
Cruz Biotechnology, 50 % slurry) were added and incubated for one hour at 4° C on a 
rotator. In the end, beads were washed three times (300 x g, 5 min, 4 °C) with NP40-lysis 
buffer, mixed with 40 μl 3x Laemmli buffer, incubated for 5 min at 95 °C and subjected to 
western blot analysis or stored at -20 °C.  
 
3.2.2.7 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The separation of proteins from CCLs and affinity purification experiments was performed 
by SDS-PAGE. Therefore, proteins were denatured and reduced using Laemmli buffer 
(see chapter 3.2.2.1), so that the separation of proteins could be done according to their 
molecular weight (Weber and Osborn, 1969). Protein samples were concentrated in a 5 % 
SDS stacking gel (20 mA, 250 V per gel) and separated in a 10 % SDS resolving gel 
(20 mA, 300 V per gel). The determination of the protein size was done with the help of a 
prestained protein marker (broad range, 6.5-175 kDa, NEB).  
Resolving gel: 8 ml Lower buffer 
(1.5 M Tris/HCl pH 8.8, 
14 mM SDS, in ddH2O) 
 6 ml 30 % AA/BAA  
 13.4 ml ddH2O 
 30 μl TEMED 









Stacking gel: 3.75 ml Upper buffer 
(0.5 M Tris/HCl pH 6.8, 
14 mM SDS, in ddH2O) 
 2.4 ml 30 % AA/BAA  
 8.9 ml ddH2O 
 15 μl TEMED 
 150 μl 10 % APS  
 
SDS running buffer: 25 mM Tris/HCl 
 192 mM Glycine 
 0.1 % (w/v)  SDS 
  in ddH2O 
 
3.2.2.8 Western blot analysis 
The detection of SDS-PAGE separated proteins was done by western blot analysis. 
Therefore, proteins were transferred onto a nitrocellulose membrane by semi-dry blotting 
(Towbin et al., 1979). To this end, two Whattman paper, a nitrocellulose membrane and 
the SDS-polyacrylamide gel were soaked in blotting buffer and stacked according to the 
following arrangement: Whattman paper, membrane, gel, Whattman paper. Importantly, 
air bubbles were removed by rolling with a glass pipette for efficient blotting. Blotting was 
performed at 1 mA/cm2 for 60 min.  
Blotting buffer: 48 mM Tris/HCl 
 39 mM Glycine 
 0.0375 % (v/v) SDS 
 20 % MeOH 
  in ddH2O 
   
3.2.2.9 Immunostaining  
Immunostaining was performed to visualize proteins that were previously transferred onto 
a nitrocellulose membrane. Here, specific antibodies (primary antibodies), which bind to 
the proteins of interest, and secondary HRPO-coupled antibodies, which recognize the 
Fc-region of primary antibodies, were used in combination with the ECL detection system 
for protein visualization. To do this, the membrane was blocked with 5 % BSA in TBS-T 
for 1 h at RT on a shaker, followed by two washing steps with TBS-T in excess for 5 min 
each. Incubation with the primary antibodies was done overnight shaking at 4 °C. Next 




day, the membrane was washed three times with TBS-T in excess and incubated with 
secondary antibodies for 1 h at RT on a shaker. In the end, the membrane was washed 
again three times with TBS-T in excess and visualization of proteins was done using 4 ml 
ECL solution in combination with the Chemilux Camera System (Intas). 
TBS-T: 25 mM Tris/HCl pH 8.0 
 125 mM NaCl 
 0.1 % Tween20 
  in ddH2O  
adjust to pH 7.4 
 
ECL solution: 4 ml Solution A: 250 mg/ml Luminol in 0.1 M Tris/HCl 
pH 8.6 
 400 μl Solution B: 1.1 g/L para-hydroxycoumaric acid in 
DMSO 
 1.2 μl 30 % H2O2  
 
3.2.3 Cell biology 
3.2.3.1 Media for cell culture  
Media for cell culture were bought from the company Biochrom. For culturing of DG75, 
HEK 293 and Plat E cells further ingredients were added: 
Medium for DG75, HEK 293 and Plat E cells (R10): RPMI 1640 (+GlutaMax) 
 10 % FCS 
 1 % Penicillin/Streptomycin 
 1 mM L-glutamine 
 50 μM ß-mercaptoethanol 
 
3.2.3.2 Cell lines 
DG75 (DSMZ-No: ACC 83) 
The DG75 cell line constitutes the human B cell model cell line in my PhD project. It was 
derived from a pleural diffusion of a 10-year-old boy with a burkitt lymphoma (refractory, 
terminal) in 1975. It is a male, diploid B cell line with the translocation: t(8;14)(q24;q32) 
(Ben-Bassat et al., 1977). 




Table 3.13: DG75 characteristics. – indicates not detected, + indicates detected characteristics in 
immunology and viruses. 
Topic Characteristic 
Immunology CD3 -, CD10 +, CD13 -, CD19 +, CD34 -, 
CD37 +, CD38 +, CD80 +, CD138 -, HLA-
DR +, cyIgG -, cyIgM +, cykappa +, 
cylambda - 
Fingerprint multiplex PCR of minisatellite markers 
revealed a unique DNA profile 
Cytogenetic human near diploid karyotype with 6% 
polyploidy - 46<2n>XY, t(8;14)(q24;q32) 
Viruses ELISA: reverse transcriptase negative; 
PCR: EBV -, HBV -, HCV -, HHV-8 -, HIV -, 
HTLV-I/II -, MLV -, SMRV - 
 
In my PhD project, different DG75 sub-lines were used in genetic and biochemical 
approaches. To this end, DG75 cells were equipped with an ecotropic receptor (referred 
to as EB) to enable retroviral infection with Moloney Murine Leukemia Virus.  
Table 3.14: DG75 knock out sub-lines. 
DG75 genetic background Reference 
RAC2-/- This work 
SLP-65-/- This work 
VAV1-/- This work 
 
HEK 293  
The HEK (human embryonic kidney) 293 cell line is an adherent cell line that is often used 
in cell biology due to its easy handling. In this project, HEK 293 cells were exclusively 
used as negative control for Vav1 expression.  
 
Platinum E (Plat E) 
The Plat E cell line (platinum retroviral packaging cell line) originates from HEK 293 cells. 
It contains Moloney Murine Leukemia Virus (MMLV) genes, which are stably integrated 
into the genome, coding for gag, pol and env proteins. For the generation of a virus that 




can infect non-murine cells, Plat E cells are transiently transfected with a plasmid 
encoding for the glycoprotein of the vesicular stromatitis virus (VSV-G) enabling efficient 
infection (Morita et al., 2000). In the case of DG75 EB cells, additional transient 
transfection of Plat E cells with VSV-G constructs is not necessary any more due to the 
ecotropic expressed receptor.  
 
3.2.3.3 Cell culture of none-adherent cells 
The none-adherent human DG75 cell line (3.2.3.2) was used as model system in my PhD 
project. Cells were grown in culture dishes using R10 an incubated in a HeraCell 150 
incubator with 5 % CO2 at 37 °C. Every second day, cells were passed 1:10. 
 
3.2.3.4 Cell culture of adherent cells 
The adherent Plat E and HEK 293 cell lines were cultured under the same conditions as 
DG75 cells. For passaging, medium was removed, cells were washed once with 1x PBS 
and treated with 0.05 % trypsin-EDTA (Invitrogen) to detach them from the bottom of the 
culture dish. Subsequently, fresh R10 medium was added to dilute the trypsin-EDTA, 
which stops the detachment process. Every second day, cells were passed 1:10. 
 
3.2.3.5 Long-term storage of cells 
Cells were harvested (300 x g, 5 min, RT) and resuspended in freezing medium (10 % 
DMSO in FCS) with a cell number of 1x107 cells/ml. After the transfer into a cryo-tube, 
cells were stored subsequently at -80 °C in a polystyrene box. The next day, the cryo-
tubes were placed at -150 °C for long-term storage. 
 
3.2.3.6 Revitalization of cells 
Cells stored at -150 °C were thawed in a water bath (37 °C). Subsequently after thawing, 
cells were transferred into 9 ml fresh medium (RT). Cells were centrifuged (300 x g, 4 °C, 
5 min), the supernatant was discarded and cells were taken up in 10 ml fresh medium 
(RT). 
 
3.2.3.7 Isolation of primary human B cells 
Blood samples were taken from volunteers using syringes coated with heparin to prevent 
clotting of blood. Blood was transferred into 50 ml tubes and mixed 1:1 with 1x PBS 




containing 1 mM EDTA. The equal amount of Ficoll (Amersham Bioscience) was provided 
in a fresh 50 ml tube and the blood-PBS mix was transferred by very gently pipetting. 
Centrifugation of the Ficoll gradient was done using 800 x g, 20 min and RT (lowest 
setting for break). Afterwards, the PBMC ring (interface) was carefully transferred into a 
new 50 ml tube. Washing of PBMCs was done with 30 ml 1x PBS containing 1 mM EDTA 
and 0.5 % BSA (300 x g, 15 min, RT). The PBMC pellet was resuspended in 20 ml of the 
previous buffer and cells were counted. Two 100 μl aliquots were taken and kept on ice 
for later FACS analysis.  
B cell purification was performed using the B cell purification kit II (MACS Milteny). 
PBMCs were centrifuged (300 x g, 10 min, RT), the supernatant completely aspirated and 
the cell pellet resuspended in 40 μl MACS buffer per 10x106 cells. Afterwards, 10 μl 
Biotin-antibody-cocktail per 10x106 cells were added, mixed and incubated for 5 min at 
4° C. Subsequently, 20 μl Biotin-antibody-cocktail per 10x106 cells were added, mixed and 
incubated for 10 min at 4 °C. The minimal volume for magnetic separation is 500 μl, so 
that the volume was adjusted with MACS buffer. LS-column was placed to the separator 
and rinsed with 3 ml MACS buffer. The cell suspension was added and the flow through 
was collected in a 15 ml tube. In addition, 3 ml MACS buffer were added to the column 
and collected. Eluted B cells were counted and aliquots were taken for purity control using 
FACS analysis with anti-human CD19-Pe and anti-human IgM-APC antibodies.     
MACS buffer: 1x PBS 
 0.5 % BSA 
 2 mM EDTA 
 pH 7.2 
 
3.2.3.8 Transfection methods 
3.2.3.8.1 Transfection via nucleofection 
Nucleofection of DG75 cells was done using the Lonza Human B cell Nucleofector® Kit 
according to the manufacturer’s instructions. In brief, 2x106 cells were harvested (90 g, 10 
min, RT), the supernatant was completely removed and cells were resuspended in the 
nucleofection mix containing 82 μl human B cell Nucleofector® solution and 18 μl 
supplement 1. After addition of 2 μg plasmid DNA, the cell suspension mix was 
transferred into a nucleofection cuvette and nucleofection was done using the Amaxa 
NucleofectorTM II (program T-015). In the case of a nucleofection with two plasmids, 2 μg 
of plasmid DNA were used of each plasmid. Finally, cells were cultured on a 6 well plate 
containing 2 ml pre-warmed R10 medium per well. 




3.2.3.8.2 Retroviral transfection/infection 
For retroviral transfection, the packaging cell line Plat E was used, which expresses 
gag/pol and env genes derived from the Moloney Murine Leukemia Virus (MMLV). 24 h 
before retroviral transfection, roughly 1.5x106 cells were seeded on a 6 cm dish to reach 
60-70 % confluence the next day. For transfection, 250 μl R0 medium were mixed with 8 
μl Trans-IT solution (Mirus) and 3-4 μg plasmid DNA, followed by 30 min incubation at RT. 
In the meanwhile, the old R10 medium from Plat E cells was replaced with 2 ml fresh, pre-
warmed R10 medium. The transfection mix was carefully distributed over the Plat E cells. 
After 24 h, further 3 ml R10 medium were added carefully on the 6 cm dish, so that Plat E 
cells were not detached from the plate bottom. Further 24 h later, the virus containing 
Plat E supernatant was taken and centrifuged for 5 min at 300 x g and RT to remove 
detached Plat E cells from the virus supernatant. Simultaneously, 1-2x106 DG75 cells 
were centrifuged using the same conditions. After removing the supernatant from DG75 
cells, 4 ml virus supernatant was used to resuspend the DG75 cells and to plate them on 
a 6 cm culture dish. In addition, 1 ml R10 medium supplemented with the cationic polymer 
polybrene (Sigma) with a final concentration of 3-4 μg/ml was added to the cells. After 
48 h, infection was stopped by replacement of the virus containing medium with 5 ml R10 
medium (300 x g, 5 min, RT). The next day, cells were selected by the addition of the 
required antibiotic. 
Antibiotic Concentration 
Puromycin 1 μg/ml 
Blasticidin 10 μg/ml 
Bleomycin 50 μg/ml 
 
3.2.3.9 Flow cytometry 
3.2.3.9.1 Expression analysis of surface receptors 
To measure the amount of cell surface receptors, 0.5-1.0x106 DG75 cells were harvested 
and washed once with 4 ml 1x PBS (300 x g, 5 min, RT). The supernatant was discarded 
and the remaining cell pellet resupended in 100 μl 1x PBS containing 1 μl of anti-human 
IgM-APC (0.1 mg/ml), anti-human CD19-PE or anti-human CD8-FITC. After a 20 min 
incubation on ice in the dark, cells were washed once with 1x PBS (300 x g, 5 min, RT) 
and subjected to flow cytometry. 
 




3.2.3.9.2 Expression analysis of ectopic expressed fluorophore-tagged proteins 
For expression analysis of fluorophore-tagged proteins, approximately 0.5x106 cells were 
washed once with 3-4 ml 1x PBS (300 x g, 5 min, RT), resuspended in 400 μl 1x PBS and 
subjected to flow cytometry.  
 
3.2.3.9.3 Cell sorting 
Cell sorting was done in cooperation with the cell sorting facility of the university medical 
center. In brief, 1-5x106 cells were washed once with 10 ml 1x PBS (300 x g, 5 min, RT) 
and resuspended in 500 μl 1x PBS for cell sorting. Cells were stored on ice until the 
beginning of cell sorting. Afterwards, cells were washed and resuspended in R10 medium 
(300 x g, 5 min, RT).    
 
3.2.3.9.4 Analysis of Ca2+-mobilization 
Ca2+-mobilization measurements were done to investigate Ca2+ changes within the 
cytoplasm of DG75 cells after BCR stimulation. The measurement is based on a Ca2+ 
sensitive dye, named Indo-1 AM, which changes its fluorescence emission from ~475 nm 
to ~400 nm after binding of Ca2+. For Ca2+-mobilization measurement, 2-3x106 DG75 cells 
per sample were centrifuged at 300 x g, 5 min, RT. The supernatant was discarded, cells 
were resuspended in 500 μl R10 and transferred into light protected tubes. After the 
addition of 200 μl master mix containing 1 μM Indo-1 and 0,015 % pluronic acid, cells 
were incubated for 20 min shaking at 30 °C, followed by an incubation for 10 min shaking 
at 37 °C (Grynkiewicz et al., 1985). Next, cells were washed twice with 1x Krebs-Ringer 
solution containing 1 mM CaCl2 (300 x g, 3 min, RT). Finally, cells were resuspended in 
900 μl 1x Krebs-Ringer solution (1 mM CaCl2) and kept on 30 °C for 30 min before 
measurement. Measurements were recorded with the LSRII (Becton Dickinson, San Jose, 
CA, USA). A 25 s base line was recorded before cells were stimulated with 20 μg/ml anti-
human IgM F(ab’)2 fragments. The total measurement time was set to 5 min. 
Krebs-Ringer buffer: 10 mM HEPES, pH 7.0 
 140 mM NaCl 
 4 mM KCl 
 1 mM MgCl2 
 1 mM CaCl2 
 10 mM glucose 
  in ddH2O 




3.2.3.10 Confocal microscopy 
A confocal laser scanning microscope was used (Leica, objective HCX OL APO 63.0x1.32 
OIL UV) to detect the intracellular localization of fluorescent labeled proteins. To do this, 
0.5-1.0x106 DG75 cells were washed twice with 1 ml 1x Krebs-Ringer buffer containing 1 
mM CaCl2 (300 x g, 3 min, RT), resuspended in 400 μl 1x Krebs-Ringer buffer (1 mM 
CaCl2) and transferred into a 4-well chamber. After 20-30 min of cell settlement, images 
were recorded before and 3 min after stimulation with 20 μg/ml α-human IgM F(ab’)2 
fragments. For each measurement, a 4x digital zoom was used.      
 
3.2.4 Gene targeting methods 
3.2.4.1 Transcription Activator-like Effector Nucleases - TALEN 
TALEN is a gene targeting method that can be used to generate knock out cell lines. It is 
based on transiently expressed fusion proteins that contain a DNA binding segment for 
specific DNA targeting and an endonuclease that introduces DNA double-strand breaks. 
The plasmid kit used for the generation of TALENs was a gift from Daniel Voytas and 
Adam Bogdanove (Addgene kit # 1000000024). The generation of TALEN constructs was 
done according to the manufacturer’s protocol. Noteworthy, changes within the TALEN 
vectors were done for improved TALEN assembly and efficiency.  
 
Design of TALEN constructs 
The design of TALEN constructs was done with the help of the TALEN targeter software. 
Here, the desired Exon sequence was analysed for possible TALEN sites. TALEN 
constructs were chosen that have the following attributes: 
1. TALEN constructs contain 15-18 DNA binding modules. 
2. The spacer region between the two TALEN constructs is 17 bp in size. 
3. The predicted TALEN cleavage site overlaps with a endonuclease 
binding/restriction site for later activity screening.  
     
Assembly of TALEN constructs - Optimization of the Golden Gate Ligation 
TALEN constructs were assembled according to the protocol of the Voytas lab. For the 
assembly, the Golden Gate Ligation method is used to minimize the number of cloning 
steps. Following the protocol, up to ten cDNAs encoding DNA binding modules can be 




cloned in one cloning step. However, the procedure revealed some obstacles regarding 
efficiency and reliability. Therefore, I reconstructed the Golden Gate Ligation kit. In detail, I 
changed the DNA backbone of the cloning vectors resulting in different sticky ends, so 
that I divided a ‘10 module cloning step’ in two ‘5 module cloning steps’. Hence, I also had 
to change sticky ends of additional cloning vectors to ensure a consensus of sticky ends 
and to allow cloning into the backbone vector. Changes are outlined below: 
Table 3.15: Optimization of Golden Gate Ligation kit. 
Old vector Number of modules New vector Number of modules 
pFusA30A 10 modules pFusA5A 5 modules 
pFusA30B 10 modules pFusA5B 5 modules 
pFusB5 5 modules pFusA5C 5 modules 
pFusB1 1 module pFusB1B 1 module 
pFusB2 2 modules pFusB2B 2 modules 
pFusB3 3 modules pFusB3B 3 modules 
pFusB4 4 modules pFusB4B 4 modules 
 
Example of the TALEN construct 22 used for the generation of a Vav1-deficient DG75 
sub-line: 
Table 3.16: Vectors and modules used for the generation of TALEN construct 22. 
Vector Number of modules Modules 
pFusA5A 5 modules pNI, pHD, pNI, pHD, pHD 
pFusA5B 5 modules pHD, pNG, pNN, pNG, pHD 
pFusB4 4 modules pNG, pNN, pHD, pNG 
pLR-HD half module half HD module 
pTAL4Tit final backbone Containing FokI endonuclease, NLS, HA-tag 
 
In addition, I changed the vector backbone of the pTAL4 vector that contains the FokI 
endonuclease cDNA and renamed the new designed backbone vector into 
pTAL4Titanium (pTAL4Tit). Changes were done according to Miller et al.. Here deletions 
were introduced into the DNA backbone, reducing the linker regions N-terminal and C-
terminal of the DNA binding modules. In addition, I introduced ‘SHARKEY’ mutations in 
the FokI endonuclease leading to a higher activity without increasing off-target effects 
(Guo et al., 2010). To enable TALEN protein expression determination by western blot 
analysis, I introduced an HA-tag N-terminal of the TALEN construct. Finally, to increase 
translation efficiency, I equipped the pTAL4Tit vector with a Kozak consensus sequence 




5’ of the TALEN start codon. The described changes are shown in figure 4.1 in the results 
chapter. 
 
Nucleofection and expression of TALEN constructs 
For expression of TALEN proteins the pmax vector from the company LONZA was used. 
This was modified by Niklas Engels with a multiple cloning site derived from the 
pBlueScript KS vector and an IRES-EGFP site (pmaxKS IRES-EGFP). In addition, I 
introduced an AflII restriction site into the multiple cloning site and erased a present AflII 
site from the vector backbone. Furthermore, I used the newly designed vector backbone 
to generate the pmaxKS IRES-tagRFP vector. The pmaxKS IRES-EGFP and pmaxKS 
IRES-tagRFP were used for transient expression of TALEN constructs. Nucleofection of 
TALEN constructs was done using the Lonza Human B cell Nucleofector® Kit. 
 
Cell sorting, activity test and sub-cloning of DG75 cells 
36-48 h after nucleofection, cells were sorted for EGFP/tagRFP double-positive cells in 
the cell sorting facility of the university medical center. After recovery of the cells, they 
were used in a TALEN activity test. Therefore, a proportion of cells were harvested (300 x 
g, 5 min, RT) and genomic DNA was isolated. Afterwards, the targeted exon region was 
amplified by PCR, purified and used in the TALEN activity assay with an endonuclease, 
whose binding/restriction site overlaps with the TALEN target site. In the case of a high 
TALEN activity, exon restriction should be dramatically diminished. If TALEN constructs 
were active, cells were sub-cloned onto 96-well plates and grown until a sufficient number 
of cells was reached for western blot analysis. 
 
3.2.4.2 CRISPR/Cas 
The CRISPR/Cas gene targeting method was used according to Ran et al. 2013. In my 
project, I used the pSpCas9(BB)-2A-GFP vector for CRISPR/Cas gene targeting. The 
pSpCas9(BB)-2A-GFP (PX458) vector was a gift from Feng Zhang (Addgene plasmid 
# 48138). This offers the advantage of a one vector system, which encodes for all 
necessary elements. The design of CRISPR/Cas constructs was done with the help of the 
CRISPR/Cas Design software. Constructs were chosen that showed a high score 
indicating a low number of off-target sites and that had an overlapping targeting site with 
an endonuclease binding/restriction site. Assembly of the CRISPR/Cas construct is faster 




compared to the TALEN system, since only a phosphorylated 25 bp oligonucleotide dimer 
has to be cloned into the backbone vector. Phosphorylated oligonucleotides were ordered 
from Eurofins Genomics. Cloning of oligonucleotides was done according to the protocol 
of the Feng Zhang group (Ran et al., 2013). Further steps are identical to the TALEN gene 






4.1 The guanine nucleotide exchange factor Vav1 is a key 
regulator of BCR-proximal signaling in human B cells 
4.1.1 Establishment of the TALEN method to generate a Vav1-deficient sub-
line of DG75 
In order to investigate the function of the guanine nucleotide exchange factor (GEF) Vav1 
in BCR-proximal signaling events in a human B cell line, I had to establish the recently 
developed Transcription Activator-like Effector Nuclease (TALEN) gene targeting method 
in our laboratory. The TALEN method is based on chimeric proteins that can introduce 
DNA double strand breaks (DSBs) in specific genomic DNA loci. The DSB repair 
mechanisms of cells are error prone, so that insertions or deletions frequently occur at the 
repair site that can cause frame shift mutations, which lead to a disturbed gene 
expression (Cermak et al., 2011; Sanjana et al., 2012).     
An individual TALEN protein consists of an N-terminal nuclear localization signal (NLS), a 
central DNA binding region and a C-terminal FokI nuclease, which needs to dimerize to be 
enzymatically active (figure 4.1 A). The central DNA binding region is composed of 15-30 
DNA binding modules that contain 34 amino acids each. In total, four different module 
types exist, which have a nearly identical amino acid sequence. Only the amino acids at 
positions 12 and 13 differ between the DNA binding modules. This amino acid pair is 
responsible for the DNA contact with the respective nucleotide and thus determines the 
module’s binding specificity (figure 4.1 A). For genomic targeting, two TALEN constructs 
have to bind 17-18 base pairs (bps) apart from each other on opposite DNA strands to 
allow efficient FokI dimerization and activity (figure 4.1 B). 
For generation of TALEN constructs, the Golden Gate TALEN assembly kit was retrieved 
from Addgene and used following the instructions of the Voytas lab (Cermak et al., 2011). 
However, some changes were made to increase TALEN efficiency according to the 
modifications described by the group of Rebar (Miller et al., 2011). Deletions within the 
regions N-terminal and C-terminal of the DNA binding region were made to increase 
TALEN efficiency (figure 4.1 C). In addition, deletions reduced the final vector size, thus 
improving transfection rates. Furthermore, two amino acid substitutions S418P and K441E 
(‘SHARKEY’ variant) inside the FokI nuclease were introduced to increase FokI activity 
(Guo et al., 2010). Moreover, a Kozak consensus sequence was introduced into the 





TALEN proteins in the transfected cells. For detection of the TALEN proteins via western 
blot, they were equipped with an N-terminal HA-tag (figure 4.1 C).  
 
Figure 4.1: Schematic overview of the TALEN method. A) Schematic drawing of the domain architecture of 
an individual TALEN construct, which is composed of a N-terminally located nuclear localization signal (NLS), 
an array of centrally located DNA binding modules, which are followed by a linker region and the FokI 
nuclease domain at the C-terminal end. The central DNA binding modules are composed of 34 amino acids 
each. The amino acids at positions 12 and 13 are responsible for DNA interaction and determine the 
specificity of the module. Four different DNA binding modules exist, which specifically bind to their respective 
nucleotide. B) Schematic drawing of a TALEN construct pair binding its genomic target. The TALEN 
constructs have to bind 17-18 base pairs apart from each other at opposite DNA strands to achieve efficient 
FokI dimerization and cleavage of DNA. C) Schematic drawing of TALEN construct modifications to improve 
TALEN efficiency. TALEN constructs were equipped with an HA-tag to allow detection via western blot. In 
addition, two amino acids substitutions (SHARKEY variant) within the FokI nuclease were introduced to 
increase FokI enzymatic activity. Furthermore, N-terminal and C-terminal deletions in linker regions were 
generated to decrease the size of TALEN constructs and thus improving transfection efficiency of TALEN 
expression vectors. Finally, a Kozak sequence was introduced 5’ of start codons of the TALEN constructs to 






For the expression of TALEN constructs, the pmax vector from the company Lonza was 
used because of its minimal size of 2.8 kbps. It was equipped with either an IRES-EGFP 
(pmax-IE) or an IRES-tagRFP (pmax-IR) cassette, respectively, to allow for indirect 
expression control of the TALEN constructs as well as sorting of doubly transfected cells 
to increase the overall efficiency. 
After optimization of TALEN constructs and expression vectors, the gene targeting system 
was used to generate a Vav1-deficient variant of the human B cell line DG75. As target 
site, the VAV1 exon 3 was chosen, since it is contained in all described protein coding 
VAV1 mRNA isoforms (based on Ensembl data base, figure 4.2 A). Furthermore, TALEN 
constructs were designed in a way that the restriction enzyme AvaII could be used for 
TALEN activity screening.  
Cloning of TALEN constructs was done as described in chapter 3.2.4.1. The TALEN 
constructs 22 and 40 cloned into pmax-IE and pmax-IR, respectively, were nucleofected 
into DG75 cells to achieve a transient construct expression. Next, EGFP/tagRFP double-
positive cells were sorted to get rid of all non-transfected or single-transfected cells. 
Roughly 6 % double positive cells were collected for further cultivation and subsequent 
analysis (figure 4.2 B). 
To test the activity of the TALEN construct pair 22/40, genomic DNA was isolated from 
EGFP/tagRFP-sorted cells as well as parental DG75 cells and the exon 3 containing 
genomic region (referred to as ‘exon 3’) of VAV1 was amplified via PCR. The ‘exon 3’ 
amplicon was cut using the restriction enzyme AvaII, whose binding site overlays with the 
TALEN target site (see figure 4.2 A). Figure 4.2 C shows that the ‘exon 3’ of parental 
DG75 cells was completely cut by the AvaII restriction enzyme, whereas the amplicon of 
TALEN-treated DG75 cells was not cut at all indicating that the AvaII site was damaged by 
TALEN mediated indel (insertion/deletion) mutations. In conclusion, the TALEN construct 
pair 22/40 is active in DG75 cells. To further verify TALEN activity, sequencing of the 
‘exon 3’ amplicon from the sorted DG75 cells was performed (figure 4.2 D). The 
sequencing chromatogram shows that the ‘exon 3’ was derived from a polyclonal 
population. 
To isolate Vav1-deficient clones from the polyclonal population, sorted DG75 cells were 
sub-cloned by limited dilution and the resulting cell clones were analyzed by western blot 
for Vav1 protein expression. Figure 4.2 E shows that twelve analyzed clones (#1 - #12) 
lack Vav1 expression, which indicates that the generation of Vav1-deficient DG75 cell 
clones was successful. Altogether, 36 clones were tested for Vav1 expression, 33 of 






Figure 4.2: Generation of a Vav1-deficient DG75 sub-line. A) Schematic drawing of the VAV1 genomic 
organization indicating the TALEN target region in exon 3. B) DG75 cells were nucleofected with pmax 
expression vectors containing the TALEN constructs 22 and 40 along with either an IRES-EGFP or IRES-
tagRFP cassette. Subsequently, double-positive cells (GFP+, RFP+ gate) were sorted for further cultivation. 
C) To test the activity of the TALEN construct pair 22/40, the genomic region containing the targeted VAV1 
exon 3 was amplified by PCR and cleaved with the restriction enzyme AvaII. The AvaII binding site overlaps 
with the TALEN target site and therefore can be used for TALEN activity testing. D) Sequencing result of the 
VAV1 ‘exon 3’ amplicon from sorted cells. The predicted targeting site of TALEN constructs 22 and 40 is 
indicated. E) Screening of DG75 cell clones for Vav1 deficiency was done using western blot analysis. 
Cleared cellular lysates of 1x10
6
 DG75 cells were loaded per lane and separated by SDS-PAGE. Immunoblots 
were probed with anti-Vav1 and anti-Actin antibodies as indicated below individual blots. The molecular weight 
of marker proteins (in kDa) is indicated on the left. F) Characterization of Vav1-deficient DG75 clone #2 was 
done by cloning the VAV1 ‘exon 3’ amplicon into the pCR2.1 vector and subsequent sequencing of individual 





To analyze the underlying genetic alterations that cause the loss of Vav1 protein 
expression, the Vav1-deficient DG75 clone #2 was used for further characterization. To 
sequence both VAV1 alleles separately, the VAV1 ‘exon 3’ amplicon was cloned into the 
pCR2.1 cloning vector. The sequencing results show that both alleles carry nucleotide 
deletions (figure 4.2 F). In detail, allele 1 has a deletion of 5 nucleotides, whereas allele 2 
has a deletion of 16 nucleotides resulting in premature stop codons in both cases. DG75 
VAV1-/- clone #2 was used in all following experiments and is hereafter referred to as 
Vav1-deficient DG75 cells.   
 
4.1.2 Vav1 is essential for BCR-induced Ca2+-mobilization 
Since Vav1 is described to be an essential regulator of various signaling pathways 
including BCR signaling (see introduction), the generation of a Vav1-deficient DG75 cell 
line using the TALEN method opened new opportunities for Vav1 investigations.  
One key event in BCR signaling is the influx of Ca2+ from the endoplasmic reticulum (ER) 
and external sources into the cytoplasm of B cells. For that reason, I investigated the 
influence of Vav1 on Ca2+-mobilization upon BCR stimulation in DG75 cells. Figure 4.3 A 
shows that the three Vav1-deficient DG75 cell clones #2, #3 and #6 have a dramatically 
reduced Ca2+-mobilization compared to parental DG75 cells, which indicates an obligatory 
role of Vav1 for BCR-induced Ca2+-mobilization. To exclude that the observed phenotype 
is caused by off-target TALEN effects, Vav1-deficient cells were reconstituted with a 
Citrine-tagged variant of wild-type Vav1. Figure 4.3 C shows that this reconstitution 
restored BCR-induced Ca2+-mobilization and even led to elevated Ca2+-mobilization upon 
BCR stimulation compared to parental DG75 cells. In accordance, additional ectopic 
expression of wild-type Vav1 in DG75 cells also led to an elevation of Ca2+-mobilization 
compared to parental cells (figure 4.3 E,F,G). In conclusion, BCR-induced Ca2+-
mobilization requires the presence of Vav1 and its intensity is regulated by the amount of 






Figure 4.3: Vav1 controls Ca
2+
-mobilization upon BCR stimulation in DG75 cells. A) Parental DG75 as 
well as Vav1-deficient cell clones #2, #3 and #6 were analyzed for Ca
2+
-mobilization upon BCR stimulation. 
Cells were loaded with the Ca
2+
-sensitive fluorophore Indo-1 AM in order to measure intracellular Ca
2+
-
changes by flow cytometry. After base line recording for 25 s, cells were stimulated with 20 μg/ml anti-human 
IgM F(ab’)2 fragments (α-IgM) as indicated by an arrow. The graph is representative of three independent 
experiments. B) Surface BCR expression measured by flow cytometry. Surface staining was performed using 
anti-human IgM-APC antibodies. The unstained negative control is depicted in black. Samples have the same 
color code as in A). C) Vav1-deficient DG75 cells expressing Citrine-tagged wild-type Vav1 were analyzed for 
Ca
2+
-mobilization as in A). Parental DG75 cells were used as positive and Vav1-deficient DG75 cells as 
negative control, respectively. D, F) Expression levels of Citrine-tagged proteins were determined by flow 
cytometry. E) DG75 cells expressing Citrine-tagged wild-type Vav1 were analyzed for BCR-induced Ca
2+
-





Cleared cellular lysates of 1x10
6
 DG75 cells were loaded per lane and separated by SDS-PAGE. Immunoblots 
were probed with anti-Vav1 and anti-Actin antibodies as indicated below individual blots. The molecular weight 
of marker proteins (in kDa) is indicated on the left. 
 
4.1.3 Vav1 and Vav3 control Ca2+-mobilization upon BCR stimulation in 
DG75 B cells 
Vav1 is expressed exclusively in the hematopoietic cell lineage indicating that it has 
specialized functions in these cells. However, the Vav protein family contains two 
additional family members, namely Vav2 and Vav3, which may also have important 
functions in BCR signaling. Therefore, I investigated the expression of Vav proteins in 
primary and DG75 B cells by western blot analysis with antibodies against the three Vav 
family members. Differences were observed with regard to the abundance of individual 
Vav members. Vav1 levels are elevated in DG75 cells, whereas Vav2 and Vav3 have a 
higher abundance in primary B cells (figure 4.4 A).  
Having shown the expression of all Vav family members in human DG75 B cells, the 
question arose whether Vav2 and Vav3 have a function in BCR signaling. To analyze their 
influence on BCR-induced Ca2+-mobilization, Vav1-deficient DG75 cells were retrovirally 
transfected with constructs encoding Citrine-tagged Vav2 or Vav3 followed by Ca2+-
mobilization analysis. Figure 4.4 B shows that Vav2 was not capable to replace Vav1 in 
Ca2+-mobilization upon BCR stimulation, even though it was expressed in higher amounts 
(figure 4.4 C). In contrast, additional ectopic expression of Vav3 did not only restore the 
Ca2+-mobilization defect of Vav1-deficient DG75 cells, but led to an elevated and more 
sustained Ca2+-influx compared to cells reconstituted with Vav1. This result may indicate 
that the remaining Ca2+-mobilization upon BCR stimulation in Vav1-deficient DG75 cells is 
brought about by the relatively weak expression of Vav3. Even though Vav3 was only 
poorly expressed in DG75 cells in comparison to primary B cells, Vav3 appears to be the 
most potent protein member within the Vav protein family in the context of BCR-induced 
Ca2+-mobilization. In summary, Vav1 and Vav3 have the potential to control Ca2+-
mobilization upon BCR stimulation in human DG75 B cells, whereas Vav2 seems to have 







       
Figure 4.4: Vav3, but not Vav2, can restore Ca
2+
-mobilization in Vav1-deficient DG75 B cells. A) 
Expression analysis of Vav family members in human B cells. Cleared cellular lysates of 1x10
6
 cells were 
loaded per lane and separated by SDS-PAGE. Immunoblots were probed with antibodies against the three 
Vav proteins and Actin as indicated below individual blots. The molecular weight of marker proteins (in kDa) is 
indicated on the left. B) Vav1-deficient DG75 cells expressing Citrine-tagged wild-type Vav1, Vav2, Vav3 or 
EGFP as negative control were analyzed for Ca
2+
-mobilization upon BCR stimulation as before. The graph is 
representative of three independent experiments. C) Expression levels of the analyzed proteins were 
determined by flow cytometry. 
 
In contrast to the functions of Vav family members in the human DG75 B cell model 
system (figure 4.4), Vav proteins behave differently in primary mouse B cells. The group 
of Klaus-Dieter Fischer showed that an individual loss of either Vav1 or Vav2 in mice has 
no effect on BCR-induced Ca2+-mobilization (Tedford et al., 2001). Only in Vav1/Vav2 
double-deficient mice a severe impact on Ca2+-mobilization could be detected, whereas in 
the human DG75 B cell line the loss of Vav1 is sufficient to dramatically reduce Ca2+-
mobilization. 
To test potential differences between mouse and human Vav family members, I 
retrovirally transfected Vav1-deficient DG75 cells with constructs coding for Citrine-tagged 
murine Vav proteins and investigated their ability to restore the Ca2+-mobilization defect. 
The results show that mouse Vav1 and mouse Vav3 were both capable to restore Ca2+-
mobilization and thus seem to have the same function as their human counterparts (figure 
4.5 A, E). Murine Vav2, like human Vav2, was not capable to restore the Ca2+-mobilization 





4.5 C, D). In summary, mouse Vav proteins closely resembled their human counterparts 
with regard to their ability to support Ca2+-mobilization upon BCR stimulation in human B 
cells. Therefore, the described phenotypical differences between Vav-deficient murine B 
cells and the human model system might depend on cell-intrinsic differences rather than 
on Vav proteins themselves. 
 
Figure 4.5: The mouse Vav protein family behaves similar to their human counterparts in the context 
of BCR-induced Ca
2+
-mobilization. A, C, E) Vav1-deficient DG75 cells expressing Citrine-tagged human (h) 
Vav1 or mouse (m) Vav1 (A), hVav2 or mVav2 (C), hVav3 or mVav3 (E) or EGFP as negative control were 
analyzed for Ca
2+
-mobilization upon BCR stimulation as before. The graphs show Ca
2+
-mobilization of gated 
cells (positive gates (B, D, F)) and are representative of three independent experiments. B, D, F) Expression 






4.1.4 Loss of Vav1 does not influence the assembly of the Ca2+-initiation 
complex 
The analysis of BCR-induced Ca2+-mobilization in Vav1-deficient DG75 B cells showed 
that Vav family members are essential signaling components in that process. Ca2+-
mobilization critically depends on the correct formation of the Ca2+-initiation complex 
consisting of the adaptor protein SLP-65, the tyrosine kinase Btk and the phospholipase 
PLCγ2 (Engelke et al., 2007). Since Vav1-deficient DG75 cells showed a reduced Ca2+-
mobilization, it appeared possible that the lack of Vav1 disturbs the formation of the Ca2+-
initiation complex. The outcome of the Ca2+-initiation complex formation is the 
phosphorylation and thereby activation of PLCγ2. This is followed by the production of the 
key second messenger IP3 that induces the release of Ca
2+ from the ER.  
To test the influences of Vav1 on activation of PLCγ2, I analyzed BCR-induced PLCγ2 
phosphorylation in DG75 cells lacking or expressing Vav1. To this end, PLCγ2 was affinity 
purified from cellular lysates followed by western blot analysis with α-pTyr antibodies. 
Figure 4.6 A shows the phosphorylation kinetics of PLCγ2 and PLCγ2-associated proteins 
upon BCR stimulation in each of the cell lines. The PLCγ2 tyrosine phosphorylation 
intensity is similar in the tested cell lines. In addition, further phospho-tyrosine signals of 
co-purified proteins at roughly 60 kDa and between 30-46 kDa were indicative of 
phosphorylated SLP-65 (Engels et al., 2009) and Igα/Igβ proteins, respectively. Moreover, 
phosphorylation of SLP-65 and Igα/Igβ proteins was slightly increased in Vav1-deficient 
DG75 cells. Since PLCγ2 tyrosine phosphorylation as well as the binding to SLP-65 was 
not affected in the absence of Vav1, I assume that the formation of the Ca2+-initiation 
complex is not disturbed.    
To verify that finding, I investigated SLP-65 phosphorylation and plasma membrane 
recruitment, which both are necessary for Ca2+-initiation complex formation (Abudula et 
al., 2007). To determine the influence of Vav1 on the phosphorylation status of SLP-65, I 
analyzed SLP-65 phosphorylation in Vav1-deficient cells compared to Vav1-expressing 
cells (figure 4.6 B). As seen in figure 4.6, SLP-65 phosphorylation was slightly increased 





                        
Figure 4.6: The formation of the Ca
2+
-initiation complex is not altered in Vav1-deficient DG75 cells. A) 
Affinity purification of PLCγ2 to check its phosphorylation status upon BCR stimulation. DG75 cells, Vav1-
deficient cells and Vav1-deficient cells reconstituted with Citrine-tagged wild-type Vav1 were stimulated with 
20 μg/ml α-IgM F(ab’)2 fragments for different periods of time (0 min, 3 min, 10 min ,15 min). PLCγ2 was 
affinity purified from cleared cellular lysates with anti-PLCγ2 antibodies followed by western blot analysis with 
anti-pTyr and anti-PLCγ2 antibodies as loading control. The molecular weight of marker proteins (in kDa) is 
indicated on the left. Data are representative of three independent experiments. B) Cleared cellular lysates (A) 
were used for western blot analysis with anti-pSLP-65 antibodies and anti-Actin antibodies as loading control. 
Data are representative of three independent experiments. C) Confocal microscopy of DG75 and Vav1-
deficient DG75 cells expressing constructs encoding N-terminally Citrine-tagged wild-type SLP-65. Images 
were taken before and 3 min after BCR stimulation with 20 μg/ml α-IgM F(ab’)2 fragments. Data are 





To investigate whether membrane recruitment of SLP-65 relies on Vav1, I expressed an 
N-terminally Citrine-tagged SLP-65 variant in parental and Vav1-deficient DG75 cells and 
analyzed SLP-65 localization using confocal microscopy. There was no difference in SLP-
65 plasma membrane recruitment between parental DG75 and Vav1-deficient DG75 cells 
(figure 4.6 C). In both cell lines, SLP-65 was located in the cytoplasm of non-stimulated 
cells, whereas a pool of SLP-65 was recruited to the plasma membrane upon BCR 
stimulation. Based on these findings, the reduced Ca2+-mobilization in Vav1-deficient 
DG75 cells cannot be attributed to an alteration in Ca2+-initiation complex formation. 
 
4.1.5 Vav1 influences Akt activation upon BCR stimulation 
Having described an essential role of Vav1 in BCR-proximal Ca2+-signaling, further 
characterization of distal BCR signaling effectors was performed. Since DG75 cells are a 
Burkitt lymphoma cell line in which proliferation-promoting pathways are more active than 
in primary cells, investigation of certain effectors was not possible due to pre-activation 
(data not shown). Therefore, I investigated the phosphorylation of Akt and the MAPK Erk 
as representatives for distal effectors in Vav1-deficient and Vav1-expressing DG75 cells. 
                       
Figure 4.7: Vav1 positively influences the Akt signaling pathway. DG75 cells, Vav1-deficient DG75 cells 
and Vav1-deficient DG75 cells reconstituted with Citrine-tagged wild-type Vav1 were stimulated for 3 min, 10 
min and 15 min with 20 μg/ml anti-human IgM F(ab’)2 fragments. Unstimulated cells served as control. 
Cleared cellular lysates of 1x10
6





probed with antibodies indicated below individual blots. Anti-Actin and anti-Vav1 antibodies served as loading 
controls. The molecular weight of marker proteins (in kDa) is indicated on the left. Data are representative of 
three independent experiments. 
 
The results show that phosphorylation of Akt was reduced in Vav1-deficient DG75 
compared to Vav1-expressing cells (figure 4.7). However, the Akt phosphorylation kinetic 
over time was not identical between parental DG75 and Vav1-deficient DG75 cells 
reconstituted with Vav1, which might be due to differences in Vav1 expression levels in 
these cell lines (figure 4.7). Collectively, it seems that Vav1 has the ability to influence the 
phosphorylation of Akt besides its involvement in Ca2+-mobilization. In contrast, BCR-
induced Erk phosphorylation occurs independently of Vav1 in DG75 B cells. 
 
4.2 Recruitment of Vav1 to phosphorylated BCR ITAMs enables 
Ca2+-mobilization 
4.2.1 The Vav1 SH2-domain can directly bind to the BCR ITAMs and is 
essential for Ca2+-mobilization upon BCR stimulation 
Since I described in the previous chapter that Vav1 is involved in BCR-induced Ca2+-
mobilization without affecting formation and activation of the Ca2+-initiation complex, the 
question arose how exactly Vav1 is controlling BCR-induced Ca2+-mobilization. To 
investigate this issue, I first checked the interaction of Vav1 with possible Ca2+-regulating 
effector proteins. The C-terminus of Vav1 contains three protein binding-domains and 
therefore represents the adaptor region of Vav1. The center of that adaptor region 
consists of an SH2-domain, which was described to bind to the adaptor protein SLP-65 
and to the BCR-proximal tyrosine kinase Syk (Deckert et al., 1996; Wienands et al., 
1998). 
To analyze the role of the Vav1 SH2-domain in BCR-induced Ca2+-mobilization, the 
capacity of an SH2-domain-inactivated variant of Vav1 (Vav1 R696A) (Zugaza et al., 
2002) to restore Ca2+-mobilization upon BCR stimulation was analyzed. Figure 4.8 A 
shows that the Vav1 R696A variant induced a Ca2+-mobilization profile that resembled 
that of Vav1-deficient DG75 cells. In conclusion, the SH2-domain is essential for Vav1 to 





         
Figure 4.8: The SH2-domain of Vav1 is essential to promote BCR-induced Ca
2+
-mobilization. A) Vav1-
deficient DG75 cells expressing Citrine-tagged Vav1 or Vav1 R696A or EGFP as negative control were 
analyzed for Ca
2+
-mobilization upon BCR stimulation as before. The graph shows BCR-induced Ca
2+
-
mobilization of gated cells (positive gate (B)). Data are representative of three independent experiments. B) 
Expression levels of analyzed proteins were determined by flow cytometry. C) Affinity purification of Vav1 
SH2-domain binding partners. DG75 cells were stimulated with 20 μg/ml α-IgM F(ab’)2 fragments for 3 min or 
left untreated. Affinity purification of proteins was done with GST-Vav1 SH2, GST-Vav1 SH2 R696A, GST-Syk 
[SH2]2 or GST-only. Samples were subjected to western blot analysis with anti-pTyr antibodies to detect 
phosphorylated interaction partners of the Vav1 SH2-domain. The molecular weight of marker proteins (in 






To identify B cell specific interaction partners of the Vav1 SH2-domain in BCR signaling, I 
tested its binding capacity in affinity purification experiments. To this end, DG75 cells were 
stimulated with anti-IgM F(ab’)2 fragments for 3 min or left untreated. The cleared cellular 
lysates were used in affinity purification experiments with GST-fusion proteins containing 
the wild-type Vav1 SH2-domain or the R696A variant. In addition, the tandemly arranged 
SH2-domains of Syk (GST-Syk [SH2]2) and GST-only were used. Samples were 
subjected to immunoblot analysis with antibodies to anti-pTyr to detect tyrosine-
phosphorylated binding partners.  
Figure 4.8 C shows binding of the GST-Vav1 SH2-domain to proteins that resemble the 
molecular weight of the already described binding partners SLP-65 and Syk. Furthermore, 
so far undescribed interaction partners between 30 kDa and 46 kDa were detected. The 
molecular weight of these proteins was similar to that of the BCR components Igα and 
Igβ, which are specifically bound by the GST-Syk [SH2]2-domains (Fütterer et al., 1998). 
Figure 4.8 C shows a similar Igα/Igβ phospho-protein signal for both GST-SH2-domain 
fusion proteins, indicating that Vav1 can interact with Igα and/or Igβ. Moreover, neither the 
inactive Vav1 SH2 R696A variant nor GST-only were able to interact with any tyrosine-
phosphorylated protein.   
To verify the newly identified interaction between Vav1 and the BCR, phosphorylated and 
non-phosphorylated peptides containing either the ITAM or the non-ITAM sequence of Igα 
were used for affinity purification of binding partners from lysates of DG75 B cells (figure 
4.9 A). The results show that Vav1 could be purified with the phosphorylated peptide 
containing the Igα-ITAM sequence (figure 4.9 A, B). This binding resembles the interaction 
between the phosphorylated Igα-ITAM peptide and its known interaction partner Syk 
(Fütterer et al., 1998). In addition, a weak interaction between Vav1 and the 
phosphorylated non-ITAM tyrosine of Igα was detected. However, this interaction is 
negligible compared to the interaction of this phosphorylation motif with its known binding 





           
Figure 4.9: Vav1 can directly bind to the ITAMs of the Igα/Igβ heterodimer of the BCR. A) Schematic 
drawing of Igα-peptides used for affinity purifications. B) Affinity purification of proteins from cleared cellular 
lysate of DG75 cells using phosphorylated and non-phosphorylated Igα-peptides I and II. Samples were 
subjected to western blot analysis with anti-Vav1, anti-Syk and anti-SLP-65 antibodies as indicated. C) Affinity 
purifications were performed using the non-phosphorylated or phosphorylated form of the Igα-peptide I in 
combination with the purified GST-Vav1 SH2-domain, the GST-Vav1 SH2 R696A-domain (negative control) or 
GST-only (negative control). Samples were subjected to western blot analysis with anti-GST antibodies. The 
molecular weight of marker proteins (in kDa) is indicated on the left. Data of B) and C) show one 
representative example of two independent experiments.   
 
Furthermore, to exclude that the interaction between Vav1 and the Igα/Igβ heterodimer is 
indirectly mediated by other proteins like SLP-65 and Syk, an affinity purification was 
performed using the non-phosphorylated or phosphorylated α-peptide I in combination 
with the purified GST-Vav1 SH2-domain. In addition, GST-only and the GST-Vav1 SH2 
R696A-domain were used as negative controls. Samples were analyzed by western blot  
with anti-GST antibodies to check for protein-peptide binding. The results show a strong 
interaction between the phosphorylated peptide containing the Igα-ITAM sequence and 
the GST-Vav1 SH2-domain, whereas no interaction could be detected with the non-
phosphorylated Igα-ITAM peptide and the negative controls (figure 4.9 C).  
Summarized, the ITAMs of the Igα/Igβ heterodimer of the BCR could be identified as a 
new binding partner of Vav1. This interaction is mediated by the Vav1 SH2-domain, which 






4.2.2 The Vav1 SH2-domain can be functionally replaced by SH2-domains 
of other Igα/Igβ interacting proteins 
Having established that Vav1 can directly interact with the BCR, it remained unknown if 
this interaction is functionally relevant for BCR signaling. Inactivation of the Vav1-
interacting ITAM-tyrosines would corrupt the entire BCR signaling cascade. To circumvent 
this problem, I generated Vav1 constructs that contain either the SH2-domain of SLP-65 
or the tandem SH2-domains of Syk instead of the Vav1 SH2-domain (figure 4.10 A). Both, 
the SLP-65 and Syk SH2-domains are well known to interact primarily with the Igα/Igβ 
heterodimer of the BCR (Fütterer et al., 1998; Engels et al., 2001), so that the resulting 
chimeric Vav1 proteins should bind the BCR. Constructs encoding Vav1, Vav1-Syk 
[SH2]2, Vav1-SLP-65 SH2 or EGFP were expressed in Vav1-deficient DG75 cells and 
Ca2+-mobilization was measured. The results show that Vav1-deficient DG75 cells 
expressing wild-type Vav1 or either of the chimeric proteins had an increased Ca2+-
mobilization compared to control cells (figure 4.10 B), even though cells expressing the 
Vav1-SLP-65 SH2 chimera showed a somewhat reduced Ca2+-mobilization compared to 
cells reconstituted with wild-type Vav1. In contrast, Vav1-deficient DG75 cells expressing 
the Vav1-Syk [SH2]2 chimera showed a dramatically enhanced Ca
2+-mobilization. 
Collectively, both chimeric proteins could restore Ca2+-mobilization in Vav1-deficient DG75 
cells albeit with different efficiencies.  
To prove that the chimeric proteins can indeed bind the Igα/Igβ heterodimer, I tested their 
binding capability in affinity purification experiments. Therefore, I generated GST-fusion 
proteins consisting of the C-terminal adaptor region of Vav1 (hereafter referred to as C2) 
containing either the wild-type Vav1 SH2 or the SH2 domains of SLP-65 or Syk (figure 
4.10 D). In addition, GST-only was used as negative control. Purified proteins were 
subjected to western blot analysis with antibodies to Igα, Igβ or GST, showing that all 
chimeric proteins could bind Igα as well as Igβ, except the negative controls (figure 
4.10 E).  
Taken together, I could show that Vav1 chimeric proteins containing other BCR-binding 
SH2-domains can functionally replace the Vav1 SH2-domain in the context of BCR-
induced Ca2+-mobilization. This indicates that Vav1 needs to be localized close to the 











Figure 4.10: BCR-binding SH2-domains can replace the Vav1 SH2-domain in the context of BCR-
induced Ca
2+
-mobilization. A) Schematic drawing of the domain architecture of Vav1 and the chimeric Vav1-
SLP-65 SH2 and Vav1-Syk [SH2]2 proteins. In addition, the binding capabilities of the individual SH2-domains 
are depicted, which can bind different phosphorylated tyrosines (P) in the cytoplasmic tails of Igα/Igβ. B) 
Vav1-deficient DG75 cells expressing Citrine-tagged wild-type Vav1, Vav1-SLP-65 SH2, Vav1-Syk [SH2]2 or 
EGFP were analyzed for Ca
2+
-mobilization upon BCR stimulation as before. The graph shows Ca
2+
-
mobilization of gated cells (positive gate (C)). Data show one representative example of three independent 
experiments. C) Expression levels of analyzed proteins were measured by flow cytometry. D) Domain 
architecture of the used GST-fusion proteins in affinity purifications. E) Affinity purifications with C2 regions of 
chimeric Vav1 proteins. DG75 cells were stimulated with 20 μg/ml α-IgM F(ab’)2 fragments for 3 min or left 
untreated. Cleared cellular lysates were used for affinity purification with GST-C2 Vav1, GST-C2 Vav1 SH2 
R696A, GST-C2 Vav1-Syk [SH2]2, GST-C2 Vav1-SLP-65 SH2 or GST-only. Samples were subjected to 
western blot analysis with anti-Igα, anti-Igβ and anti-GST antibodies as indicated. The molecular weight of 
marker proteins (in kDa) is indicated on the left. Data show one representative example of three independent 
experiments.  
 
To further characterize the functional relevance of the Vav1-BCR interaction for Ca2+-
mobilization upon BCR stimulation, I generated an experimental system that combines the 
Vav1-SLP-65 SH2-chimera and a chimeric receptor consisting of the extracellular part of 
CD8 and the intracellular part of Igα (figure 4.11 A). The intracellular part of Igα contains 
the non-ITAM tyrosine (Y204), which is described as exclusive binding site for SLP-65 
(Engels et al., 2001). Vice versa, The SLP-65 SH2-domain is described to bind primarily 
to the phosphorylated non-ITAM Y204 of Igα, so that binding of the Vav1-SLP-65 SH2 
chimera to the CD8/Igα chimera can be selectively investigated and is supposed to 
resemble the interaction between the Vav1 SH2-domain and the BCR. 
I first expressed CD8/Igα or CD8/Igα Y204F chimeric proteins in Vav1-deficient DG75 
cells. Next, the resulting two cell lines were retrovirally transfected with constructs coding 
for wild-type Vav1, Vav1-SLP-65 SH2, Vav1-SLP-65 SH2 R372L or EGFP and Ca2+-
mobilization was measured upon stimulation of the CD8 chimeras with anti-CD8 
antibodies. Figure 4.11 B shows that expression of Vav1 and Vav1-SLP-65 SH2 in Vav1-
deficient DG75 cells led to Ca2+-mobilization, which resembles the Ca2+-mobilization 
signal of DG75 cells stimulated via the endogenous BCR (figure 4.10). This indicates that 
the chimeric receptor can mimic the endogenous BCR. The function of the chimeric Vav1-
SLP-65 SH2-domain fusion protein relies on its SH2-domain since inactivation of the SH2-
domain (Vav1-SLP-65 SH2 R372L) led to a Ca2+-mobilization defect similar to Vav1-










Figure 4.11: Interaction of Vav1 with the BCR is sufficient for Vav1 function in Ca
2+
-mobilization. A) 
Schematic drawing of the domain architecture of Vav1 and the chimeric Vav1-SLP-65 SH2 and Vav1-SLP-65 
SH2 R372L proteins. In addition, the binding capability of the individual SH2-domains is depicted, which can 
bind different phosphorylated tyrosines (P) in the cytoplasmic tail of CD8/Igα or CD8/Igα Y204F. B, E) Vav1-
deficient DG75 cells expressing CD8/Igα or CD8/Igα Y204 were retrovirally transfected with constructs coding 
for Citrine-tagged wild-type Vav1, Vav1-SLP-65 SH2, Vav1-SLP-65 SH2 R372L or EGFP and analyzed for 
Ca
2+
-mobilization as before. Cells were stimulated with 10 μg/ml anti-human CD8 antibodies. The graph 
shows Ca
2+
-mobilization of gated cells (positive gate (D, G)). One representative example of three 
independent experiments is shown. C, D, F, G) CD8 staining was performed with anti-human CD8-FITC 
antibodies and expression levels of analyzed proteins were determined by flow cytometry. Colour code is 
equivalent in B), C), D). The same is true for E), F), G). 
   
Moreover, when cells expressed the CD8/Igα Y204F variant, only Vav1, which binds to 
phospho-ITAMs, could mobilize Ca2+ upon CD8 stimulation (figure 4.11 E). By contrast, 
the Vav1-SLP-65 SH2 chimera could not restore Ca2+-mobilization, when its docking site, 
Y204, was inactivated. Collectively, I could show by mutational analysis that recruitment of 
Vav1 to phosphorylated BCR tyrosine residues enables BCR-induced Ca2+-mobilization. 
 
4.3 The interaction between Vav1 and SLP-65 permits BCR-
induced Ca2+-mobilization 
4.3.1 Generation of a SLP-65-deficient DG75 sub-line 
The previously described results of my PhD thesis show an important function of Vav1 in 
BCR-induced Ca2+-mobilization. Furthermore, I could show an interaction between Vav1 
and the BCR, which is sufficient for Vav1 to function in the context of Ca2+-mobilization 
upon BCR stimulation in DG75 B cells. Besides this novel signaling mechanism, SLP-65 
was reported to be involved in Vav1 localization and function (Johmura et al., 2003). The 
interaction between Vav1 and SLP-65 is mediated by the SH2-domain of Vav1 (figure 4.8, 
chapter 4.2.1), which is supposed to bind tyrosine 72 of human SLP-65 based on the 
results by the group of Andrew Chan (Chiu et al., 2002). However, the Vav1 SH2-domain 
is able to bind a diverse set of tyrosine-phosphorylated proteins upon BCR stimulation 
(figure 4.8, chapter 4.2.1), so that Vav1 with a non-functional SH2-domain loses 
interaction to many proteins and thus is not conclusive. To be able to investigate 
specifically the Vav1-SLP-65 interaction, I generated a SLP-65-deficient DG75 sub-line to 





      
Figure 4.12: Generation of a SLP-65-deficient DG75 sub-line. A) Schematic drawing of the genomic 
organization of the SLP-65 gene indicating the TALEN target region. B) To test the activity of the TALEN 
constructs, the genomic region containing the targeted SLP-65 exon 6 was amplified by PCR from DG75 cells 
that had been transiently transfected with TALEN constructs 39 and 55 and sorted. The PCR product was cut 
with the restriction enzyme BmrI, whose binding site overlaps with the TALEN target site and therefore can be 
used for TALEN activity testing. C) Screening of DG75 cell clones for SLP-65 deficiency was done using 
western blot analysis. Cleared cellular lysates of 1x10
6
 DG75 cells were loaded per lane and separated by 
SDS-PAGE. Immunoblots were probed with anti-SLP-65 and anti-Actin antibodies as indicated below the 
individual blots. Cleared cellular lysates of DG75 cells served as positive control (+). The molecular weight of 
marker proteins (in kDa) is indicated on the left. D) Characterization of the SLP-65-deficient DG75 clone #7. 
The genomic region containing exon 6 of the SLP-65-deficient DG75 cell clone #7 could not be amplified by 
PCR for further genomic characterization. To test PCR conditions, I amplified the SLP-65 exon 5 genomic 
region by PCR to prove the quality of the genomic DNA template and I amplified the SLP-65 exon 6 genomic 






To this end, a TALEN pair was constructed to target exon 6 of the human SLP-65 gene 
located on chromosome 10 (figure 4.12 A). Exon 6 was chosen as target region, because 
it is present in all described protein coding SLP-65 mRNAs (based on Ensembl data base) 
and it showed a good availability of restriction enzyme sites for later activity screening. 
Transient transfection of TALEN constructs, cell sorting, activity test and subsequent sub-
cloning was performed as before (see chapter 4.1.1). Resulting cell clones were screened 
for SLP-65 protein expression by western blot with anti-SLP-65 antibodies. Figure 4.12 C 
shows no detectable SLP-65 signal in cell clones #1, #7, #14 and #28 indicating that the 
TALEN pair 39/55 was active in these cell clones. In addition, a decreased SLP-65 signal 
compared to parental DG75 cells was detected in cell clones #6, #16 and #17.  
To characterize the SLP-65-deficient DG75 clone #7 genetically, I amplified the exon 6 
containing genomic region (referred to as ‘exon 6’) of SLP-65 via PCR for subsequent 
cloning and sequencing. However, despite of using different primer pairs, amplification of 
the ‘exon 6’ was not successful. To test the PCR conditions, I amplified the genomic 
region of SLP-65 exon 5 to prove the quality of the genomic DNA template. In addition, I 
amplified the ‘exon 6’ of SLP-65 from genomic DNA of parental cells. Both controls 
showed optimal PCR results (figure 4.12 D). In conclusion, the TALEN targeting of SLP-
65 exon 6 in clone #7 led to a genomic deletion that includes surrounding intron regions 
and thus interfered with primer annealing and PCR amplification of ‘exon 6’. At any rate, 
based on western blot analysis and PCR-assays, DG75 cell clone #7 was considered a 
SLP-65-deficient sub-line and was used in the following experiments. It is hereafter 
referred to as SLP-65-deficient DG75 cells.          
 
4.3.2 SLP-65 is essential for BCR-induced Ca2+-mobilization in DG75 cells 
Previous experiments of several laboratories including our group have established an 
essential function of SLP-65 in Ca2+-mobilization in murine B cells and the chicken DT40 
cell line (Fu et al., 1998; Jumaa et al., 1999; Chiu et al., 2002). In accordance with these 
results, SLP-65-deficient DG75 cell clones showed a decreased Ca2+-mobilization signal 
compared to parental DG75 cells (figure 4.13 A). Reconstitution of SLP-65-deficient DG75 
cells with wild-type SLP-65 fully restored BCR-induced Ca2+-mobilization and thus proved 
that the Ca2+-mobilization defect in the knock out cells was due to the lack of SLP-65 






Figure 4.13: Human SLP-65 has a pivotal role in Ca
2+
-mobilization upon BCR stimulation. A) Parental 
DG75 as well as SLP-65-deficient cell clones #1, #7, #14 and #28 were analyzed for Ca
2+
-mobilization upon 
BCR stimulation as before. The graph is representative of three independent experiments. B) Expression 
levels of BCRs were measured by flow cytometry. Surface staining was done using anti-human IgM-APC 
antibodies. Unstained cells are depicted in black. Samples have the same color code as in A). C) SLP-65-
deficient DG75 cells expressing Citrine-tagged wild-type SLP-65 were analyzed for Ca
2+
-mobilization as 
before. Parental DG75 cells and SLP-65-deficient EGFP-expressing cells were used as positive and negative 
control, respectively. The graph shows Ca
2+
-mobilization of gated cells (positive gate (B)) and it is 
representative of three independent experiments. D) Expression levels of analyzed proteins were determined 
by flow cytometry. 
 
4.3.3 SLP-65 tyrosines 72, 84 and 119 are important for its function in BCR-
induced Ca2+-mobilization 
The 3D structure of SLP-65 is not completely defined. The N-terminus is predicted to bind 
phospho-lipids of membranes (Herrmann, 2009), whereas the C-terminus contains a 
phospho-tyrosine binding SH2-domain. The center of SLP-65 is described as principally 
unstructured (Pirkuliyeva, 2015) and contains a number of tyrosines that on 
phosphorylation can serve as docking sites for proteins like Btk (Y96) and PLCγ2 (Y84, 
Y119, Y178 and Y189) (Chiu et al., 2002; Engelke et al., 2013). Importantly, SLP-65 
tyrosine 72 (Y72) was described to be the interaction site for Vav1 (Chiu et al., 2002).  
To analyze whether Vav1-SLP-65 binding is indeed mediated by Y72, I checked the 
binding capability of Vav1 to several tyrosine-to-phenylalanine (YF) mutant variants of 





experiments with the Vav1 SH2-domain. Purified proteins were subjected to western blot 
analysis with anti-SLP-65 antibodies. Each SLP-65 YF variant could be bound by the 
GST-Vav1 SH2-domain (figure 4.14 A, B), although binding was reduced compared to 
wild-type SLP-65. SLP-65 Y72F and SLP-65 Y84F showed the weakest interaction with 
the Vav1 SH2-domain. Furthermore, the Vav1 SH2-domain was still able to interact with 
double YF variants of SLP-65, with SLP-65 Y72/84F showing the weakest interaction. 
Collectively, the tyrosines 72, 84 and 119 of SLP-65 showed impaired binding of Vav1. 
However, a complete loss of SLP-65 binding by Vav1 could not be detected, so that I 
assume that Vav1 has the ability to bind more than one phosphorylated tyrosine of SLP-
65. 
Next, I tested the functional importance of the interaction between Vav1 and SLP-65 for 
BCR-induced Ca2+-mobilization. Each SLP-65 YF variant was able to mobilize Ca2+ after 
BCR stimulation, yet to different extents, which in any case did not reach the level of cells 
expressing wild-type SLP-65 (figure 4.14 C, E). The strongest decrease in Ca2+-
mobilization was seen in cells expressing the SLP-65 Y119F variant. In comparison, Ca2+-
mobilization in SLP-65-deficient DG75 cells expressing either the SLP-65 Y72F or the 
SLP-65 Y84F variant was only marginally reduced.  
Furthermore, SLP-65 Y72/84F and SLP-65 Y72/119F double mutant variants were 
investigated. Here, in addition to the substitution of tyrosine 72, also tyrosine 84 or 
tyrosine 119 were substituted with phenylalanine. Both SLP-65 double YF-mutant variants 
showed a reduced Ca2+-mobilization compared to the SLP-65 Y72F single mutant variant 
(figure 4.14 C, E). In conclusion, I could show that the SLP-65 tyrosines 72, 84 and 119 
are involved in BCR-induced Ca2+-mobilization. In addition, each tyrosine might interact 
with a specific protein indicated by the additive effect in Ca2+-mobilization upon BCR 
stimulation. 
Taken together, Vav1 binding to SLP-65 YF-mutant variants correlates to the signaling 
competence of these variants in BCR-induced Ca2+-mobilization. However, whether the 
reduced Ca2+-mobilization of cells expressing individual YF-mutant SLP-65 variants 
depends exclusively on the reduced interaction between Vav1 and SLP-65, needs to be 
unraveled. 







Figure 4.14: Phosphorylation of several SLP-65 tyrosines is important for BCR-induced Vav1 binding 
and Ca
2+
-mobilization. A, B) Cells were stimulated with 20 μg/ml α-IgM F(ab’)2 fragments for 3 min or left 
untreated. SLP-65 YF-mutant variants were affinity purified from cleared cellular lysates using the GST-Vav1 
SH2-domain. Samples were subjected to western blot analysis with anti-SLP-65, anti-Actin and anti-GST 
antibodies as indicated. The molecular weight of marker proteins (in kDa) is indicated on the left. Data show 
one representative example of three independent experiments. C, E) SLP-65-deficient DG75 cells expressing 
Citrine-tagged wild-type SLP-65, SLP-65 Y72F, SLP-65 Y84F, SLP-65 Y119F, SLP-65 Y72/84F, SLP-65 
Y72/119F or EGFP were analyzed for Ca
2+
-mobilization upon BCR stimulation as before. The graph shows 
Ca
2+
-mobilization of gated cells (positive gate (D, F)). Data show one representative result of three 





4.3.4 Recruitment of Vav1 to SLP-65 enables BCR-induced Ca2+-
mobilization. 
Due to the fact, that I could not generate a variant of SLP-65 that selectively lost its 
interaction with Vav1, it remained unclear whether the Vav1-SLP-65 interaction is 
important for BCR-induced Ca2+-mobilization. To check the functional relevance of this 
protein-protein interaction, chimeric Vav1 proteins were designed containing the SH2-
domain of either Btk or Itk instead of the Vav1 SH2-domain and expressed in Vav1-
deficient DG75 cells (figure 4.15 A). These SH2-domains are described to bind SLP-65 at 
tyrosine 96 (Y96) (Su et al., 1999).  
Figure 4.15 B shows a slightly increased Ca2+-mobilization in cells expressing the Vav1-
Btk SH2-chimera compared to EGFP-expressing control cells (figure 4.15 B). In contrast, 
the Vav1-Itk SH2-chimera led to a significantly higher Ca2+-mobilization even though it did 
not reach the level of cells expressing wild-type Vav1 (figure 4.15 B). These results show 
that the recruitment of Vav1 to SLP-65 enabled BCR-induced Ca2+-mobilization. In 
addition, the different extent of Ca2+-mobilization indicates that the binding affinities of the 
Btk and Itk SH2-domains to phospho-tyrosine 96 in SLP-65 might differ.    
To test whether the chimeric Vav1 proteins can indeed bind phospho-SLP-65, affinity 
purifications were performed using GST-fusion proteins consisting of the C-terminal 
adaptor region (referred to as C2) containing the different SH2-domains of Btk or Itk 
(figure 4.15 D). The results show that each of the GST-fusion proteins could bind to the 
adaptor protein SLP-65 although with different affinity. In detail, the GST-fusion protein 
containing the wild-type C2 region of Vav1 showed the strongest interaction with phospho-
SLP-65, followed by the C2 region containing the SH2-domain of Itk. On the contrary, 
affinity purification performed with the C2-Btk SH2 region showed only a weak SLP-65 
interaction. This suggests that the affinity of the interaction between Vav1 and SLP-65 
regulates the intensity of BCR-induced Ca2+-mobilization. Note that only the wild-type C2 
region of Vav1 could bind to the Igα protein of the BCR, which might explain why this 
protein gives rise to the strongest Ca2+-signal (figure 4.15 E). 
In summary, the association of Vav1 and the adaptor protein SLP-65 enables BCR-






Figure 4.15: The interaction between Vav1 and SLP-65 enables Ca
2+
-mobilization upon BCR 
stimulation. A) Schematic drawing of Vav1 SH2-chimeras and their binding sites in SLP-65. B) Vav1-







-mobilization upon BCR stimulation as before. The graph shows Ca
2+
-mobilization of gated 
cells (positive gate (C)). Data show one representative example of three independent experiments. C) 
Expression levels of analyzed proteins were determined by flow cytometry D) Schematic structure of the GST-
fusion proteins used in affinity purifications. E) Affinity purifications with C2 regions from chimeric Vav1 
proteins. DG75 cells were stimulated with 20 μg/ml α-IgM F(ab’)2 fragments for 3 min or left untreated. SLP-65 
was affinity purified with GST-C2 Vav1, GST-C2 Vav1-Btk SH2, GST-C2 Vav1-Itk SH2 or GST-only. Samples 
were subjected to western blot analysis with anti-Igα, anti-SLP-65 and anti-GST antibodies as indicated. The 
molecular weight of marker proteins (in kDa) is indicated on the left. Data show one representative example of 
three independent experiments. 
 
4.3.5 CD19-mediated Vav1 recruitment is not involved in BCR-induced 
Ca2+-mobilization 
Besides the interactions between Vav1 and the BCR as well as Vav1 and SLP-65, a SH2-
domain-mediated interaction of Vav1 with the co-stimulatory B cell receptor CD19 is well 
established (O’Rourke et al., 1998). However, it remains unclear if the Vav1-CD19 
interaction is important in the context of BCR-induced Ca2+-mobilization. 
To address this question, a CD19-negative population of DG75 cells that was isolated by 
repeated cell sorting (N. Engels, unpublished) was analyzed for Ca2+-mobilization upon 
BCR stimulation. Figure 4.16 A shows that CD19-negative DG75 cells had a BCR-induced 
Ca2+-mobilization, which resembled that of parental DG75 cells. In conclusion, CD19 is 
not involved in BCR-induced Ca2+-mobilization, which indicates that the Vav1-CD19 
interaction is not important in that context. 
 
Figure 4.16: CD19 is not involved in Ca
2+
-mobilization upon BCR stimulation. A) Parental DG75 cells as 
well as CD19-negative cells were analyzed for Ca
2+
-mobilization upon BCR stimulation as before. Data show 
one representative example of three independent experiments. B) Surface expression levels of CD19 on the 
cells analyzed in A) were measured by flow cytometry. Surface staining was done using anti-human CD19-PE 






4.4 The structural integrity of the DH-PH-ZF-domain unit of Vav1 
is essential for BCR-induced Ca2+-mobilization 
4.4.1 The Vav1 DH-domain is critical for Vav1 function in the context of 
BCR-induced Ca2+-mobilization 
In the previous chapters, I focused on the identification of functionally important interaction 
partners of Vav1 and its connection to the BCR signalosome. However, it remains to be 
elucidated, which functions Vav1 fulfills in Ca2+-mobilization upon BCR stimulation. The 
best studied function of Vav1 is its GEF activity for the Rho family of small G-proteins 
(Movilla et al., 2001; Zugaza et al., 2002; Palmby et al., 2004). Activation of small 
G-proteins results most commonly in cell growth and proliferation (Tybulewicz and 
Henderson, 2009). In B cells, it is not known if the Vav1 GEF function is involved in BCR-
induced Ca2+-mobilization. 
 
Figure 4.17: The structural integrity of the Vav1 DH-domain is crucial for BCR-induced Ca
2+
-
mobilization. A, C) Vav1-deficient DG75 cells expressing Citrine-tagged wild-type Vav1, Vav1 LK334/335AA, 
Vav1 L213Q or EGFP were analyzed for Ca
2+
-mobilization upon BCR stimulation as before. The graph shows 
Ca
2+
-mobilization of gated cells (positive gate in (B D)). Data show one representative example of three 
independent experiments. B, D) Expression levels of analyzed proteins were determined by flow cytometry. 
 
To address this question, I generated two Vav1 variants with non-functional DH-domains 
based on previous publications. One Vav1 variant carries two amino acid substitutions, 





that are located directly in the active center of the DH-domain without affecting its 
structural integrity (Saveliev et al., 2009). The other Vav1 variant contains a leucine-to-
glutamine substitution at amino acid position 213 (L213Q) that is located away from the 
active center and is affecting the overall structure of the DH-domain (Zugaza et al., 2002). 
The Vav1 mutant variants were expressed in Vav1-deficient DG75 cells and BCR-induced 
Ca2+-mobilization was measured. Figure 4.17 A shows that Ca2+-mobilization was fully 
restored in cells expressing the Vav1 LK334/335AA variant. Hence, Vav1 DH-domain 
GEF activity is most likely not involved in BCR-induced Ca2+-mobilization. In contrast, the 
Vav1 L213Q variant failed to restore Ca2+-mobilization (figure 4.17 C). Derived from these 
results, the structural integrity of the Vav1 DH-domain appears to be essential for BCR-
induced Ca2+-mobilization in the human DG75 B cell line, whereas the catalytic GEF 
activity of the DH-domain seems to be dispensable in that process.       
  
4.4.2 The DH-domain is not involved in plasma membrane recruitment of 
Vav1 
Even though I could show that the structural integrity of the Vav1 DH-domain is important 
for BCR-induced Ca2+-mobilization, it remained unknown what function the Vav1 DH-
domain fulfills in BCR signaling. Since GEF activity might be excluded as possible function 
(see chapter 4.4.1), I investigated whether plasma membrane recruitment via specific 
binding partners could be a possible function. The small G-protein Rac1 is a well 
described interaction partner for the Vav1 DH-domain (Zugaza et al., 2002; Brooun et al., 
2007). Rac1 contains a so-called CAAX box at its C-terminus, which is responsible for 
Rac1 plasma membrane targeting via fatty acid modification (Roberts et al., 2008). Hence, 
Vav1 plasma membrane recruitment could be mediated through binding of the Vav1 DH-
domain to plasma membrane attached Rac1.  
To test this hypothesis, I generated a chimeric construct containing Vav1 fused to the N-
terminus of Rac1. This construct was expressed in Vav1-deficient DG75 cells to analyze 
its localization and plasma membrane recruitment upon BCR stimulation using confocal 
microscopy. Figure 4.18 A shows that the Vav1-Rac1 chimeric protein was preferentially 
localized in the cytoplasm of DG75 cells. Only a small proportion of the chimeric protein 
was localized at the plasma membrane. Upon BCR stimulation, the Vav1-Rac1 chimera 
translocated from the cytoplasm to the plasma membrane. In contrast, plasma membrane 
translocation was not observed for wild-type Vav1 (data not shown). Hence, fusion of 





Next, I investigated the Vav1-Rac1 chimera in the context of a functional or a non-
functional DH-domain in Ca2+-mobilization upon BCR stimulation. To this end, I inactivated 
the DH-domain in the Vav1-Rac1 chimera by introducing the L213Q mutation (Vav1 
L213Q-Rac1). Figure 4.18 B shows that the Vav1-Rac1 chimeric protein was able to 
restore Ca2+-mobilization in Vav1-deficient DG75 cells, whereas the L213Q-mutant 
chimera was non-functional.  
 
Figure 4.18: The DH-domain does not mediate the translocation of Vav1 to the plasma membrane. A) 
Confocal microscopy of Vav1-deficient DG75 cells expressing a N-terminally Citrine-tagged Vav1-Rac1 
chimera. Images were taken before and 3 min after stimulation with 20 μg/ml α-IgM F(ab’)2 fragments. The 
data show one representative example of two independent experiments. B, D) Vav1-deficient DG75 cells 
expressing either Citrine-tagged wild-type Vav1, Vav1-Rac1, Vav1 L213Q, Vav1 L213Q-Syk [SH2]2, Vav1 
L213Q-Rac1 or EGFP were analyzed for Ca
2+
-mobilization upon BCR stimulation as before. The graph shows 
Ca
2+
-mobilization of gated cells (positive gate (C, E)). Data show one representative example of three 
independent experiments. C, E) Expression levels of analyzed proteins were determined by flow cytometry.  
 
To further elucidate the role of the Vav1 DH-domain in translocation processes, I 





SH2-domains of Syk instead of the Vav1 SH2-domain. The Syk SH2-domains mediate 
strong binding to the BCR and lead in the context of the Vav1 protein to increased BCR-
induced Ca2+-mobilization (see chapter 4.2.2). The constructs were expressed in Vav1-
deficient DG75 cells and Ca2+-mobilization was measured. Figure 4.18 D shows that the 
Vav1 L213Q-Syk-[SH2]2 variant was not able to mobilize more Ca
2+ than Vav1-deficient 
cells upon BCR stimulation. This indicates, that the positive effect of the tandem SH2-
domains of Syk within the Vav1 protein cannot rescue the function of the DH-domain. In 
conclusion, plasma membrane recruitment can be excluded as possible function of the 
Vav1 DH-domain in the context of Ca2+-mobilization. 
 
4.4.3 DH-domain surrounding regions of Vav1 influence its Ca2+-promoting 
function 
In addition to the DH-domain itself, other regions of Vav1 were described to influence the 
function and stability of the DH-domain. Structural analyses of Chrencik et al. revealed 
that the N-terminally located CH domain as well as the acidic region between the CH and 
DH-domains of Vav1 adopt a specific protein folding that is described as inhibitory loop. 
This regulates Vav1 GEF activity on the one hand by blocking the active center of the DH-
domain and on the other hand by structural stabilization of the DH-domain (Chrencik et 
al., 2008). The ZF-domain of Vav1 has a contact interface with the Vav1 DH-domain 
(Chrencik et al., 2008). Mutations inside the ZF-domain impair GEF activity of Vav1 
(Zugaza et al., 2002). This indicates a ZF-domain-mediated structural stabilization of the 
DH-domain, since the mutations inside the Zn-finger are far away from the Vav1 catalytic 
center.  
To test the importance of the ZF-domain in BCR-induced Ca2+-mobilization, I generated 
Vav1 variants containing different mutations inside the Zn-finger, glutamine-to-alanine and 
tyrosine-to-alanine at positions 542 and 544, respectively. These were described to lead 
to a loss of Vav1-mediated Rac1 activation (Zugaza et al., 2002). The constructs were 
expressed in Vav1-deficient DG75 cells and Ca2+-mobilization was measured. Figure 4.19 
A shows that both Vav1 Q542A and Vav1 Y544A severely affected Ca2+-mobilization. 
These results are in line with previous results of the Vav1 L213Q variant (see chapter 
4.4.1) that showed the importance of a structurally intact Vav1 DH-domain in BCR 
signaling. 
The acidic amino acid region between the CH and the DH-domain of Vav1 contains three 
specific tyrosines (Y142 ,Y160 ,Y172) that are reported to inhibit DH-domain by blocking 





these tyrosines, the so-called inhibitory loop loosens up and Vav1 GEF activity increases. 
To test, if the deletion of the acidic region has an influence on Vav1’s function in BCR-
induced Ca2+-mobilization, I generated a Vav1 variant that lacks the acidic stretch 
including the three inhibitory tyrosines (∆AR Vav1, figure 4.19 C). Figure 4.19 D shows 
that this ∆AR Vav1 variant led to an increased Ca2+-mobilization compared to control cells. 
Given that the Vav1 GEF activity was not involved in BCR-induced Ca2+-mobilization (see 
chapter 4.4.1), the increased Ca2+-mobilization in cells expressing the ΔAR Vav1 variant 
might be a result of a better accessibility of the DH-domain for effector proteins. However, 
since interactions with small G-proteins appear to be transient and could not be detected 
in affinity purification experiments (data not shown), it remains unclear whether binding of 
small G-proteins is the task of the Vav1 DH-domain that allows Ca2+-mobilization in 
human B cells.  
 
Figure 4.19: The ZF-domain and the acidic region regulate Vav1 activity in BCR-induced Ca
2+
-
mobilization. A, D) Vav1-deficient DG75 cells expressing Citrine-tagged wild-type Vav1, Vav1 Q542A, Vav1 
Y544A, ∆AR Vav1 or EGFP were analyzed for Ca
2+
-mobilization upon BCR stimulation as before. The graph 
shows Ca
2+
-mobilization of gated cells (positive gate (B, E)). Data show one representative example of three 
independent experiments. B, E) Expression levels of analyzed proteins were determined by flow cytometry. C) 






4.4.4 Do Rac family proteins influence BCR-induced Ca2+-mobilization? - 
Generation of a Rac2-deficient DG75 sub-line 
Since I demonstrated in chapter 4.4.1 and 4.4.3 that a structurally intact Vav1 DH-domain 
is indispensable for Ca2+-signaling in human B cells and given that small G-proteins of the 
Rho family are the only reported binding partners of the Vav1 DH-domain, an interaction 
between these proteins might be essential to allow BCR-induced Ca2+-mobilization. 
However, a direct interaction between Vav1 and Rac1 in BCR-induced Ca2+-mobilization 
could not be observed in affinity purification experiments so far (data not shown).  
Nevertheless, there are some indications in the literature that small G-proteins might be 
involved in BCR-induced Ca2+-signaling. Experiments performed with Rac1/Rac2 double-
deficient mice demonstrated a pivotal role of both proteins for B cell development and 
signaling (Walmsley et al., 2003) and resemble partially the phenotype of Vav1/Vav2 
double-deficient mice. In addition, Walliser et al. reported that Rac2 has the ability to bind 
to PLCγ2 and thus might influence PLCγ2 enzymatic activation in a chicken B cell line.   
Since Rac2 was reported to be more important than Rac1 in B cells (Walmsley et al., 
2003; Walliser et al., 2015), I generated a Rac2-deficient DG75 sub-line to check the 
influence of Rac2 on BCR-induced Ca2+-mobilization in DG75 cells. Therefore, I used the 
CRISPR/Cas method to target exon 3 of the RAC2 gene located on chromosome 22 
(figure 4.20 A). Transfection, cell-sorting, sub-cloning and screening for Rac2-deficient 
DG75 cells (figure 4.20 B-D) was performed as described for the TALEN method (see 
chapter 4.1.1). Subsequently, the Rac2-deficient DG75 clone #4 was further analyzed with 
regard to its genomic mutations in the RAC2 exon 3. A genomic region containing exon 3 
of the RAC2 gene (referred to as ‘exon 3’) was amplified by PCR and ligated into a 
cloning vector for sequencing of single alleles. In total, 10 sequencing reactions were 
performed, which documented a 2 nucleotide deletion on one allele and a 4 nucleotide 
deletion on the second allele leading to premature stop codons in both cases (figure 4.20 







Figure 4.20: Generation of a Rac2-deficient DG75 sub-line. A) Schematic drawing of the RAC2 genomic 
organization indicating the CRISPR/Cas target region. B) To test the activity of the CRISPR/Cas construct 2 
(CC2), the targeted RAC2 ‘exon 3’ was amplified by PCR from CC2-treated DG75 cells. The PCR product was 
cleaved with the restriction enzyme BsmBI, whose binding site overlaps with the CC2 target site and therefore 
can be used for CC2 activity testing. C) Sequencing result of the RAC2 ‘exon 3’ amplicon. The targeting site of 
the CC2 construct is indicated. D) Screening of DG75 cell clones for Rac2 deficiency was done using western 
blot analysis. Cleared cellular lysates of 1x10
6
 DG75 cells were loaded per lane and separated by SDS-





Cleared cellular lysates of DG75 cells served as positive control (+). The molecular weight of marker proteins 
(in kDa) is indicated on the left. E) Characterization of the Rac2-deficient DG75 clone #4 was done by cloning 
the RAC2 ‘exon 3’ amplicon into the pCR2.1 vector followed by sequencing of individual alleles. The result is 
representative for 10 sequencing reactions. F) Genomic control of DG75 RAC2
-/-
 #4 by activity test as 
described in B), since one sequencing reaction showed wild-type sequence. 
 
4.4.5 Rac2-deficient DG75 cells are capable to mobilize Ca2+ upon BCR 
stimulation 
The Rac2-deficient DG75 cells were used to analyze BCR-induced Ca2+-mobilization. The 
results show that the Rac2-deficient DG75 cell clones #1 and #4 were still able to mobilize 
Ca2+ upon BCR stimulation similar to parental cells with only a marginal reduction (figure 
4.21 A), indicating that Rac2 is either not involved in BCR-induced Ca2+-mobilization or 
has redundant functions with other small G-proteins of the Rho family. Hence, up to now 
the definite role of Rac proteins in BCR-induced Ca2+-signaling remains unclear. 
 
Figure 4.21: Human Rac2 in Ca
2+
-mobilization upon BCR stimulation. A) Parental DG75 as well as Rac2-
deficient cell clones #1 and #4 were analyzed for Ca
2+
-mobilization upon BCR stimulation as before. The data 
show one representative example of three independent experiments. B) Expression levels of BCRs were 
measured by flow cytometry. Surface staining was done using anti-human IgM-APC. Unstained cells are 
depicted in black. Samples have the same color code as in A). 
 
4.5 Analysis of the Vav1 CH-domain  
4.5.1 The Vav1 CH-domain is critical for BCR-induced Ca2+-signaling 
In the previous chapter, I focused on the Vav1-Rac signaling axis as possible signaling 
knot in the context of BCR-induced Ca2+-mobilization. Here, I have already described 
different Vav1 regions that influence Vav1 GEF activity and structural integrity of the DH-
domain. Nevertheless, the N-terminally located type 3 CH-domain has been described to 
affect Vav1 GEF activity, too (Zugaza et al., 2002). Five different types of CH-domains 





mediate binding to the Actin cytoskeleton (Gimona et al., 2002). In contrast, functions of 
type 3, 4 and 5 CH-domains are poorly characterized and seem to depend on the 
individual protein context. In Vav1, the type 3 CH-domain influences the GEF activity by 
forming an inhibitory loop with the centrally located DH-PH-ZF-domain unit (Zugaza et al., 
2002; Chrencik et al., 2008). Deletion of the CH-domain leads to an increased GEF 
activity, which indicates an inhibitory role that is comparable to the already described 
acidic region between CH- and DH-domain (chapter 4.4.3). Deletion of the inhibitory acidic 
region enhances Ca2+-mobilization upon BCR stimulation. However, the role of the Vav1 
CH-domain in BCR-induced Ca2+-signaling has not been described so far.  
To test the influence of the CH-domain on BCR-induced Ca2+-mobilization, I expressed a 
Vav1 variant carrying a deletion of the complete CH-domain (∆CH Vav1) in Vav1-deficient 
DG75 cells and measured BCR-induced Ca2+-mobilization (figure 4.22 A, B). This 
∆CH Vav1 variant of Vav1 shows a massively reduced Ca2+-mobilization compared to 
wild-type Vav1 indicating that the CH-domain has two different tasks. On the one hand, it 
serves as inhibitory unit for the GEF activity and on the other hand, it fulfills a pivotal 
function in BCR-induced Ca2+-mobilization.  
To characterize the CH-domain in more detail, I generated Vav1 variants carrying single 
substitutions of conserved amino acids within the CH-domain in an attempt to inactivate 
the domain. Substitution positions were selected by alignment of typical type 3 CH-
domains and screening for conserved regions. Here, amino acids tryptophan 10 (W10), 
aspartate 39 (D39) and aspartate 98 (D98) displayed a high degree of conservation and 
were all individually substituted with alanine. The mutant Vav1 variants were expressed in 
Vav1-deficient DG75 cells and Ca2+-mobilization was measured. The results show that 
cells expressing the W10A and D39A variants have a Ca2+-kinetic similar to that of Vav1-
deficient cells (figure 4.22 D). However, expression of these variants was low compared to 
wild-type Vav1, so that it is unclear, if the Ca2+-mobilization phenotype depends on 
signaling defects or the low expression levels of the individual CH-domain mutants. In 
contrast, the D98A Vav1 variant shows an almost normal BCR-induced Ca2+-mobilization 
(figure 4.22 D). Collectively, the Vav1 CH-domain is pivotal for BCR-induced Ca2+-
signaling, since single amino acid substitutions or deletion of the complete CH-domain 






Figure 4.22: The CH-domain of Vav1 is critical for BCR-induced Ca
2+
-mobilization. A) Schematic 
architecture of wild-type Vav1 and the ∆CH Vav1 variant. B, D) Vav1-deficient DG75 cells expressing Citrine-
tagged wild-type Vav1, ∆CH Vav1, Vav1 W10A, Vav1 D39A, Vav1 D98A or EGFP were analyzed for Ca
2+
-
mobilization upon BCR stimulation as before. The graph shows Ca
2+
-mobilization of gated cells (positive gate 
(C, E)). Data show one representative example of three independent experiments. C, E) Expression levels of 
analyzed proteins were determined by flow cytometry.  
 
4.5.2 Actin-binding CH-domains cannot functionally replace the Vav1 CH-
domain 
Having shown that the Vav1 CH-domain is critical for Ca2+-mobilization upon BCR 
stimulation, I further focused on the functional principle of the CH-domain. As mentioned 
in chapter 4.5.1, type 1 and 2 CH-domains are described to bind the Actin cytoskeleton. 
Yet, there is no direct proof that the Vav1 type 3 CH-domain is not able to bind to the Actin 
cytoskeleton.  
To test whether known Actin-binding CH-domains can substitute the Vav1 CH-domain in 
the context of BCR-induced Ca2+-mobilization, I generated Vav1 chimeras having the 
tandem type 1 and 2 CH-domains of β-Spectrin ([CH]2 β-Spectrin-Vav1) or the type 3 CH-





instead of the Vav1 CH-domain. Constructs were expressed in Vav1-deficient DG75 cells 
and Ca2+-mobilization was measured. Both chimeras showed reduced BCR-induced Ca2+-
mobilization (figure 4.23 B) similar to the ∆CH Vav1 variant (figure 4.22 B, see chapter 
4.5.1). Since the Actin-binding type 1 and 2 CH-domains of β-Spectrin could not 
functionally replace the Vav1 CH-domain, an association with the Actin cytoskeleton might 
not be the task of the Vav1 CH-domain in BCR-induced Ca2+-mobilization. 
 
Figure 4.23: Actin-binding CH-domains cannot functionally substitute the Vav1 CH-domain in Ca
2+
-
mobilization. A) Schematic architecture of wild-type Vav1 and the chimeric CH IQGAP Vav1, [CH]2 β-
Spectrin-Vav1 proteins B) Vav1-deficient DG75 cells expressing Citrine-tagged wild-type Vav1, [CH]2 β-
Spectrin-Vav1, CH IQGAP-Vav1 or EGFP were analyzed for Ca
2+
-mobilization upon BCR stimulation as 
before. The graph shows Ca
2+
-mobilization of gated cells (positive gate (C)). Data show one representative 
example of three independent experiments. C) Expression levels of analyzed proteins were determined by 
flow cytometry.  
 
4.5.3 The CH-domain of Vav1 functions independently of its intramolecular 
localization 
Structural studies of the group from Xose Bustelo revealed that the CH-domain has the 
ability to contact the ZF-domain and thereby regulating the GEF activity of Vav1 (Zugaza 
et al., 2002), so that it seemed possible that the CH-domain provides structural support for 
the DH-PH-ZF-domain unit. To test whether the CH-domain mediates its critical role in 
BCR-induced Ca2+-mobilization independently of the DH-PH-ZF-domain unit, I generated 
a Vav1 variant containing the CH-domain at the C-terminus instead of the N-terminus 





backbone (figure 4.24 A). BCR-induced Ca2+-mobilization in cells expressing the Vav1 
CHCT variant was similar to that of cells expressing wild-type Vav1 (figure 4.24 B). This 
indicates that the CH-domain might work independently of the other Vav1 domains, since 
the structural displacement of the CH-domain has no functional consequences for Ca2+-
mobilization. 
 
Figure 4.24: The CH-domain of Vav1 functions also at Vav1’s C-terminus. A) Schematic architecture of 
wild-type Vav1 and the Vav1 CHCT variant B) Vav1-deficient DG75 cells expressing Citrine-tagged wild-type 
Vav1, Vav1 CHCT or EGFP were analyzed for Ca
2+
-mobilization upon BCR stimulation as before. The graph 
shows Ca
2+
-mobilization of gated cells (positive gate (C)). Data show one representative example of three 
independent experiments. C) Expression levels of analyzed proteins were determined by flow cytometry. 
  
4.5.4 The CH-domain of Vav1 is not involved in plasma membrane 
recruitment 
The results of the previous chapters point out, that the Vav1 CH-domain fulfills a specific 
function and acts independently of the DH-PH-ZF-domain unit. However, the functional 
mechanism of the CH-domain in the context of BCR-induced Ca2+-mobilization is still 
unclear. A possible function could be the recruitment of Vav1 to the plasma membrane 
where BCR-signaling complexes are located.  
To test this hypothesis, I generated a Vav1 chimera in which I replaced the CH-domain 
with the first 23 amino acids of the Lyn tyrosine kinase containing a signal for plasma 
membrane attachment (Lynmyr-∆CH Vav1) (Kovářová et al., 2001). This chimera was 
expressed in Vav1-deficient DG75 cells and its subcellular localization was analyzed by 
confocal microscopy. The results show that the Lynmyr-∆CH Vav1 chimera was 





sequence was functional in Vav1 (figure 4.25 A). However, this constitutively membrane-
bound variant of ΔCH Vav1 was a poor activator of BCR-induced Ca2+-signaling (figure 
4.25 C).  
 
Figure 4.25: The CH-domain is not a membrane-targeting device. A) Confocal microscopy of Vav1-
deficient DG75 cells expressing Lynmyr-∆CH Vav1 C-terminally tagged with Citrine. Images were taken before 
and 3 min after stimulation with 20 μg/ml α-IgM F(ab’)2 fragments. Data show one representative example of 
three independent experiments. B) Schematic architecture of wild-type Vav1 and the used Vav1 variants. C, 
E) Vav1-deficient DG75 cells expressing Citrine-tagged wild-type Vav1, Lynmyr-∆CH Vav1, ∆CH Vav1-Syk 
[SH2]2, Vav1-Syk [SH2]2 or EGFP were analyzed for Ca
2+
-mobilization upon BCR stimulation as before. The 
graph shows Ca
2+
-mobilization of gated cells (positive gate (D, F)). Data show one representative example of 






Moreover, I tested whether the tandem SH2 domains of Syk, which were previously 
shown to have an amplifying effect on Ca2+-mobilization, can restore the Ca2+-mobilization 
defect of the ΔCH Vav1 variant. Figure 4.25 E shows that the positive effect of the tandem 
SH2-domains of Syk on Ca2+-mobilization (see figure 4.10) was abolished by the deletion 
of the Vav1 CH-domain(ΔCH Vav1-Syk [SH2]2). The results show that the Vav1 CH-
domain is not involved in targeting Vav1 to the BCR, but rather is involved in another yet 
to be identified function. 
This unknown function of the CH-domain could involve protein-protein interactions. 
Hence, I focused on the identification of putative protein interaction partners. Therefore, I 
generated a GST-fusion protein containing the CH-domain of Vav1, which I used for 
affinity purification of interaction partners from lysates of SILAC (stable isotope labeling 
by/with amino acids in cell culture) labeled DG75 cells. The purified proteins were 
identified by mass spectrometry (Proteomics Service Facility, UMG), but the obtained 
results were not conclusive and hence did not reveal promising binding partner candidates 
(data not shown). 
 
4.6 Phosphatidyl-inositol-4-phosphate 5-kinase in BCR-induced 
Ca2+-mobilization 
I described in the previous chapters that Vav1 is essential for BCR-induced Ca2+-
mobilization without affecting the formation of the Ca2+-initiation complex. How Vav1 
controls the activity of PLCγ2 and subsequent Ca2+-mobilization remains unclear. The 
substrate of PLCγ2 is phosphatidyl-inositol-4,5-bisphosphate (PIP2). The Production of 
PIP2 is mainly executed by the phosphatidyl-inositol-4-phosphate 5-kinase (PIP5K) (van 
den Bout and Divecha, 2009). Notably, the small G-protein Rac1 was shown to interact 
with PIP5K (Halstead et al., 2010). Thus, Vav1, being an activator of Rac1, could be a 
potential regulator of PIP5K function and of cellular PIP2 levels. 
To test the influence of PIP5-kinases on Ca2+-mobilization upon BCR stimulation, I 
ectopically expressed the PIP5K member PIP5K1a in DG75 cells. The results in figure 
4.26 A show that expression of PIP5K1a in DG75 cells amplified Ca2+-mobilization 
compared to parental DG75 cells indicating a supporting function of PIP5K1a in BCR-
induced Ca2+-signaling.  
Next, I tested whether additional expression of PIP5K1a could substitute the lack of Vav1 
in BCR-induced Ca2+-mobilization. To this end, the PIP5K1a construct was expressed in 





additional expression of PIP5K1a caused only a marginal increase of Ca2+-mobilization in 
Vav1-deficient cells (figure 4.26 C). Therefore, overexpression of PIP5K1a cannot 
compensate the lack of Vav1. Furthermore, the much weaker Ca2+-amplification by 
overexpression of PIP5K1a in Vav1-deficient cells compared to parental DG75 cells might 
indicate that PIP5K1a needs Vav1 in order to fulfill its function in BCR-induced Ca2+-
mobilization.  
 
Figure 4.26: PIP5K1a influences Ca
2+
-mobilzation, but cannot restore Vav1 function in human DG75 B 
cells. A, C, E) Parental DG75 cells or Vav1-deficient DG75 cells expressing Citrine- or EGFP-tagged wild-
type Vav1, PIP5K1a, Syk [SH2]2-PIP5K1acore, rPLCγ2-PIP5K1acore or EGFP were analyzed for Ca
2+
-
mobilization upon BCR stimulation as before. The graph shows Ca
2+
-mobilization of gated cells (positive gate 
(B, D, F)). Data show one representative example of three independent experiments. B, D, F) Proteins were 
N-terminally ([SH2]2 Syk-PIP5K1acore), C-terminally (Vav1, PIP5K1a) tagged with Citrine or N-terminally 







To test whether the dramatically reduced Ca2+-mobilization in Vav1-deficient DG75 cells is 
due to defective PIP5K1a positioning, I generated chimeric PIP5K1a variants that were N-
terminally tagged with either the tandem SH2-domains of Syk (Syk [SH2]2-PIP5K1acore) or 
full length rat PLCγ2 (rPLCγ2-PIP5K1acore). This approach was intended to target 
PIP5K1a either directly to the BCR via the tandem SH2-domains of Syk or to couple to it 
directly to its product consumer PLCγ2. Here, I used the isolated PIP5K1a kinase core 
domain, which was described to be the minimal unit for kinase activity (Nelson et al., 
2008). The constructs were expressed in Vav1-deficient DG75 cells and Ca2+-mobilization 
was measured. Figure 4.26 E shows only a marginal increase of BCR-induced Ca2+-
mobilization in cells expressing either Syk [SH2]2-PIP5K1acore or the rPLCγ2-PIP5K1acore 
chimera compared to Vav1-deficient cells. This indicates that incorrect positioning of 
PIP5K1a might not be the reason for the Ca2+-mobilization defect in Vav1-deficient DG75 
cells. Collectively, PIP5K1a activity might depend on the presence of a functional Vav1, 
since PIP5K1a loses its Ca2+-promoting function in the absence of Vav1. 







Engagement of the B cell antigen receptor (BCR) initiates the generation of membrane 
lipid-derived second messengers followed by an increase of the cytosolic Ca2+-
concentration, which is a hallmark of B cell activation. However, the underlying molecular 
signaling pathway is not completely understood. Genetic mouse models indicated a 
paramount role of Vav guanine nucleotide exchange factors in this context, yet they did 
not explain its operating principle. Therefore, the aim of this study was to analyze the role 
of Vav family members in BCR-induced Ca2+-mobilization in human B cells. In my PhD 
project, I identified the Vav protein family as an essential signaling knot in BCR-induced 
Ca2+-mobilization. Focusing on the hematopoietically expressed Vav1 family member, I 
investigated the importance of individual protein domains and their respective molecular 
mechanisms in connection to BCR-induced Ca2+-mobilization. The main achievements of 
my PhD project are outlined below: 
 
1. Generation of genetic model systems to study BCR-induced Ca2+-signaling in 
human B cells. 
 
2. Identification of Vav family proteins as crucial factors in BCR-proximal Ca2+-
signaling. 
 
3. Identification of essential Vav1 protein domains for BCR-induced Ca2+-
mobilization.  
 
4. Identification of key interaction partners of the SH2-domain of Vav1. 
 
5. Identification of the Vav1 DH-PH-ZF-domain unit integrity as a prerequisite for 
BCR-proximal Ca2+-signaling, which strongly indicates Rho family G-proteins as 







5.1 Vav proteins constitute a major signaling knot in BCR-induced 
Ca2+-mobilization 
In the beginning of my PhD project, I established the TALEN gene targeting method in our 
laboratory to generate new genetic model systems for the investigation of human BCR 
signaling. Previously, efficient genetic manipulation was almost exclusively restricted to 
mouse models or the chicken DT40 B cell line. Human B cell lines, however, revealed 
technical obstacles in the context of efficient gene targeting. Based on the new gene 
targeting methods making use of site-specific engineered endonucleases, genetic 
manipulations are now technically feasible in human B cell lines, which improves the 
comparability with data from primary human B cells. 
To investigate the role of Vav proteins in BCR-induced Ca2+-mobilization, I generated a 
sub-line of the human DG75 B cell line deficient for the hematopoietically expressed 
family member Vav1. The characterization of this Vav1-deficient cell line revealed that 
Vav1 is a critical signaling factor in BCR-induced Ca2+-signaling in DG75 cells. In addition, 
I showed that Vav1 is the predominant Vav family member expressed in DG75 cells, 
explaining the dramatic effect of the loss of Vav1 in the context of Ca2+-mobilization. 
Nevertheless, Vav2 and Vav3 are also expressed, but to a lower extent. In primary B 
cells, the situation appears slightly different. Here, Vav2 and Vav3 are the predominantly 
expressed Vav family members indicating a more prominent role of these proteins in 
primary B cells.    
The process of BCR-induced Ca2+-mobilization requires the formation of the so-called 
Ca2+-initiation complex resulting in the phosphorylation and activation of PLCγ2 (Engelke 
et al., 2007). However, Ca2+-initiation complex formation is not altered in Vav1-deficient 
DG75 cells, since I could show that SLP-65 phosphorylation and plasma membrane 
recruitment as well as PLCγ2 phosphorylation are normal. In conclusion, Vav1 controls 
BCR-induced Ca2+-mobilization downstream or independent of the canonical Ca2+-
initiation complex formation. These findings are in agreement with results achieved from 
the group of Klaus-Dieter Fischer showing that Vav1/Vav2 double-deficient mouse B cells 
have reduced BCR-induced Ca2+-mobilization, but unaltered phosphorylation kinetics of 
SLP-65 and PLCγ2 (Tedford et al., 2001). However, it should be noted that in mice an 
isolated deficiency of Vav1 has no influence on BCR-induced Ca2+-signaling (Tedford et 
al., 2001), which is indicative for redundant roles of Vav family members in murine B cells. 
This is supported by the signaling phenotype of B cells from mice lacking all three Vav 
proteins that show an even stronger signaling defect than Vav1/Vav2 double-deficient B 





but not Vav2, could restore BCR-induced Ca2+-mobilization in Vav1-deficient DG75 cells. 
Thus Vav1 and Vav3 have redundant functions in terms of Ca2+-signaling in human B 
cells. In agreement with this finding, Vav3 was demonstrated to be an important factor of 
BCR-induced Ca2+-signaling in the chicken B cell line DT40 (Inabe et al., 2002). However, 
Vav3-deficiency in DT40 cells led to a decreased phosphorylation of PLCγ2, which is not 
consistent with the results gained in Vav1/Vav2 double-deficient mouse (Tedford et al., 
2001) and my Vav1-deficient human model system.  
Collectively, the available data show that Vav proteins fulfill an indispensable function in 
BCR-induced Ca2+-mobilization. Nevertheless, discrepancies exist for the requirement of 
Vav family members, especially Vav2, in B cells from different species. This indicates an 
evolutionary divergent development of Vav family members. To test potential differences 
between human and murine Vav family members, I expressed murine Vav proteins in 
Vav1-deficient DG75 cells and analyzed their functionality in BCR-induced Ca2+-
mobilization. Like their human counterparts, only murine Vav1 and Vav3, but not Vav2, 
were able to support Ca2+-mobilization in DG75 cells. In conclusion, the differential ability 
of mouse Vav2 to support Ca2+-signaling might not depend on the Vav protein itself, but 
rather on its proximal interaction network that might differ between species.  
 
5.2 BCR-proximal localization of Vav1 enables efficient Ca2+-
mobilization 
BCR engagement drives the recruitment of first-line kinases like SFKs and Syk building up 
the first signaling complex proximal to the BCR (Reth and Wienands, 1997). In turn, a 
second assembly takes place mediated by the key adaptor protein SLP-65, forming the 
Ca2+-initiation complex (Engelke et al., 2007; Scharenberg et al., 2007), followed by 
second messenger-induced Ca2+-mobilization. The BCR-induced translocalization process 
of Vav1, however, is basically unknown in that context. Nevertheless, investigations 
focusing on Vav3 in the chicken B cell line DT40 suggest an involvement of the adaptor 
proteins SLP-65 and Grb2 in Vav3 recruitment to membrane rafts (Johmura et al., 2003). 
In agreement with this, Vav3 was found to be a component of BCR-induced micro-
signalosomes (Weber et al., 2008). To elucidate the positioning of Vav1 upon BCR 
stimulation, I used a Citrine-tagged Vav1 variant to detect its localization by live cell 
imaging. Even though Citrine-tagged Vav1 was expressed and localized in the cytoplasm, 
no BCR-induced re-localization processes were observed indicating that the experimental 
set up might not be feasible for this purpose (data not shown). Therefore, I focused my 





mobilization using genetic and biochemical approaches. Many Vav1 interactions are 
mediated by its C-terminal adaptor part, which consists of an SH3-SH2-SH3-domain 
arrangement. Here, the SH2-domain is of particular importance, since it has the 
competence to guide Vav1 to active signaling spots. By inactivating the Vav1 SH2-
domain, I could show that it is pivotal for Vav1-mediated Ca2+-mobilization. To identify B 
cell-specific SH2-domain interaction partners, I performed affinity purifications using the 
Vav1 SH2-domain, which revealed a complex pattern of binding partners including the 
previously reported interaction partners SLP-65 and Syk (Deckert et al., 1996; Wienands 
et al., 1998; Chiu et al., 2002). Most remarkably, however, I showed a so far undescribed 
interaction between the Vav1 SH2-domain and the Igα/Igβ heterodimer of the BCR. Since 
Igα/Igβ contain ITAM and non-ITAM phosphorylation motifs, I further characterized this 
interaction and identified the ITAM sequence as Vav1 docking site.  
As mentioned above, affinity purification experiments using the Vav1 SH2-domain 
confirmed the previously reported interaction with SLP-65 (Wienands et al., 1998). The 
group of Andrew Chan identified the tyrosine 91 (Y91) in chicken SLP-65 as exclusive 
binding site of Vav1 (Chiu et al., 2002). To check whether the equivalent tyrosine residue 
in human SLP-65 (Y72) serves as docking site for Vav1, I generated a SLP-65 deficient 
DG75 sub-line, reconstituted these cells with a SLP-65 tyrosine 72-to-phenylalanine 
(Y72F) variant and tested the association of  the Vav1 SH2-domain with this SLP-65 
mutant. Even though binding between Vav1 and SLP-65 was reduced, it was not absent. 
Additionally, I also tested the Y72 proximally located tyrosine 84 (Y84) and tyrosine 119 
(Y119) for Vav1 binding, which are described together with tyrosine 178 (Y178) and 
tyrosine 189 (Y189) as PLCγ2 binding sites (Chiu et al., 2002; Engelke et al., 2013). Since 
Y84 and Y119 could also be identified as possible Vav1 docking sites and even the 
Y72/84F and Y72/119F double SLP-65 variants still interacted with Vav1, it must be 
assumed that Vav1 has multiple SLP-65 interaction points. This contradicts the previous 
results of Chiu et al. and leads to a less restricted mode of interaction in which Vav1 can 
bind to different SLP-65 tyrosines depending on available positions similar to what has 
been described for the PLCγ2-SLP-65 interaction (Chiu et al., 2002). Based on these 
results, SLP-65 constitutes a central building block on which effector proteins might be 
arranged in different ways, what might cause diverse signaling outcomes. Consequently, 
the data of the used genetic and biochemical approaches illustrate a conceivable 
recruiting mechanism involving a direct Vav1 BCR-recruitment and a Vav1-SLP-65 
interaction in the context of BCR-induced signaling.               
To test which interaction partner of the Vav1 SH2-domain, Igα/β or SLP-65, has a 





containing either BCR- or SLP-65-binding SH2-domains to decipher the importance of the 
two recruiting mechanisms. In fact, both Vav1-recruiting mechanisms enabled BCR-
induced Ca2+-mobilization, although each to a different extent. Since recruitment to SLP-
65 results in a more transient BCR-induced Ca2+-mobilization, direct recruitment of Vav1 
to BCR ITAMs leads to a more sustained Ca2+-flux. Whether the different signaling 
strengths depend on different localization or on different affinities is not completely solved, 
however, it is clear that Vav1 localization is not restricted to a specific signaling spot, but 
rather to BCR-proximal areas in the context of Ca2+-mobilization.  
In addition to that, CD19 is described to recruit Vav1 to its cytoplasmic tail after co-ligation 
with the BCR, which potentiates BCR-derived signals (Weng et al., 1994; Sato et al., 
1997; Fujimoto et al., 1999). However, this process seems to be not involved in BCR-
induced Ca2+-signaling, since CD19-negative DG75 cells show normal Ca2+-mobilization 
upon BCR stimulation.  
 
5.3 The structural integrity of the Vav1 DH-PH-ZF-domain unit is 
an essential prerequisite for BCR-signaling 
Since I could show that Vav1 does not influence the formation of the Ca2+-initiation 
complex in DG75 cells upon BCR stimulation, I focused on alternative mechanisms by 
which Vav1 might regulate Ca2+-signaling. Functional characterizations of Vav1 in the past 
mainly focused on Vav1’s GEF activity towards small G-proteins of the Rho-family 
(Bustelo, 2001; Zugaza et al., 2002). In that context, it is well established that Vav1 is a 
transducer of activating signals leading to cell proliferation (Tarakhovsky et al., 1995; 
Bonnefoy-Bérard et al., 1996). The connection between Vav1’s GEF activity and BCR-
induced Ca2+-mobilization, however, remained unclear. To address this question, I 
generated two Vav1 variants containing non-functional DH-domains, one affecting the 
center of the catalytic DH-domain (Vav1 LK334/335AA), the other one damaging the 
structural integrity outside of its catalytic site (Vav1 L213Q) (Zugaza et al., 2002; Saveliev 
et al., 2009). Since the Vav1 LK334/335AA variant enabled normal BCR-induced Ca2+-
mobilization, it seems unlikely that activation of Rho family G-proteins is involved in that 
context. In agreement with this, TCR-induced Ca2+-mobilization is not reduced in T cells 
from Vav1-deficient mice expressing the Vav1 LK334/335AA variant either (Saveliev et 
al., 2009). However, it needs to be considered that inactivation of the Vav1 LK334/335AA 
DH-domain was only tested in connection to Rac1 activation (Saveliev et al., 2009). 
Importantly, amino acid substitutions of residues involved in binding of small G-proteins 





et al., 2002; Rossman et al., 2005). Whether activation of other small G-proteins like RhoA 
is also impaired by the LK334/335AA mutations, remains unknown and needs to be tested 
in future experiments. On the other hand, I could demonstrate that the structural integrity 
of the DH-domain is critical for BCR-induced Ca2+-mobilization. Thus, the role of the Vav1 
DH-domain in BCR-induced Ca2+-signaling may be to associate with critical signaling 
factors rather than to activate small G-proteins. Since the only known function of DH-
domains is to activate small G-proteins, these proteins are the only described interaction 
partners. Hence, I assume that small G-proteins fulfill a critical role in BCR-induced Ca2+-
signaling. Vav1 activates and therefore binds the small G-proteins Rac1, Rac2 and RhoA 
(Movilla et al., 2001; Palmby et al., 2004; Heo et al., 2005; Rapley et al., 2008). The role 
of Rac1 and Rac2 in B cell biology has been demonstrated in mice deficient for either 
Rac1 or Rac2 or both. B cells from Rac2-deficient mice show reduced BCR-induced Ca2+-
mobilization (Walmsley et al., 2003). In addition, expression of a dominant-negative 
variant of RhoA in the murine B cell line A20 was shown to reduce BCR-induced Ca2+-
mobilization (Saci and Carpenter, 2005) indicating that activation of RhoA by GEFs is 
involved in that context. Even though RhoA can be activated by Vav1 (Movilla et al., 2001; 
Rapley et al., 2008), its activation might not be relevant, since I could show that the 
catalytically inactive Vav1 LK334/335AA variant enabled BCR-induced Ca2+-mobilization.  
For binding and activation of small G-proteins, Vav proteins are specially equipped with 
further domains. The central DH-PH complex is a conserved feature among Rho GEFs 
and constitutes the minimal catalytic entity (Bustelo, 2001; Zugaza et al., 2002). C-
terminal of the DH-PH-domain arrangement, Vav1 contains a ZF-domain, which interacts 
with and thus stabilizes the DH-domain. This gives rise to the DH-PH-ZF-domain unit 
(Zugaza et al., 2002; Brooun et al., 2007). Results obtained from fluorescence anisotropy 
and NMR chemical shift mapping experiments indicate that the isolated Vav1 ZF-domain 
is able to directly associate with Rac1 (Heo et al., 2005). Regarding Vav2, the same group 
demonstrated the participation of the ZF-domain in binding as well as activation of small 
G-proteins like Rac1, Cdc42 and RhoA. In agreement with that, substitutions of glutamine 
542 (Q542) or tyrosine 544 (Y544) with alanines within the Vav1 ZF-domain caused a 
dramatic reduction of Rac1 activation supporting the critical role of the ZF-domain in that 
context (Zugaza et al., 2002). I tested the same Vav1 ZF-domain variants and showed 
that an intact Vav1 ZF-domain is essential for BCR-induced Ca2+-mobilization. This 
supports the hypothesis of G-proteins as critical factors for Vav1-mediated Ca2+-signaling. 
Additional support is gained from experiments focusing on the acidic region of Vav1 N-
terminal of the DH-PH-ZF-domain unit (Zugaza et al., 2002). This region is described to 
inhibit Vav1 GEF activity by forming a so-called inhibitory loop in combination with the CH-





described to intramolecularly bind the DH-PH-ZF-domain unit, the acidic region blocks the 
entry of the catalytically active site of the DH-domain. The latter interaction is regulated via 
phosphorylation of three conserved tyrosines in the acidic region, which causes release of 
the inhibitory loop, allowing small G-proteins to bind and get activated (Zugaza et al., 
2002; Yu et al., 2010). Experimentally, substitution of these tyrosines is followed by an 
increased GEF activity of Vav1 (Zugaza et al., 2002). I generated a Vav1 variant carrying 
a deletion of the complete acidic region (∆AR Vav1) including the three conserved 
tyrosine residues. This ∆AR Vav1 variant causes an elevated BCR-induced Ca2+-
mobilization in DG75 cells. In conclusion, an improved DH-domain accessibility for small 
G-proteins seems to increase Vav1’s capability to promote Ca2+-mobilization. 
The available data suggest the concept, that small G-proteins are critical for Vav1-
mediated BCR-induced Ca2+-mobilization. To test directly the role of small G-proteins, I 
generated a Rac2-deficient DG75 sub-line. Analysis of this DG75 sub-line revealed only a 
marginal reduction in BCR-induced Ca2+-mobilization. Given the high degree of homology 
between Rac2 and Rac1, this result may indicate redundant functions of these proteins. 
As previously mentioned, B cells of Rac2-deficient mice have only partial defects in B-cell 
signaling including BCR-induced Ca2+-mobilization (Walmsley et al., 2003). Some of these 
defects are stronger in B cells of Rac1/Rac2 double-difficient mice, however, whether this 
applies to BCR-induced Ca2+-mobilization is not known (Walmsley et al., 2003). How 
exactly Rac proteins may control BCR-induced Ca2+-mobilization is not known either. 
Noteworthy, Rac2 has the capability to directly interact with PLCγ2 in chicken DT40 cells. 
A variant of PLCγ2 incapable of binding to Rac2 could not fully reconstitute BCR-induced 
Ca2+-mobilization in PLCγ2-deficient DT40 cells (Walliser et al., 2015). I used the identical 
amino acid substitution in rat PLCγ2 and expressed this variant in a PLCγ2-deficent DG75 
sub-line (kindly provided by Caren Bartsch). BCR-induced Ca2+-mobilization was not 
completely restored in these cells either (data not shown). Whether the reduced Ca2+-
mobilization really depends on the loss of the PLCγ2-Rac2 interaction needs to be further 
characterized. Collectively, the obtained data indicate a potential signaling axis starting 
with the recruitment of Vav1 to the BCR and SLP-65 bringing it into close proximity of 
PLCγ2, where it might facilitate small G-protein-mediated PLCγ2 activation.  
 
5.4 The Vav1 CH-domain is an indispensable regulator region of 
Vav1 activities   
The CH-domain of Vav1 is believed to act mainly as an intramolecular inhibitor of the 





acidic region by binding to intramolecular sites within the DH-PH-ZF-domain unit (Zugaza 
et al., 2002; Yu et al., 2010). The function of the CH-domain of Vav1 in BCR-induced 
Ca2+-mobilization is not completely clear. Deletion of the CH-domain (∆CH Vav1) causes 
a dramatically reduced Ca2+-mobilization in T cells upon TCR stimulation (Li et al., 2013). I 
could show that the same holds true for DG75 B cells as well. However, the function of 
type 3 CH-domains is not well defined and might depend on the individual protein context 
(Gimona et al., 2002). As opposed to type 1 and type 2 CH-domains, it is not known 
whether the type 3 CH-domain of Vav1 can bind to the Actin cytoskeleton. Actin 
cytoskeleton rearrangements are discussed to be involved in the regulation of early 
events of B cell activation (Batista et al., 2010). To test if Actin-binding is involved in Vav1-
mediated Ca2+-mobilization, I substituted the Vav1 CH-domain with the Actin-binding CH-
domains of β-Spectrin or IQGAP, respectively (Bañuelos et al., 1998; Umemoto et al., 
2010). However, these Vav1 variants were not able to restore Ca2+-mobilization upon 
BCR stimulation indicating that an association of Vav1 with Actin is not crucial in this 
process.  
BCR-proximal signaling including formation of the Ca2+-initiation complex takes place at 
the plasma membrane (Engelke et al., 2007; Scharenberg et al., 2007). As described 
above, Vav1’s SH2-domain serves as a crucial recruitment domain via binding to the BCR 
and SLP-65. In addition, also the PH-domain is involved in recruitment processes as it 
binds different plasma membrane resident PIPs. Since these mechanisms are described 
to influence Vav1 activity (Han J. et al., 1998), I tested whether the CH-domain might be 
involved in plasma membrane recruitment. For this purpose, I substituted the CH-domain 
with the membrane-targeting region of the Src-kinase Lyn (Lynmyr-∆CH Vav1) (Casey, 
1995; Kovářová et al., 2001). Despite efficient plasma-membrane targeting of the Lynmyr-
∆CH Vav1 variant, it did not restore the Ca2+-mobilization defect of cells expressing the 
∆CH Vav1 variant. Thus, plasma membrane targeting is most likely not the function of the 
CH-domain in that context.    
Considering that the CH-domain is involved in intramolecular interactions with the 
indispensable DH-PH-ZF-domain unit (Zugaza et al., 2002; Yu et al., 2010), the CH-
domain could serve in structurally stabilizing this unit to allow for efficient Vav1-mediated 
Ca2+-mobilization. To test this hypothesis, I removed the CH-domain from the inhibitory 
loop by transferring it from the N-terminus to the C-terminus. Strikingly, this positional 
change of the CH-domain has no functional consequences for Ca2+-mobilization. Thus, 
the CH-domain might not structurally stabilize the DH-PH-ZF-domain unit. However, the 
C-terminus of Vav1 is reported to loop back to the center of Vav1 as a second inhibitory 





interact with the DH-PH-ZF-domain unit. Hence, stabilization of the Vav1 3D structure by 
the CH-domain cannot be completely excluded as a possible function of the CH-domain. 
As mentioned above, Vav2 cannot restore the BCR-induced Ca2+-mobilization in Vav1-
deficient DG75 cells. Yet, the simple exchange of the CH-domain of Vav2 with the CH-
domain of Vav1 leads to a functional Vav2 chimera (data not shown). Vice versa, Vav1 
containing the CH-domain of Vav2 also enables BCR-induced Ca2+-mobilization (data not 
shown). In conclusion, the CH-domain of Vav2 as well as all other domains of Vav2 are in 
principle functional. However, in Vav2 the interplay between these domains might be 
impaired. In conclusion, this indicates a close cooperation between the CH-domain and 
other Vav domains with separate functions that are indispensable for Vav-mediated Ca2+-
mobilization. 
 
5.5 Does Vav1 influence the generation of PIP2 in BCR-induced 
Ca2+-signaling?  
Besides activation of PLCγ2 by activated Btk, supply of its substrate PIP2 is a prerequisite 
for BCR-induced Ca2+-mobilization. PIP2 comprises only about 1 % of the phospholipids in 
the plasma membrane, so that it might be rapidly exhausted after BCR stimulation 
(McLaughlin and Murray, 2005). Hence, refilling of PIP2 levels could be a critical aspect for 
sustained BCR-induced Ca2+-mobilization. In principle, PIP2 is generated by the family of 
PIP5Ks (van den Bout and Divecha, 2009). Vav1-deficient mouse B cells show a reduced 
PIP5K activation as well as impaired Ca2+-mobilization upon CD19 and BCR co-ligation 
(O’Rourke et al., 1998). Since Rac1 was shown to interact with PIP5Ks (Halstead et al., 
2010), a potential signaling axis including Vav1, Rac1 and PIP5K might be important for 
efficient BCR-induced Ca2+-signaling. In accordance with this hypothesis, ectopic 
expression of PIP5Ks improves BCR-induced Ca2+-mobilization in DG75 cells, indicating a 
potential function of PIP5Ks in that context. However, ectopic expression of PIP5K1a in 
Vav1-deficient DG75 cells could not enhance BCR-induced Ca2+-mobilization, indicating 
that Vav1 is probably needed for PIP5K function in Ca2+-mobilization. To characterize this 
in more detail, I fused the catalytic domain of PIP5K1a directly to rat PLCγ2 (rPLCγ2-
PIP5K1acore) to bypass a possible Vav1-mediated PIP5K recruitment. However, this 
chimera did not restore Ca2+-mobilization in Vav1-deficient cells. Yet, it needs to be noted 
that PIP5K activity of the rPLCγ2-PIP5K1acore chimera was not tested in my experiments. 
Given that Vav1 was not expressed in cells expressing the rPLCγ2-PIP5K1acore chimera, 
the PIP5K1a catalytic domain might lack proper activation via the Vav1/small G-protein 





PIP2 following BCR stimulation remains a possible scenario (figure 5.1). In that context, 
Rac2 is not the key G-protein, since BCR-induced Ca2+-mobilization in Rac2-deficient 
DG75 cells is almost unaltered. Therefore, further G-proteins have to be tested for their 
function in BCR-induced Ca2+-mobilization.  
 
 
Figure 5.1: Schematic domain architecture of Vav1 indicating possible domain functions in the context 
of BCR-induced Ca
2+
-mobilization. The DH-PH-ZF-domain unit (mechanism 1) and the CH-domain 
(mechanism 2) of Vav1 seem to cooperate for a completely functional Vav1 protein in BCR-induced Ca
2+
-
mobilization. In that context, the DH-PH-ZF-domain unit is interacting with small G-proteins that are reported 
to orchestrate the activity of several downstream factors including PLCγ2 and PIP5K, which have described 
functions in Ca
2+
-signaling (mechanism 1). The CH-domain could be identified as crucial region in the context 
of Ca
2+
-mobilization (mechanism 2), however, its exact function is not completely solved. In addition, Vav1 
functionality strictly depends on interactions mediated by its SH2-domain. Besides, the previously described 
interaction partner SLP-65, I identified an interaction between Vav1 and the Igα/Igβ heterodimer (marked in 
red) and showed that this interaction enables BCR-induced Ca
2+






The results of my PhD project demonstrate an additional mechanism by which early B cell 
activation is controlled. So far, it was thought that the process of BCR-induced Ca2+-
mobilization is exclusively regulated by the phosphorylation-dependent activation of 
PLCγ2, which is based on the correct assembly of the Ca2+-initiation complex. The 
absence of Vav guanine nucleotide exchange factors, however, strongly impairs the BCR-
induced Ca2+-mobilization, but does not affect the phosphorylation-dependent activation of 
PLCγ2. Hence, Vav proteins are not required to control the canonical PLCγ2 activation 
process, but rather act by an additional mechanism to promote mobilization of Ca2+ upon 
BCR stimulation (figure 6.1). Based on my results, the structural integrity of regions 
involved in binding and activation of small Rho family G-proteins is crucial for the 
functionality of Vav1 in that context.  
 
 
Figure 6.1: Model of Vav1 in BCR-induced Ca
2+
-mobilization. Cross-linking of BCRs leads to 
phosphorylation of ITAMs in the Igα/Igβ heterodimer, followed by the recruitment of Syk, which phosphorylates 
SLP-65 leading to the formation of the core Ca
2+
-initiation complex, including Btk and PLCγ2. Recruitment of 
Vav1 into the BCR signalosome requires the binding to SLP-65 or to the ITAM motifs of the BCR. The Ca
2+
-
promoting function of Vav1 strictly depends on the binding/activation of small G-proteins. The plus in 







This emphasizes a potential role of Rho family G-proteins in the process of PLCγ2-
controlled Ca2+-mobilization and opens the possibility for an additional regulation pathway 
with regard to the generation of key second messengers that is indispensable for the 
activation and thus differentiation of B cells into antibody secreting plasma cells. 
Moreover, the data of my PhD project provide the basis for future investigations focusing 
on the Vav1/small G-protein signaling axis. 
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ABS Actin-binding site 
Ag Antigen 
AP Affinity purification 
APC Allophycocyanin 
APS Ammonium persulphate 
AR Acidic region 
ATP Adenosine triphosphate 
BASH B cell adaptor protein containing SH2 domain 
BCR B cell antigen receptor 
BLNK B cell linker protein 
bp Base pair 
BSA Bovine serum albumin 
Btk Bruton’s tyrosine kinase 
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C2 Adaptor region of Vav1 
Cas CRISPR-associated protein 
Cbl Casitas B-lineage lymphoma 
CC CRISPR/Cas construct 
CCL Cleared cellular lysate 
CD Cluster of differentiation 
cDNA  Complementary DNA 
CH Calponin-homology  
CH Heavy chain constant domain 
CIN85 Cbl-interacting protein of 85kDa 
CIP Calf intestinal phosphatase 
Cit Citrine 
CL Heavy chain constant domain 
CRAC Ca2+ release-activated channel 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
C-terminal Carboxy-terminal 
3D Three dimensional 
DAG Diacylglycerol 
DH Dbl-homology 
DH Heavy chain diversity gene segment 
DMSO Dimethylsulfoxide 






DSB Double strand break 
DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen 
EB EcoBlast (Ecotropic receptor, Blasticidin resistance in vector) 
ECL Enhanced chemical luminescence 
E. coli Escherichia coli 
EGFP Enhanced green fluorescent protein 
env Envelope, gene encoding glycoprotein 160 
ER Endoplasmic reticulum 
Erk Extracellular signal-regulated kinase 
F(ab’)2 Bivalent antigen-binding fragment 
FACS Fluorescence activated cell sorter 
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FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
g Gram 
x g Times gravity 
gag Gene encoding p55 (core protein) 
GDI GDP-dissociation inhibitor 
GDP Guanosine diphosphate 
GEF Guanine nucleotide exchange factor 
GFP Green fluorescent protein 
Grb2 Growth factor receptor-bound protein 2 
GST Glutathione S-transferase 
GTP Guanosine triphosphate 
h Hours 
HA Hemagglutinin 
HEK Human embryonic kidney 
HEPES 2-[4-(2-Hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid 
hnRNP Heterogeneous nuclear ribonucleoprotein 
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Indo-1 AM 1H-indole-6-carboxylic acid, 2-[4-[bis[2[(acetyloxy) 
methoxy]-2-oxoethyl]amino]-3-[2-[2-[bis[2 [(acetyloxy) 
methoxy]-2oxoethyl]amino]-5methylphenoxy] 
ethoxy]phenyl] (acetyloxy)methyl ester 
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IQGAP IQ motif containing GTPase activating protein 
IRES internal ribosome entry site 
ITAM Immunoreceptor tyrosine-based activation motif 
Itk IL2-inducible T-cell kinase 
JH Heavy chain joining gene segment 
JL Light chain joining gene segment 
JNK c-JUN NH2-terminal kinase 
L Liter 
LB Lysogeny broth 
Lyn Lck/yes-related tyrosine kinase 
kDa Kilo Dalton 
M Mole 
mA Milliampere 
MACS Magnetic-activated cell sorting 
MAPK Mitogen activated protein kinase 







MMLV Moloney Murine Leukemia Virus 
mRNA Messenger RNA 
Myr myristoylation 
Nck Non-catalytic region of tyrosine kinase 
NFAT Nuclear factor of activated T cells 
NF-κB Nuclear factor of κ light polypeptide gene enhancer in B cells 
NLS Nuclear localization signal 
NP40 nonidet P40 
N-terminal Amino-terminal 
OD Optical density 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 







PI3K phosphoinositide 3’-kinase 
PIP Phosphatidyl-inositol-phosphate 
PIP2 Phosphatidyl-inositol-4,5-bisphosphate  
PIP3 Phosphatidyl-inositol-3,4,5-trisphosphate 
PIP5K Phosphatidyl-inositol-4-phosphate 
PKC Protein kinase C 
PKB Protein kinase B 
Plat E Platinum E 
PLCγ2 Phospholipase Cγ2 
PR Proline rich 
PTPN6 Tyrosine-protein phosphatase non-receptor type 6 
pTyr Phospho-tyrosine 
pY Phospho-tyrosine 
Rac Ras-related C3 botulinum toxin substrate 
Ras Rat sarcoma 
RasGRP Ras guanine nucleotide release protein 
RFP red fluorescent protein 
Rho Ras homolog 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute medium 
RT Room temperature 
s Seconds 
SDS Sodium dodecyl sulfate 
SFK Src family kinase 
SH2 Src homology 2 domain 
SH3 Src homology 2 domain 
SLP-65 SH2-domain-containing leukocyte adaptor protein of 65 kDa 
SLP-76 SH2 domain-containing leukocyte phosphoprotein of 76 kDa 
SOC Store-operated Ca2+  channel 
STIM Stromal interaction molecule 
Syk Spleen tyrosine kinase 
TAE Tris acetate EDTA buffer 
tagRFP ‘tag’ red fluorescent protein 
TALEN Transcription activator-like effector nuclease 





TCR T cell receptor 
TEMED N,N,N’,N’-tetramethylethylene-diamine 
Tris Tris-(hydroxymethyl)-aminomethane 
Triton X-100 4-(2’,2’,4’,4’tetramethylbutyl) phenyldecaethyleneglycolether 
UV Ultraviolet 
V Volt 
VH  Variable heavy chain segment 
VL Variable light chain segment 




Xid X-linked immunodeficiency 
XLA X-linked agammaglobulinemia 






Deoxyadenosine monophosphate A 
Deoxycytidine monophosphate C 
Deoxyguanine monophosphate G 




















Name 3-letter code 1-letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic Acid Asp D 
Cysteine Cys C 
Glutamic Acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
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